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The subject of this dissertation is dielectrophoresis and human mesenchymal 
stem cells (hMSCs) for cell separation and type 1 diabetes treatment. Dielectrophoresis 
is a unique characterization technology with a variety of utilities explicitly identified 
within the dissertation. hMSCs are a specialized source of cells readily acquired from 
bone-marrow, and have been explored as a therapeutic option for type 1 diabetes 
(research motivation). 
The aim of this work is to provide sufficient background information on 
hMSCs to illustrate their utility in the medical field, introduce DEP as an advantageous 
separation technique to purify hMSCs after extraction from bone-marrow, and define 
a new DEP data collection technique.  
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ABSTRACT 
Type 1 diabetes affects over 108,000 children, and this number is 
steadily increasing. Current insulin therapies help manage the disease but are not 
a cure. Over a child’s lifetime they can develop kidney disease, 
blindness, cardiovascular disease and many other issues due to the 
complications of type 1 diabetes. This autoimmune disease destroys beta cells 
located in the pancreas, which are used to regulate glucose levels in the body. 
Because there is no cure and many children are affected by the disease there is a 
need for alternative therapeutic options that can lead to a cure.  
 Human mesenchymal stem cells (hMSCs) are an important cell source for 
stem cell therapeutics due to their differentiation capacity, self-renewal, and 
trophic activity. hMSCs are readily available in the bone marrow, and act as an 
internal repair system within the body, and they have been shown to differentiate into 
insulin producing cells. However, after isolation hMSCs are a heterogeneous cell 
population, which requires secondary processing. To resolve the heterogeneity issue 
hMSCs are separated using fluorescent- and magnetic-activate cell sorting 
with antigen labeling. This techniques are efficient but reduce cell 
viability after separation due to the cell labeling. Therefore, to make 
hMSCs more readily available for type 1 diabetes therapeutics, they should 
be separated without diminishing there functional capabilities. 
Dielectrophoresis is an alternative separation technique that has the capability 
to separated hMSCs.  
xxiv 
? ???????????????????????????????????????????????????????????????????????????????????
??? ??????? ???? ????? ??? ??? ???? ?????? ??????????? ?????????? ??? ?? ??????????? ?????????
????????????the antigen labeling implemented with FACS and MACS. DEP has 
been used to characterize other cell systems, and is a viable separation technique 
for hMSCs.  
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Chapter 1 Introduction 
Stem cell therapy has gained popularity in medical research especially as a 
therapeutic option for chronic disease treatment. This chapter will overview the main 
topic of this dissertation, which is utilizing dielectrophoretic technology to purify 
human mesenchymal stem cells for type 1 diabetes treatment. The sections to follow 
will motivate the work with statistics on the prevalence of type 1 diabetes in the U.S. 
and world, briefly describe human mesenchymal stem cells differentiation toward 
insulin producing cells, dielectrophoresis, microfluidics, and the combination of the 
technologies. 
1.1 Motivation: Stem Cell Therapy and Diabetes Mellitus 
Heart disease, stroke, and diabetes mellitus are chronic diseases that 27.3 
million Americans (or 8.7% U.S. population) live with and these diseases claim 
800,000 lives each year [1-4]. Many chronic diseases are treatable by diet and 
exercise [5, 6] while others like type 1 diabetes (0.8 % of all diabetes mellitus cases) 
require therapeutic options [7]. Type 1 diabetes, mostly diagnosed in children, is a 
result of the pancreas not producing insulin and thus requiring insulin therapeutics 
[8]. This means that young children, through their entire life, inject themselves with 
insulin multiple times a day, making the disease difficult to manage. More than 
108,000 children between 0-14 years have type 1 diabetes with 16,000 new cases 
diagnosed each year [9]. In 2007, it cost ~$116 billion to treat diabetes, and as 
children become adults complications include heart disease, stroke, blindness, kidney 
1 
disease, hypertension, amputations, dental disease, and pregnancy complications 
[10]. Insulin therapy is in place as a management tool, but does not solve the main 
issue of beta cell destruction in type 1 diabetes. This necessitates the development of 
treatment options that can potentially cure type 1 diabetes rather than just 
intermittently managing it. The International Diabetes Federations tracks the shows 
the prevalence of diabetes in adults and children worldwide. For the western 
hemisphere, diabetes in most prevalent in Mexico with > 12% of the population 
affected.  The U.S. and Brazil come in second with 9-12% of the population affected. 
It is projected that 592 million people will suffer from diabetes in 2035 compared to 
382 million people in 2013 [9], (see http://www.idf.org/diabetesatlas ).  
Human mesenchymal stem cells (hMSCs) are an interesting cell source to 
researchers because of their regenerative [11, 12] and immunological properties [13]. 
hMSCs are exciting in medical research because they can serve as an internal repair 
system in the body. Upon injury, signals are sent to hMSCs and they migrate to those 
specific injured areas, differentiate, and promote healing [12, 14]. hMSCs are 
unspecialized cells isolated primarily from bone-marrow [15] demonstrating 
significant properties such as high differentiation capacity (adipocytes, chondrocytes, 
osteoblasts, etc.) [14, 16, 17], self-renew [18, 19], and secretion of bioactive 
molecules (trophic activity) [12, 13, 20, 21].  Trophic activity is significant to 
hMSCs function because signals are sent to surrounding cells and trigger them to 
perform specific roles such as tissue regeneration [20, 21].  
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One problem associated with hMSC bone-marrow isolation is that they are 
obtained as a heterogeneous mixture [22, 23]. In order for hMSCs to be used as an 
effective therapeutic, they must first be purified. For therapeutic treatments, 
obtaining hMSCs is a multistep process. Following bone-marrow isolation, hMSCs 
are centrifuged via density gradient solution (step 1), adhered to a plastic cell culture 
dish (step 2), and separated using trypsinization (step 3) [24]. This method is 
inefficient and time consuming taking days to complete [25], so other separation 
techniques have been employed. Fluorescent- and magnetic-activated cell sorting 
(FACS and MACS) use unique cell-surface recognition elements to tag target cells. 
This cell labeling alters cellular function, which is not desirable in therapeutics.  Cell 
culture purification, FACS, and MACS approaches all require expensive raw 
materials and are labor intensive [25-27].  
Other drawbacks with hMSCs are that their natural inherent biological 
functions are not well understood, and within one population hMSCs, cells express 
different membrane surface proteins [28]. Currently there is not one unique marker 
(surface proteins, differentiation pathway, plasticity in cell culture, etc.) that 
distinguishes hMSCs from other cell populations [22, 29] or identify their disposition 
to differentiate to specific cell types.  The minimum requirements established by the 
International Society for Cellular Therapy to name a cell population hMSCs are: (1) 
plastic adherence (generic cellular property [14]); (2) positive expression of 
biosurface markers CD105, CD73, and CD90; (3) negative expression for CD34, 
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CD45, CD11a, CD19, CD14, and HLA-DR; and (4) adipogenic, osteogenic, and 
chondrogenic differential potential [17, 30].  
Additionally, hMSCs morphology varies creating subpopulations [31], which 
adds another dimension to overcome for effective purification. From this point 
forward, purification and separation terminology will be used interchangeably. 
According to Haasters et al., hMSCs can be assigned three morphological 
subpopulations: (1) rapidly self-renewing cells, triangular or star-like shape; (2) 
elongated, fibroblastic-like, spindle-shaped cells; and (3) slowly-replicating, large 
cuboidal or flattened cells [31]. These subpopulations are dependent on cytoskeleton, 
cell adhesion, and active pathways that directly determine cell fate and 
differentiation [31]. Others have looked at hMSCs viscoelastic properties, the 
tendency to exhibit viscous and elastic characteristics under deformation, because it 
plays an important role in a cell’s biological response [32]. In the study completed by 
Darling et al., the elasticity and viscoelasticity of two distinct spherical and spread 
star-like hMSC morphologies were examined. The elasticity was found to be 2.5kPa 
for spherical and 3.2kPa for spread star-like hMSCs, while the viscoelasticity of the 
spherical morphology was 0.47kPa the spread star-like was 2.2kPa. These results 
show how hMSC morphology changes subpopulation properties.  
Elastin-like polypeptide (ELP) polyethyleneimine (PEI) is a positively 
charged water soluble block copolymer that directs cells morphology, and can be 
used to remove variations in cellular population/subpopulations [33].  ELP is a 
mammalian elastin made from amino acids including valine, proline, and glycine; it 
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has previously been used in drug delivery and tissue engineering applications [34, 
35]. Recent studies have shown that ELP-PEI successfully induces spheroid 
formation of rat hepatocytes [36]. The potential benefit of using ELP-PEI is to 
eliminate variations in hMSCs morphology as discussed in Chapter 4 [37].  Despite 
the shortcomings of currently available separation technologies, hMSCs therapeutics 
have demonstrated their healing potential. 
1.2 Successful hMSC Therapies and Insulin Producing MSCs 
The purpose of this section is to contextualize the power of using hMSCs for 
disease treatment. Medical researchers have focused on hMSCs impact on chronic 
diseases suffered by children. An 11-year-old and 2-year-old were both treated with 
hMSCs [30] for dilated cardiomyopathy, heart muscle disease in which the left 
ventricle becomes enlarged and cannot sufficiently pump blood to the body [38]. 
For the 11-year-old, 6mL of autologous, meaning derived from the child’s own 
tissue, therapeutic solution containing 4.8 x 106 cells/mL of hMSCs were 
transplanted into the child using a catheter. hMSCs were transplanted into the 
proximal left main coronary artery and cardiac function improved from IV (initial) to 
II [30]. The 2-year-old’s treatment differed slightly, a coronary balloon dilation 
catheter was placed in the left anterior artery, and low pressure was used for 
inflation. 270 million bone-marrow derived hMSCs were autologously transplanted 
into the child by an intracoronary bolus injection. The left ventricular injection 
fraction improved heart function from 24% to 45% 6 months after the hMSC therapy 
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[30]. These studies illustrate that hMSC therapies have been successful in children, 
and it is key to point out that a large number of cells were used for treatment, so 
extensive cell culture magnification and purification were conducted. 
Figure 1.1 Flow diagrams outlining the steps necessary to achieve hMSC isolation 
using (a) density centrifugation with FACS or MACS and (b) the presently explored 
dielectrophoretic separation.  
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Researchers from Tehran University in Iran have examined hMSCs 
differentiation into insulin producing cells, which would directly benefit children 
afflicted with type 1 diabetes. Their approach was to direct adipose-derived hMSCs 
toward insulin producing cells in a three-step cell culture protocol. In each step, the 
cell culture media was enhanced with glucose, alcohol, vitamin B3, and an insulin 
promoter peptide, exendin-4. The cells were treated with this enhanced media over 
the course of 24 days. Verification of insulin producing hMSCs was completed using 
dithizone staining, RT-PCR, immunochemistry, and morphology evaluation [39]. 
This work is important because it adds scientific evidence that hMSCs can 
potentially be used as a therapeutic option for diabetes treatment. A full review of 
hMSCs and their potential medical impact is in Chapter 2. Although hMSCs are 
promising in diabetes treatment, the current separation methods are labor and 
resource intensive, and have been shown to reduce viability such that extremely large 
concentrations of cells are required for effective therapies [40]. 
In summary, hMSCs have the potential to be used in clinical applications for 
disease treatment, but new methods for cell separation are needed to selectively 
isolate hMSCs from diverse cell populations. Therefore, the objective of this body of 
work is to develop a first generation technology for label-free, one-step, rapid 
hMSCs separation and purification without altering cellular function or reducing 
cell viability.  This work outlines a new separation technique for improved hMSCs 
treatment efficacy that couples dielectrophoresis (DEP) and microfluidics to more 
efficiently separate hMSC populations. Additionally, this work developed a new 
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DEP data collection approach by frequency sweeping which enables an automated 
data analysis method. These tools can work in tandem in a noninvasive manner to 
interrogate the exterior and interior cell structure and then cause translational motion 
harness-able for separations. These technologies also reduce the number of steps 
needed to achieve hMSC separation, as shown in Figure 1.1.  
1.3 Dielectrophoresis and Electrokinetics 
Dielectrophoresis (DEP) is a subset of a larger phenomenon called 
electrokinetics, which uses electrical energy as a driving force to induce particle 
motion [41]. DEP is polarization of neutral or charged particles or cells due to spatial 
non-uniformities in applied alternating current (AC) or direct current (DC) electric 
fields.  For this work, DEP can function as a spatial separation technique that has 
potential to overcome the shortcomings of density gradient centrifugation, FACS, 
and MACS and could provide a rapid electrical signature for hMSCs. DEP 
technologies enable a variety of particle polarizations and manipulations with 
nonuniform AC electric fields on microchips [42, 43] to study cell systems such as 
red blood cells [44, 45], cancer cells [46, 47], white blood cells [48], and yeasts cells 
[49, 50]. The advantages to coupling DEP with microfluidics are microliter sample 
size, quick analysis (~minutes to achieve results), little sample preparation, and 
minimal waste production. Disadvantages are that extended electric field exposure 
times (>5mins) can negatively affect cell properties and viability [51]. 
8 
DEP, also known as dielectric dispersion, is unique because in AC electric 
fields at specific frequencies, dipoles can be induced in or around particles and the 
permittivity of that particle changes with frequency [41, 52]. At low frequencies, this 
permittivity change is attributed to the polarization at the interface of the suspended 
particle, and for hMSCs this interface is equivalent to its membrane [42, 52]. At 
higher frequencies, the dielectric dispersion is influenced by the internal composition 
and structure of the particle; for hMSCs, cytoplasm properties play a critical role [42, 
52, 53]. This frequency-dependent phenomenon allows for biological cell systems, 
such as hMSCs to be optimized for property-specific separations. 
DEP utilizes nonuniform electric fields for cell movement based on the 
polarizability and dielectric properties (permittivity and conductivity) of their 
membrane, cytoplasm, and organelles [52]. Cells have distinct dielectric dispersions 
that can be used as an identification tool for cell purification, as depicted in Figure 
1.2. A cell’s complex permittivity is frequency dependent and chara???????????????????
?????????????????????????????????????????? ???? ????) [37]. At radio frequencies in the 
?-region, 0.10 – 10MHz, the dielectric dispersion of cells is most heavily affected by 
their membrane; high frequencies penetrate a cell’s surface and interrogates the 
internal structure [54]. Therefore, a variety of information can be obtained about a 
cell population, especially surface biomarkers, ????????-region.  
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Figure 1.2 Nonuniform dielectrophoretic particle polarization. Cells with different 
membrane (crudely illustrated) and internal properties have different polarizations; 
as a consequence, spatial particle separations can be achieved. 
In the ?-region, Maxwell-Wagner interfacial polarizations dominate the 
overall cell polarization phenomena. Based on permittivity and conductivity, 
polarized cells will exhibit either positive DEP (pDEP) force Figure 1.2b, whereby 
cells move up the electric field gradient to high electric field gradient, or negative 
DEP (nDEP) force Figure 1.2c whereby cells are repelled from areas of high electric 
field density to move down the electric field gradient [53, 55]. This cell motion in the 
spatially non-uniform electric field is defined by the Clausius-Mossotti factor, fCM, 
for core-shell spherical particles [52, 53, 56]. 
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where is the complex permittivity of the cell (i = cell) and of the medium (i =
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frequency ( ) [53]. fCM is dependent on the complex permittivity of the cell and the 
medium, equation 2. If a cell experiences pDEP, then fCM (equation 1) is positive 
indicating the cell is more polarizable than the suspending medium, cell?~  > med?~ , and 
the cell moves toward areas of high electric field density [53]. For nDEP, the fCM is 
negative and the cell is less polarizable than the suspending medium, med?~  > cell?~ , 
and the cell moves towards areas of low electric field density [53]. When fCM is zero, 
known as the cross-over frequency [52], cells transition from experiencing nDEP to 
pDEP or pDEP to nDEP and demonstrate little or no motion in the electric field. This 
cross-over frequency is an important component of a cell’s DEP spectra because 
initial estimates of cell dielectric properties can be estimated from this number. 
Equation 1 assumes a homogeneous, spherical particle, but more complex cell 
structures can be modeled for DEP polarizations by changing the shape and cell 
layers. A full review of DEP with modeling is in Chapter 3. 
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1.4 Microfluidic Technology 
Microfluidics is the manipulation of fluids and aqueous suspensions on the 
microscale [57]; devices can have many different components such as channels, 
chambers, reaction chambers, pumps, multiple layers, and electrodes.  For this 
project, electrodes are utilized to induce cell motion as a means to simply and 
directly examine biological cell properties [57, 58]. Microfluidic systems are easily 
mounted on glass microscope slides or other optically transparent platforms using 
polydimethylsiloxane (PDMS) elastomeric castings of microscale features [59]. 
Microfluidics can be used for biosensors [60], cell separation [61], cell lysis [62], 
protein analysis [63], bacteria detection [64], and droplet formation [65]. 
Microfluidics can also be used to mimic organs for drug therapy optimization [66]. 
The overlap of these techniques with biological cell analysis enables new dimensions 
bioprocessing, characterizations, and separations. Each of these example processes 
can be performed on individual microdevices or combined together into one device 
to achieve multistep bioprocessing. Devices such as these are referred to as lab-on-a-
chip and are increasingly more prevalent due to reduced costs and user-friendly 
operation. Lab-on-a-chip microdevices have already been developed to achieve cell-
based assays like cell migration, proliferation and cell-to-cell signaling [58], and 
could be extended to quickly and effectively separate hMSCs.  
The strategic combination of dielectrophoresis and microfluidic technology is 
a powerful tool to study cellular behavior because the microdevice can facilitate 
beneficial micro-environments for the cells. Other advantages to microdevices that 
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incorporate dielectrophoretic phenomena are precise control on applied external or 
chemical forces, no mechanical parts necessary, small reagent consumption, rapid 
response time, reduced risk of sample contamination, higher reliability, 
reproducibility, low cost and the ability to run multistep processes in series or 
parallel on one device [16]. Many microdevices are being developed that incorporate 
both electrokinetic and microfluidic technologies that enable property measurements 
of specific biological cell systems and stem cells are an underexplored area in this 
field. Thus, this work explores the utility of electrokinetic and microfluidic 
technology as a solution to the challenges with current hMSC cell population 
purifications.  
1.5 Dielectrophoretic Microfluidic Devices and Diabetes Treatment 
To summarize, hMSCs are a potential therapeutic treatment for diabetes 
mellitus. The main challenge associated with hMSCs and other types of stem cells is 
the lack of a rapid, simple method to purify desired subpopulations from 
heterogeneous cell samples without altering cell function or reducing cell viability 
[40]. Also, hMSCs are a newly explored cell system so explorative studies are 
underway to understand their diverse functions within the body.  Further, a database 
has not yet been developed to correlate cell surface biomarkers to differentiation 
behaviors or cell types. A microfluidic device utilizing DEP to discern differences in 
cell dielectric properties (and thus surface biomarker expression) has the potential to 
resolve the purification problems associated with hMSCs.  
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Therefore the objectives of this body of work is to: 
Objective 1: Characterize the dielectrophoretic response of hMSCs to determine the 
DEP spectra including the cross-over frequency.  
Objective 1a:  Standardize hMSCs morphology with ELP-PEI to 
reduce size-dependent DEP variations. Characterize the DEP spectra 
of ELP-PEI treated hMSCs, then compare to native hMSCs in order 
to identify conditions for cell separations.  Subpopulation variations 
are expected to be based on molecular level expression. 
Objective 2: From the experimentally derived DEP spectra obtained in Objective 1, 
model the dielectric properties of human mesenchymal stem cells using MATLAB 
and the Core-Shell Spherical DEP Polarization models.  Use these models to 
calculate the dielectric properties of hMSCs.  
Objective 2a: Correlate these properties with known phenotypical 
molecular expressions of hMSCs. 
Objective 2b: Compare dielectric properties with other cell systems. 
Objective 3: Develop a new frequency sweep rate data collection technique for rapid 
compilation of the frequency dependent DEP spectrum. Optimize sweep rate 
parameters with polystyrene beads and verify on red blood cells.  
The two themes of this dissertation are to establish the dielectric signature of 
the novel hMSCs biological system and develop an alternative DEP experimental 
characterization and ultimately separation technique. The next chapters are literature 
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reviews on hMSCs (Chapter 2) and dielectrophoresis (Chapter 3). The DEP spectra 
for hMSCs were determined and ???????membrane???membrane, and Cmembrane (dielectric 
properties) were quantified in Chapter 4. ELP-PEI was used to standardize hMSCs 
morphology and the effects of the polymer treatment were also explored in Chapter 
4. This portion of the work demonstrates the first steps necessary toward the
development of a continuous cell sorting microdevice. Chapter 5 demonstrates the 
development of a new rapid DEP data collection technique with semi-automated data 
analysis tested on polystyrene beads and red blood cells; a patent disclosure has been 
filed on this work, with the full patent application to be submitted in July 2014. 
Finally, conclusions and a summary of the main findings of this work are 
summarized in Chapter 6. A side project not central to the theme of this dissertation 
was completed and published as a book chapter – this is included as Appendix A. 
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1Chapter 2 Human Mesenchymal Stem Cells and Type 1 
Diabetes 
2.1 Key Properties of Human Mesenchymal Stem Cells 
Stem cells are distinct unspecialized cells classified as embryonic or somatic 
(adult) and are of interest due to their ability to differentiate into specific cell types 
[1-3]. Embryonic stem cells are derived from embryos and somatic stem cells 
(mesenchymal, hematopoietic, neural, epithelial, and skin) are derived from other 
cells in the body excluding gametes. Stem cells are characterized by their 
differentiation potential with totipotent cells, being capable of differentiated into all 
cell types; pluripotent stem cells being capable of differentiating into almost all cells 
types; human embryonic stems cells most strongly demonstrate pluripotency. 
Somatic stem cells are multipotent meaning they only differentiate into closely 
related families of cells. Human mesenchymal stem cells (hMSCs) are somatic and 
ideal to work with because they are readily obtained from bone marrow and they 
have the ability to self-renew while undergoing differentiation [2]. hMSCs are an 
abundant source of cells found in various locations in the body including the 
umbilical cord [4-6], adipose tissue [4, 5, 7, 8], synovium [5, 7, 9, 10], periosteum [5, 
11, 12], and dental pulp [5, 13, 14]. hMSCs have the potential to differentiate into 
osteoblasts (bone cells), adipocytes (fat cells), chondrocytes (cartilage cells), 
1 The material contained in this chapter will be submitted for publication. 
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astrocytes (neural cells), myoblasts (muscle cells), and Langerhans islets (pancreatic 
cells) based on environmental promoters [2, 13, 14].  
Presently there is not a database of unique biosurface markers that distinctly 
defines hMSCs or their progeny [9, 15, 19-22], which is necessary for cell separation 
and purification to occur after sample isolation from the body. As a result, 
researchers have minimal understanding of the biological mechanisms that hMSCs 
display in therapeutics. Samples of hMSCs are isolated from bone marrow as 
heterogeneous mixtures [15]. In order for hMSCs to be highly efficient in cell 
therapy, isolated cells need to be purified. Therefore, new technology is needed that 
can accurately characterize hMSCs subpopulations and virility as well as reveal more 
information about their cellular function and biological mechanisms. Before 
proceeding to the technology for separating hMSCs, this chapter will review hMSCs 
key physical properties, elastin-like polypeptide polyethyleneimine (a morphology 
standardizing agent), current hMSC separation technologies, type 1 diabetes 
background, and set the foundation for dielectrophoresis as an alternative and 
superior separation technology.  
2.1.1 hMSC Self-Renewal, Differentiation Potential And Trophic 
Activity 
hMSCs are characterized by three key properties: (1) ability to self-renew, (2) 
trophic activity, and (3) differentiation potential, all of which are critical to their 
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therapeutic potential. Figure 2.1 illustrates the three key properties of hMSCs and 
each is discussed separately in the following paragraphs.  
Self-renewal is the process that hMSCs go through to create new stem cells 
[16]. Specifically, during self-renewal hMSCs divide to generate daughter cells with 
the same developmental potential as the mother cell. This property is not unique to 
stem cells, many cell types have similar self-renewal capabilities. There are two 
mechanisms for hMSC self-renewal division, symmetric and asymmetric [17]. 
During mitosis, the internal organelles of cells are equally parsed between two 
daughter cells to achieve symmetric division. The daughter cells have identical 
characteristics to the mother cell. In contrast, asymmetric division is the unequal 
parsing of cellular internal organelles between two daughter cells, resulting in 
cellular polarization [18]. The daughter cells display different characteristics from 
the mother cell. hMSCs continually undergo self-renewal [18]; differentiation into 
other cell types can concurrently occur.   
Potency describes stem cell’s ability to differentiate into other cell types. 
Cells are typically classified into one of three important levels of potency: totipotent, 
cells develop into any cell type; pluripotent, cells can form most cell types with the 
exception of placental tissues; and multipotent, cells can differentiate into many cells 
types, i.e. totipotent > pluripotent > multipotent [2]. The more potent a cell is, the 
more versatile and valuable it is for medical treatments. hMSCs are multipotent and 
differentiate into adipocytes, osteoblast, chondrocytes, and many other cells types 
[2]. For stem therapeutics, hMSCs can be selectively differentiated into specific cell 
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types using growth factors. Controlling and subsequently purifying hMSC-derived 
cell types enables tailored autologous hMSCs disease treatment, are from and used to 
treat the same individual, disease treatments [3]. For example, osteogenic 
differentiation of hMSCs is accomplished by supplementing cell culture media with 
dexamethasone, ascorbic acid, ?????-glycerolphosphate [19]. Adipocytes have been 
produced by treating hMSCs cell culture media with insulin, dexamethasone, 
isobutyl methyl xanthine, and rosiglitazone [20, 21]. There is a different protocol 
utilized to direct hMSCs differentiation toward specific cell types. This type of cell 
manipulation can and has been implemented to make hMSCs an attractive cell 
source for diabetes mellitus treatment, as discussed in section 2.3. 
The third key property of hMSCs is trophic activity, which is their ability to 
migrate to sites of injured tissues or to participate in response to injury by secreting 
growth factors [22]. Some examples of growth factors that hMSCs secrete are 
granulocyte colony-stimulating factor (G-CSF), a glycoprotein that stimulates bone 
marrow to produce granulocytes and stem cells and release them into the blood; 
leukemia inhibitory factor (LIF), a protein that influences cell growth; and 
transforming growth factor-beta 2 (TGF-???, a protein that performs many cellular 
functions [23-25]. Figure 2.1 illustrates the three key properties of hMSCs. 
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Figure 2.1 Important properties of hMSCs (a) trophic activity, (b) self-renewal, and 
(c) differentiation potential. Adapted from [2, 18, 23].  
2.1.2 hMSC Morphology 
hMSC morphology must be carefully considered when designing a 
microdevice to employ dielectrophoretic cell purification. According to Haasters et 
al., hMSCs can be assigned three morphological subpopulations: (a) rapidly self-
renewing cells, triangular or star-like shape; (b) elongated, fibroblastic-like, spindle-
shaped cells; and (c) slowly-replicating, large cuboidal or flattened cells [26]. Figure 
2.2 shows microscope images of these subpopulations. The observed morphology is 
dependent on the cytoskeleton, cell adhesion, and active pathways; therefore the 
cell’s morphology reveals information about cell fate and differentiation [26].  
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2.1.3 Elastin-Like Polypeptide Polyethyleneimine 
 To reduce variation in hMSCS morphology, elastin-like polypeptide (ELP) 
polyethyleneimine (PEI) was explored, and this cell shape variation reduction will 
assist with hMSCs separation. ELP-PEI is a postively charged block copolymer that 
directs cell morphology to a spheroidal shape. ELP is synthesized from amino acids 
valine, proline, and glycine, and has been previously used to produce H35 rat 
hepatocyte spheroids.  ELP-PEI has also been used in studies to determine the affects 
of free fatty acids and cytokines in 2D and 3D rat hepatoma cell cultures [27, 28].  
The affects of ELP-PEI on hMSCs are described in Chapter 4. 
Figure 2.2 hMSCs morphological subpopulations (a) rapidly self-renewing, star like 
shape, (b) elongated fibroblastic-like spindle shaped cells, and (c) slowly-replicating 
flattened cells. Reprinted with permission from [26].  
2.1.4 hMSCs Surface Biosurface Markers 
Additionally, hMSCs can be characterized by a variety of surface proteins, 
which are major determiners of the cell phenotype, or the expressed individual cell 
characteristics. Scientists have extensively studied hMSCs phenotypes, but scientific 
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publications do not provide a consistent catalog of surface proteins expressed on 
hMSCs surfaces. Currently, there is not a panel of unique surface proteins capable of 
characterizing hMSCs or distinguishing them from other cells. Flow cytometry has 
been used as a means to determine the phenotype of hMSCs using CD surface 
proteins. CD stands for cluster of differentiation and is the standard system by which 
newly discovered surface proteins are named [29].  
Karaoz et al., conducted immunophenotyping on hMSCs using fluorescent 
tags for the following surface proteins CD3, CD4, CD5, CD7, CD8, CD10, CD11b, 
CD13, CD14, CD15, CD19, CD29, CD34, CD44, CD45, CD71, CD73, CD90, 
CD106, CD117, CD123, CD146, CD166, HLA-DR, HLA-ABC, and HLA-G. The 
results of this immunophenotyping yielded that hMSCs positively expressed CD10, 
CD13, CD29, CD44, CD73, CD90, CD106, CD146, CD166, and HLA-A,B,C. The 
hMSCs did not express the other 18 surface proteins examined (CD3, CD4, CD5, 
CD7, CD8, CD11b, CD14, CD15, CD19, CD34, CD45, CD71, CD90, CD106, 
CD117, CD123, HLA-DR, and HLA-G). Other researchers have done similar studies 
looking at the phenotype of hMSCs and Table 1 summarizes their findings. The 
proteins summarized in Table 1 are those that researchers had prior knowledge of 
and are not meant to be all-inclusive. The major conclusions from Table 1 are that 
hMSCs have a diverse phenotype with varying numbers and types of proteins 
expressed on their cell membrane surface. Figure 2.3 cartoons this phenotype 
diversity in hMSCs within one population; all cells do not exhibit the same surface 
proteins creating subpopulations. Further, a different technology is needed that can 
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provide an alternative measure to distinguish hMSCs from other cells. Since there is 
not one unique surface protein, or group of proteins for hMSCs, it is advantageous to 
explore opportunities with dielectrophoresis that utilizes an electrical signature 
versus a protein signature.  
Table 2.1 Summary of the hMSCs immunophenotyping [15, 30-33]. 
Function Marker hMSCs 
Cell Adhesion Molecule CD44, CD54, CD106, 
CD146, CD90 
+ 
Bone Metabolism/ 
Mineralization 
Osteonectin, 
Osteopontin, 
Osteoprotegerin, 
Osteocalcin  
- 
Bone Mineralization Biglycan - 
Structural Protein of 
Cartilage 
Procollagen-1, Collagen-I, 
Collagen-III, Collagen-V, 
Collagen-VI 
- 
Structural Protein of 
Cartilage 
Collagen-II, Collagen-IX, 
Collagen-X, Aggrecan, 
Decorin 
- 
Glycoprotein CD9, CD59, CD161  + 
Integrin CD29, CD73  + 
Leukocyte Antigen HLA-A, HLA-B, HLA-C + 
Anti-adhesive Molecule Veriscan - 
Activated Leukocyte CD166  + 
CALLA CD10  + 
TGF-?????????? CD105  + 
????-????????????? CD55  + 
Aminopeptidase ??????????? CD13 + 
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Figure 2.3 Illustration of differentiation surface proteins present within one hMSCs 
population [33, 34]. 
At this point, the three main properties of hMSCs that make them ideal
candidates for stem cell therapeutics, differentiation capacity, self-renewal, and 
trophic activity have been described. However, there is not one single or 
combination of unique physical hMSC properties that make them easily identifiable 
after bone marrow isolation. To achieve this goal, the International Society for 
Cellular Therapy put in place minimum requirements to label a cell population as 
hMSCs, which are [1, 34]: 
1) Plastic adherence,
2) Positive expression of CD105, CD73, and CD90,
3) Negative expression of CD34, CD45, CD11a, CD19, CD14, and HLA-DR,
4) Adipogenic, osteogenic, and chondrogenic differentiation potential.
The plastic adherence is a general property common in many cells and the specific 
surface proteins listed overlap with other cells, like hematopoietic stem cells. 
Further, it isn’t possible to identify the propensity of individual cells toward the 
specialized cell type.  Therefore, a more descriptive property would be beneficial for 
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hMSC characterization and a separation tool to achieve quantification of the property 
would empower researchers to tailor cell populations for therapies. 
The currently known mechanical and electrical properties of hMSCs are 
discussed in the following section.  Knowledge of these key properties is critical for 
any hMSCs purification and identification efforts.   
2.1.5 hMSCs Mechanical Properties 
Mechanical properties typically measured on cells include elasticity, 
viscoelasticity, and strength (Young’s modulus, tensile, compression, and stiffness). 
Thus far, hMSCs mechanical property studies have been dominated by elastic, 
viscoelastic, and Young’s modulus measurements. These properties are exploited for 
separation and are important for therapeutic considerations. Elasticity is the measure 
of a cells tendency to return to its original form after deformation, similarly in 
viscoelasticity cells exhibit viscous and elastic characteristics under deformation 
[35]. In reviews [36-40], it’s been concluded that the viscoelastic behavior of 
biological cells plays an important role in biophysical and biological responses to 
stimuli.  
The goal of outlining the viscoelastic properties here is to demonstrate that 
hMSCs have unique physical properties that are useful for characterization and lends 
support to hMSCs having unique electrical markers. In the study completed by 
Darling et al. [35], the elasticity and viscoelasticity of two hMSC morphologies were 
examined: spherical and spread star-like. Spherical hMSCs deformation was 
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measured at the cell’s center, and the spread-like hMSCs deformation was measured 
over the cell’s nucleus.  The spread star-like hMSCs studied here are similar to those 
in Figure 2.2a, and the results are summarized in Table 2.2.  
Table 2.2 Elasticity and Viscoelasticity of hMSCs with spherical and spread star-like 
morphologies [35].  
Morphology Cell Type n Elasticity (kPa) Viscoelasticity (kPa) 
Spherical  hMSC 53 2.5 ± 1.8 0.47 ± 0.52 
Spread Star-like hMSC 67 3.2 ± 2.2 2.2 ± 1.9 
From Table 2.2, the elasticity for each hMSC morphology tested was a 
similar order of magnitude, 2.5 kPa (spherical) versus 3.2kPa (spread star-like). 
However, the viscoelasticity changed by an order of magnitude, from 0.47kPa 
(spherical) to 2.2kPa (spread star-like).  Titushkin et al. [41] corroborated hMSC 
spread star-like morphology with atomic force microscope indentation, and found the 
Young’s Modulus to be 3.2kPa.  
Just as growth factors can be added to cell culture media to direct hMSCs 
differentiation, Kim at al.[42], found that hMSC populations are sensitive to 
mechanical vibrations. Stimulation at 30Hz and 0.3g of acceleration induces 
osteogenic differentiation. This mechanical vibration increased the alkaline 
phosphatase activity and calcium depositions, which are consistent with osteoblast 
differentiation. Similarly, Subramony et al. [43], coupled nanofiber alignment with 
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tensile loading to induce fibroblastic differentiation. Controlling hMSCs 
differentiation using mechanical or other cues after purification is a powerful tool 
that can be utilized in hMSC therapeutics.  
Lastly, supporting evidence by Alexopoulos et al. [44] and Guilak and Mow 
[45], illustrate that the mechanical properties of cells can affect their physical 
interactions with surrounding extracellular matrices (ECM). ECM is a complex 
arrangement of polysaccharides and proteins secreted by cells for structural support 
[29]. The interaction of hMSC derivatives with ECM is an important consideration 
as these cells move toward therapeutic applications. 
These results show that mechanical properties may serve as a basis of 
characterization for cell subpopulations without necessitating cell tagging. The 
disadvantage to using elasticity measurements is that they may serve as a mechanical 
cue that triggers differentiation. Thus, mechanical characterizations can be classified 
as a more invasive tool. Further, it is necessary to perform individual cell mechanical 
property measurements in order to identify subpopulations prior to separation.  The 
tools to conduct these individual cell measurements followed by separation do not 
currently exist. In slight contrast, electrical measurements can determine similar 
properties as mechanical, but are much more amenable to being conducted on 
individual cells.   
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2.1.6 hMSCs Electrical Properties 
The measurement of hMSC electrical properties, and their link to physical 
properties has included impedance measurements. In the last 20 years, minimal 
literature has been published on hMSCs electrical properties. For example, a search 
of ‘human mesenchymal stem cells electrical properties’ in Web of Science yields 
only 24 articles; only two articles directly measure hMSCs electrical characteristics. 
The remaining articles relevant to hMSCs can be categorized in the following 
manner: biocompatible materials (applications in scaffolds, nanofilms, nanotubes, 
polyimide electrodes) [46-50], electrical stimulation (to monitor membrane 
mechanics and calcium dynamics) [51-53], and hMSC differentiated progeny 
impedance measurements [54-56]. The most relevant publications to this dissertation 
involve impedance measurements of the hMSCs and are more reviewed in this 
section. 
Impedance is a measure of the opposition to AC current flow in a circuit.  
When cells or cell suspensions are embedded into the circuit, information can be 
acquired about cell function and morphology. Hildebrandt et al., used impedance as 
an hMSC osteogenic differentiation indicator, and found that undifferentiated 
hMSCs and osteocytes have different impedance values, as reproduced in Figure 
2.4a. The impedance of undifferentiated hMSCs is particularly relevant to this 
research; hMSC suspensions in cell culture media (roughly 1.7 S/m) yield impedance 
values of 7.5-7.9 x104??????????????-1.3MHz [55]. Cho et al., also used impedance 
to monitor hMSC differentiation but was interested in adipocytes rather than 
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osteocytes. Cho’s work corroborates Hildebrandt’s by also demonstrating an increase 
in impedance for hMSCs derived adipocytes as reproduced in Figure 2.4b; average 
hMSC impedance was ????? [54]. It’s important to note that while these studies
quantify an electrical property of hMSCs, that property is not translatable to cell 
separations.  Impedance is a sensor tool, but does not induce any motion so is not 
amenable to use as a separation technique. These experimentally determined 
impedance values are correlated to hMSCs membrane capacitance in Chapter 4 as a 
comparison to our own hMSC experimental work. 
Figure 2.4 Impedance measurements for (a) [55] undifferentiated hMSCs (red) and
osteocyte differentiated hMSCs (blue) (yellow is a nonrelated mikrozid liquid 
treatment to induce cell necrosis), and (b) [54] undifferentiated hMSCs (labeled
control) and adipocyte differentiated hMSCs (labeled differentiation). Impedance 
increases in differentiated cells indicating differing morphology and physiological 
properties from the mother cells.  Reprint permission requested from [54, 55].  
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This review has thus far been restricted to hMSCs.  However, other electrical 
measurements have been performed on other stem cell lines.  Stem cell 
dielectrophoretic measurements are organized into Chapter 3, section 3.5 for 
continuity purposes.  
In summary, there are no direct measurements of hMSCs membrane 
capacitance and permittivity, which are key properties for designing cell separations. 
This dissertation research seeks to fill this gap in knowledge by quantifying hMSCs 
membrane capacitance and permittivity using dielectrophoresis, a noninvasive 
electrical tool capable of cell translation and thus cell population sorting.  Further, a 
polymeric membrane treatment, ELP-PEI is utilized to reduce hMSCs morphology 
variations in order to better isolate the contributions from mechanical and electrical 
properties and thus yield a more efficient hMSC purification technique for type 1 
diabetes therapeutics.  
2.2 Human Mesenchymal Stem Cells Separation Technology 
2.2.1 Research Motivation Statement 
hMSCs therapeutics are especially important for the continued advancement 
of medicine due to their differentiation capacity, self-renewal, and trophic activity. 
Highly purified hMSC samples are necessary for therapies to be effective and 
efficient.  Thus, separation after bone marrow isolation is critical and has relied upon 
flow cytometry and centrifugation. The following subsections describe current 
technologies that are used to separate hMSCs from heterogeneous cell populations. 
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Current technology disadvantages leave room for improvement and provide a 
motivation to explore other separation techniques. 
Current hMSCs separation techniques can be generalized into two categories: 
affinity-based and physical-based.  Affinity-based techniques utilize hMSCs 
biological properties, like membrane surface proteins (CD’s), to selectively purify 
the cells. Technologies that implement this separation scheme are fluorescent-
activated cell sorting (FACS) and magnetic-activated cell sorting (MACS).  
Physical-based techniques, like density gradient centrifugation, utilize hMSCs size 
and plastic adherence to achieve separations.   
2.2.2. Fluorescent and Magnetic Activated Cell Sorting for Cell 
Separations 
Fluorescent-activated cell sorting (FACS) and magnetic-activated cell sorting 
(MACS) are separation techniques employed after hMSC extraction from the body 
and cell culture to then achieve purification. FACS uses unique cell-surface antigens 
as recognition elements to tag target cells. This cell labeling alters cellular function, 
which is not desirable for medical applications [57]. More specifically, FACS is a 
specialized type of flow cytometry that uses a laser beam to capture emergent light 
from passing cells. Based on the signal, fluidics are used to direct and sort cells into 
channels. The data collected reports information on cell size, complexity, phenotype, 
and health [58]. FACS has six main components: fluidic, laser, optic, detector, 
electronic and computer system.  
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In a typical hMSC separation, cells are first labeled by incubating them with 
fluorescent conjugated antibodies (CD34, CD45, CD73, CD105 and CD166; 
conjugated with phycoerythrin or fluorescein isothiocyanate) [59] and then 
transported through the fluidic system for single cell laser analysis (for accurate data 
collection) via mechanical vibrations and hydrodynamic focusing [60]. The 
individual cells pass through the laser causing light to scattering in two ways: 
forward light scatter, where light is sent in the forward direction as it hits a cell; or 
side light scatter, where light is sent at a 90° angle from the cell.  Side scatter is 
caused by cell granularity and structural complexity [61]. Forward and side light 
scatter provide a one-dimensional and two-dimensional graphical representation of 
cell population, respectively [62]. Separate detectors translate the scattered light 
intensity into a voltage pulse, which is proportional to cell size. In the final step, 
hMSC FACS separations involve directing the cells into channels based on the 
scattered light signal.  The fluidic stream containing the laser-interrogated cells flows 
past electrodes that selectively activate to induce cell electrophoretic motion so the 
cells can be selectively collected in separate tubes. FACS enables multiparametric 
analysis of hMSCs [63-65]. Figure 2.5 illustrates the FACS system.  
There are some disadvantages associated with using FACS for separation 
including low throughput of 5000-70,000cells/s [58], high cost ($75,000+) [66], 
large electronic system (Becton Dickson FACSJazz, 125lbs, 21x20x20in) [67], 
skilled technician necessary for operation [60], sample contamination risk (due to 
sample preparation) [66], processing time (3-6hrs) [58], altered cell function/viability 
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from antibody tagging [68]. Nevertheless, this method is one of the best available 
and has been used to successfully separate hMSCs by many researchers [69-73]. 
Figure 2.5 (a) Schematic of Fluorescent-Activated Cell Sorting and (b) illustrates 
labeling of two hMSCs progenitor cells. Adapted from [63-65]. Cells of interest are 
labeled with antigens and separated based on charge. 
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MACS uses the same separation principles as FACS whereby target cells are 
labeled with antibodies (anti-immunoglobulin, anti-biotin, streptavidin, or anti-
fluorochrome) conjugated with magnetic beads approximately 50 nm in size [74]. 
The cells are labeled through incubation that lasts approximately 30 mins [75]. After 
incubation, the cell suspension goes through a steel column placed in a magnetic 
field that impacts the magnetic beads bound to the cell surfaces. Cells are either 
positively or negatively selected based on the magnetic beads attached to the cell 
surface antibodies.  Labeled cells stay in the column while the magnetic field is 
applied [76]. With the magnetic field on, the nonlabeled (unattached) cells pass 
through the column and are collected in a test tube; once the magnetic field is turned 
off, the labeled cells are eluted from the column and collected in a separate test tube 
[74, 75]. Figure 2.6 shows a schematic of the MACS system. 
The advantages to using MACS are high throughput [76], easy use [58], and 
lower cost than FACS [60]. The disadvantages associated with this separation 
technique are cell labeling alters cell function [57] and long process time [77]. 
Despite the drawbacks, MACS has been widely implemented as a separation method 
for hMSCs population control [78-82]. 
To summarize, FACS and MACS can achieve hMSC separation based on 
biosurface marker membrane expression; this approach is referred to as 
immunophenotyping [58]. FACS and MACS are widely used because there is not a 
better alternative.  The disadvantages associated with them, namely cost, throughput 
and altered cell function, are widely acknowledged and underscore the need for 
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improvements in cell separation. Microfluidic devices utilizing dielectrophoresis are 
technologies with the ability to discern cell types without any chemical labeling and 
without altering cell function [57].  These tools are explored within this work to 
improve hMSC, motivated in part by the success of other cell separations for clinical 
applications [83]. Before discussing dielectrophoresis in detail (Chapter 3), other 
separation techniques that do not incorporate cell antibody labeling are reviewed.   
Figure 2.6 (a) Schematic of Magnetic–Activated Cell Sorting, and (b) cell labeled
with magnetic beads, (c) unlabeled cell. Adapted from [74-76]. Target cells are 
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labeled with antigen conjugated magnetic beads and with magnetic field on labeled 
cells are retained inside column, unlabeled cells pass through.  
2.2.3 Density Centrifugation and Membrane Filtration 
Density centrifugation is another separation technique employed to extract 
select hMSCs from a heterogeneous cell population. This method separates hMSCs 
from other cells based on their cellular density. A centrifuge tube is prepared by 
layering Percoll or Ficoll-Paque solutions from high density at the tube bottom to 
low density at the top, producing a gradient. After the gradient is poured, an hMSC 
suspension is placed in the centrifuge tube on top of the Percoll and centrifuged. 
During centrifugation, hMSCs migrate through the gradient until each cell reaches its 
isopycnic position [58], the position where the solution density equals the cell 
density. Increasing the number of density gradient layers increases separation 
efficiency [84].  
Disadvantages with this method include: a) fluctuations in pH and osmolarity 
of density gradient solutions, which  affect cell viability (changes may kill or reduce 
cell efficacy) [58], b) density gradient preparation is laborious and tedious (layering 
in centrifuge tube) [85], and c) low selectivity (this is mainly employed as a 
preparative step before other separation methods are employed) [60].  
Another physical based separation technique that has been used for hMSC 
separation is membrane filtration. This technique has been employed due to its fast 
processing time, easy use, and low cost.  Separations are achieved based on cell size 
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and affinity for adherence to a membrane surface [8, 86], as illustrated in Figure 
2.7a. A membrane composed of rayon and polyethylene has been successfully used 
to filter hMSCs from mononuclear cells [87] as reproduced in Figure 2.7b. 
Figure 2.7  (a) Schematic of density gradient centrifugation [86] and (b) electron 
micrograph of nonwoven rayon and polyethylene with hMSCs attached. Permission 
requested for reuse [87].  
The main objective of each of these technologies is to enrich hMSCs after 
bone marrow isolation. Each of the separation methods mentioned above have 
disadvantages that reduce efficiency in processing hMSCs for therapeutics, thus 
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leaving room for improvement in hMSCs separation.  Therefore, dielectrophoretic 
(DEP) microdevices are explored in this research as an alternative separation 
method. A review of DEP microdevice systems is given in Chapter 3 before 
presenting the experimental results of this dissertation (Chapter 5 and 6). In 
conclusion, the technology employed for hMSCs purification needs to be dynamic 
for scalability for higher throughputs and achieve high resolution for clinical 
therapeutic applications (one application is reviewed next), which require high 
concentrations of pure hMSCs. 
2.3 Type 1 Diabetes Mellitus 
2.3.1 Definition 
Globally, there are 16,000 new cases of type 1 diabetes diagnosed each year 
[88]. Type 1 diabetes mellitus is a chronic autoimmune disease that diminishes the 
body’s ability to produce the insulin hormone [89], as a resultant of beta cell 
destruction in the pancreas [90] as illustrated in Figure 2.8. Autoimmune diseases are 
ones where the immune system perceives the body’s own cells as foreign and 
destroys them [91]. The beta cells are specialized cells in the body that produce 
insulin in direct proportion to glucose in the blood stream [92]. The mechanism 
responsible for this autoimmune destruction of beta cells is currently unknown, but it 
leads to absolute insulin deficiency mediated by the immune system or it may be 
idiopathic [89].  This autoimmune destruction of beta cells in Type I is very different 
from Type II diabetes where food and body habits disrupt the balance and slowly 
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wear out the functionality of the beta cells. hMSC therapies for autoimmune diseases 
are effective because they can replace destroyed cells and sometimes avoid being 
recognized as foreign by the immune system. 
At the center stage of this disease is insulin production. The pancreas, a gland 
behind the stomach, secretes insulin into the blood stream and the insulin controls 
the amount of glucose in the blood via metabolic reaction pathways. Glucose is 
necessary for cells and tissues through the body to get the energy they need; an easily 
metabolized source of energy for the cells come from glucose consumed through 
food (bread, pasta, milk, rice, etc.). In type 1 diabetes, there is not enough insulin 
present to metabolize and transport the glucose from the blood into cells therefore, 
blood glucose concentrations increase causing complications [93]. 
Figure 2.8 Schematic of Type 1 Diabetes (a) normal functioning pancreas and (b) 
diminished pancreas function, beta cells destruction. Beta cells within the pancreas 
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do not produce the insulin necessary to reduce glucose concentrations in blood [89, 
90]. 
Although the mechanism is unknown, researchers have tried to determine 
genetic predispositions to type 1 diabetes. 80% of children with IPEX (immune 
dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), characterized 
by a mutation in the Foxp3 transcription factor (protein involved in regulating the 
immune system [94]), develop type 1 diabetes [95-97]. Another gene mutation 
example is with autoimmune polyendoocrine syndrome type 1, qualified by a 
mutation in the AIRE transcription factor, resulting in 20% of children with this 
disease developing type 1 diabetes [98]. Other gene mutations that have shown 
susceptibility to type 1 diabetes are HLA (human leukocyte antigen) [99], INS 
(insulin) [100], PTPN22 (protein tyrosine phosphatase, non-receptor type 22) [101], 
IL2RA (interleukin-2 receptor alpha chain) [102], and CTLA-4 (cytotoxic T-
lymphocyte antigen 4) [103]; all of these genes are associated with the function of 
the immune system.  
Environmental factors have also been explored to understand more about 
type 1 diabetes. Data suggests that viral infections may precipitate type 1 diabetes, 
and correlations have been made between coxsackievirus (CVB4) [104], a virus that 
lives in the digestive tract and is a subset enterovirus. Increased amounts of 
neutralizing antibodies as a result of CVB4 were found in patients newly diagnosed 
with type 1 diabetes [105], and was confirmed with PCR (polymer chain reaction) 
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genetic matching [106]. Yoon et al. [107], demonstrated with mouse subjects that 
CVB4 can infect beta cells causing insulitis and diabetes.   In addition, Yoon also 
isolated CVB4 from a child with recent type 1 diabetes onset [108]. A contrasting 
study looked at the Pribilof Islands in Alaska after a CVB4 epidemic, and found that 
type 1 diabetes incidence was similar between infected and uninfected individuals 
[109], suggesting no connection between the diseases. Testing in the Finnish 
population provided positive links between individuals with enterovirus and type 1 
diabetes [110, 111]; this is corroboration in Figure 1.1 where incidence in Finland is 
greater than 24%. Other viral infections linked to type 1 diabetes are rotavirus [112], 
cytomegalovirus [113, 114], parvovirus [115], and encephalomyocarditis [116], 
although all of these still need to be confirmed in larger patient populations [117].  
Evidence has also shown that antibiotic and probiotic consumption may alter 
the gastrointestinal tract microbiota creating imbalance, which may lead to type 1 
diabetes depending on intestinal composition [118]. It has also been found in the 
Sardinian population, that mycobacterium avium subspecies paratuberculosis, shed 
in infected cow’s milk, was present in type 1 diabetes patients confirmed with blood 
tests [119]. In conclusion, there is growing evidence that links gene mutations, 
viruses, and bacteria to autoimmune disruption that causes type 1 diabetes.  These 
factors and others require more exploration. 
Although concrete factors that contribute to types 1 diabetes are still under 
investigation, diagnosis is well understood and completed via blood glucose 
assessments. A person with type 1 diabetes is characterized as having a casual blood 
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glucose level >200mg/dL, fasting blood glucose level ?126mg/dL, or blood glucose 
level >200mg/dL 2 hours after eating [89]. Currently, type 1 diabetes management 
requires insulin pens, shots, or pumps [120, 121]. Type 1 diabetes complications 
include cardiovascular disease [122], neuropathy (nerve damage) [123], nephropathy 
(kidney damage) [124], retinopathy (eye damage) [125, 126], osteoporosis (bone 
degradation) [127], hearing impairment [128], and high-risk pregnancies [129].   
2.3.2 hMSCs as a Type 1 Diabetes Treatment Option 
Currently, there is no cure for type 1 diabetes, and the various complications 
necessitate the need for a curative therapeutic option, which is much more than 
simply an insulin management strategy. An effective cure will preserve remaining 
beta cells [130], and protect newly produced beta cells from autoimmune destruction 
in the pancreas [34]. Demonstration of this beta cell replacement therapy concept has 
been achieved through human pancreas transplantation in type 1 diabetes patients, 
which reestablished their insulin-independency [130]. However, this method cannot 
be widely implemented for all type 1 diabetes patients due to the number organs 
necessary to cure all patients. Further, organ transplant approaches are extremely 
invasive, autoimmune rejection of transplanted organs must be carefully managed to 
avoid rejection or death and combined leads to exorbitant medical bills.  Thus, 
researchers have explored hMSCs as a much less invasive therapeutic option for beta 
cell replacement therapy.  
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hMSCs were transplanted into diabetic immunodeficient mice following 
which the mice’s beta cell numbers and insulin levels increased [131, 132]. Another 
animal model conducted by Ho et al., induced mice with diabetes using streptozocin 
to kill the beta cells and then subsequently treated them with multiple high MSC 
(non-human) concentrated injections. Multiple MSC injections were used because 
blood glucose homeostasis was not established after a single injection. Multiple 
injections gradually stabilized blood glucose to normal levels [133].   
Others have employed chemical based methods and found that hMSCs 
differentiate into insulin producing cells [134-136], and those cells are able to release 
insulin in a glucose-dependent manner [137]. MSC differentiation toward insulin 
producing cells is mediated with additives in the cell culture procedure.  Hisanga et 
al. [138], used activin A and betacellulin to direct murine (rat) MSCs differentiation; 
insulin producing cells were detected within 14 days of additive addition. Genetic 
modification with pancreatic duodenal homeobox-1 has also been used to 
differentiate hMSCs toward insulin producing cells [139, 140].  
In summary, there are multiple methods, chemical and genetic modification, 
in place to differentiate hMSCs toward insulin producing cells for type 1 diabetes 
therapeutics. Additionally, hMSCs without directed differentiation toward insulin 
producing cells have also been used to improve diabetic condition, thus implicating 
hMSCs differentiate into insulin producing cells without external stimulus inside the 
body. These methods all indicate that a type 1 diabetes cure with hMSCs is possible, 
and present evidence that efficient cell purification is necessary for such therapeutic 
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interventions. This provides exciting motivation to implement nondamaging 
dielectrophoretic microdevice-based separations for hMSC purification. 
2.4 Conclusions 
hMSCs hold high promise as a therapeutic treatment option for type 1 
diabetes due to their differentiation ability, replenishing capacity, and their trophic 
activity. They have been shown to differentiate into insulin producing cells through a 
variety of methods: chemical, genetic, and undifferentiated. hMSCs are easily 
obtained from bone marrow as a heterogeneous population and therefore require 
separation before utilization in type 1 diabetes therapeutics. Within a single hMSC 
population, there are a variety of progenitor cells present (adipogenic-progenitor, 
osteogenic-progenitor, chondrogenic-progenitor, etc.) and these cells have a 
propensity to differentiate toward a specific cell type. Additionally, hMSCs are not 
well characterized because there is not a unique set of biosurface markers available 
that distinguishes hMSCs from other cell populations. To compensate, current 
methodologies utilize density centrifugation paired with either FACS or MACS to 
achieve hMSC subpopulation separations. These methods are disadvantageous 
because of operation time, high cost, and cell antigen labeling which has been shown 
to alter cell function. These multistep separation processes are not ideal for the scale-
up required by clinical applications; multiple hMSCs transplantations of millions of 
cells are needed for effective therapeutic treatments. Therefore, this research seeks to 
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solve the following issues associated with hMSCs separations and ultimately 
advance type 1 diabetes hMSC therapeutics:  
1) No unique set of biosurface markers currently exists to distinguish
hMSCs from other cell populations; mappings of CD proteins overlap
with other cell systems.  Instead, minimum requirements have been
established by the International Society for Cellular Therapy.
2) Morphology variations within hMSCs populations make highly
selective separations difficult.
3) FACS and MACS are expensive, low throughput, and time-
consuming separation techniques that alter cellular function.
2.4.1 Dielectrophoresis for hMSC Separation 
Dielectrophoresis (DEP) is the separation technology explored in this 
research to resolve issues 1-3 associated with hMSC cell purification. DEP may be 
able to recognize a dielectric marker via cell membrane capacitance measurements 
making it possible to discern hMSCs from other cell populations. DEP is a quick, 
noninvasive separation method, with the potential to be low cost, and does not alter 
or damage cells [141].  Chapter 3 provides a review of DEP and the cell separations 
this technology has been able to accomplish. 
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 1Chapter 3 Dielectrophoresis Literature Review 
3.1 Brief Overview: hMSC Separation Shortcomings and Research 
Objectives 
The realization of hMSC-based diabetic therapeutics requires careful 
characterization of the unique biological and biophysical properties to enable 
separations of hMSCs from different cells or between hMSC progenitor 
subpopulations. Dielectrophoretic (DEP) technology is a tool that can be used to 
characterize cell biophysical properties (membrane capacitance, permittivity, and 
conductivity). This body of work extends DEP to the exploration of hMSCs.  DEP is 
an ideal candidate for efficient hMSCs separations because it is a rapid, 
straightforward method capable of purifying desired cell subpopulations from 
heterogeneous cell populations without changing cell functionality. Because hMSCs 
are a newly explored cell system, DEP technology can increase understanding of 
their diverse functions by characterizing the cells dielectric properties – how charges 
interact with the cell, membrane, cytosol, organelles, and proteins. This work 
primarily explores charge behaviors around the entire cell and with proteins on the 
membrane surface.  Additionally, an archive that links biosurface markers to hMSC 
differentiation behaviors has not yet been established. This work is an essential first 
step in achieving this.  Considering all of these attributes, a DEP microfluidic device 
1 The material contained in this chapter will be submitted for publication. 
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has the potential to improve the purification processes for hMSCs therapeutic 
applications.  
Therefore, as a reminder, the objectives of this research are: 
Objective 1: Characterize the dielectrophoretic response of hMSCs to determine the 
DEP spectra including the cross-over frequency.  
Objective 1a:  Standardize hMSCs morphology with ELP-PEI to 
reduce size-dependent DEP variations, and characterize the DEP 
spectra. 
Objective 2: Model and calculate hMSCs dielectric properties using MATLAB and 
the Core-Shell Spherical DEP Polarization models.  
Objective 2a: Correlate these properties with known phenotypical 
molecular expressions of hMSCs. 
Objective 2b: Compare dielectric properties with other cell systems. 
Objective 3: Develop and optimize a new frequency sweep rate data collection 
technique for rapid compilation of the frequency dependent DEP spectrum.  
Since dielectrophoresis will be used to characterize hMSCs dielectric 
properties, a review of DEP technology is provided in this chapter. The sections to 
follow will describe the dielectrophoretic phenomena, length scales and types of cell 
polarizations, types of DEP, and DEP’s current utilization. 
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3.2 Dielectrophoresis Phenomena 
DEP is a separation technique that utilizes nonuniform electric fields to 
polarize cells based on the dielectric properties of their membrane, cytoplasm, and 
organelles. The electric fields can be applied with either alternating or direct current 
(AC or DC), this research utilizes AC electric fields because the applied frequency
are controlled easier. Cells will exhibit either positive DEP forces (pDEP), where 
cells move to areas of high electric field density, or negative DEP forces (nDEP), 
where cells are repelled from areas of high electric field density. The magnitude of 
the DEP force can be changed by adjusting the electric field magnitude and shape [1-
3]. Figure 3.1 below illustrates pDEP and nDEP in one type of electric field 
geometry. The DEP force, , that a spherical-shaped cell (general case)
experiences in an AC field is given by [1, 4], 
,      (1) 
???????med is the medium permittivity (unitless), fCM is the Clausius-Mossotti factor 
(unitless), R3 is the radius of the cell (μm), and Eo is the electric potential (V). 
DEPF
?
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Figure 3.1 Schematic of the negative DEP and positive DEP a cell will experience in 
an AC electric field with quadrapole electrodes [1-3] . 
3.2.1 Polarization Mechanisms 
There are a variety polarization factors involved with DEP: electronic, 
atomic, orientational, and interfacial [5]. Consider a cell placed in a conductive 
medium with an electric field applied. The electric field will interact with the ions 
available in the medium causing them to move and align around the cells (electronic 
polarization). On the atomic level the ions present in the conductive medium will 
move relative to one another (atomic polarization), for example NaCl (Na+, Cl-); Na+ 
will move relative to Cl-; this movement has previously been assumed to be almost 
negligible in comparison to the movement associated with the cell in the electric 
field (however, other research in our group has quantified this motion and shown it 
can contribute to secondary cell phenomena). Molecules composed of multiple atoms 
in the conductive medium will also contribute to the polarization induced by the 
electric field. Water for instance has 3 atoms and a permanent dipole so, in the 
presence of an electric field, it responds by aligning with the field gradient to reduce 
potential energy [6]. 
Lastly, interfacial polarization is a resultant of electronic, atomic, and 
orientation polarization and is described as ion movement occurring at the interface 
of two phases, for cells the conductive medium is phase 1 and the cell surface is 
phase 2. Interfacial polarizations are described by Maxwell Wagner, as charges that 
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are built up at the particle-medium interface [7]. This interfacial polarization is 
characterized by the time is takes for full particle polarization to occur, the dielectric 
relaxation time, and is given by 
, (2) 
where ?p, ?m are the permittivity of the particle (or cell) and medium respectively, 
?????p, ?m is the conductivity of the particle (or cell) and medium, respectively. Any 
impedance a ion experiences during polarization is due to the dielectric properties of 
the suspended cell [6].  
With AC electric fields applied, cell polarizations occur at specific 
frequencies and are strongly dependent on cell structure. The cell response to 
frequencies is also known as the dielectric dispersion with ?-?? ?-?? ???? ?-regions. 
Since cells have different structures, this dispersion is unique to different cell 
systems. The ?-dispersion region is important when interrogating the cell’s 
membrane structure, because the electric fields penetrate the cell-conductive medium 
interface to detect surface features. The ?-dispersion region is characterized by radio 
frequencies, 0.010-10MHz, and interfacial polarizations are dominant in this region 
[8]. The other polarization mechanisms are dominant at specific frequency ranges, 
orientation polarization 0.010-10MHz and atomic polarization 1011-1013Hz; the 
polarization length scales are different. 
At radio frequencies dipolar and ionic polarizations are significant. Again, 
take a spherical shaped cell suspended in a conductive medium in a nonuniform 
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electric field. The electric field polarizes the cell and induces a moment, and the 
resultant net force exerted on the cell is represented as the effective moment dotted 
with the gradient of the electric potential [4], 
.  (2) 
Figure 3.2 illustrates the dipole particle with the electric field. The expression for 
DEP force is obtained by determining the proper expression for . The effective 
moment is determined by solving the spherical electrostatic potential boundary value 
problem using the proper boundary conditions, which gives [4], 
. (3) 
Substituting Equation 3 back into Equation 2 yields the DEP force Equation given in 
Equation 1.  
Figure 3.2 Force exerted upon a small dipole by an electric field. Adapted from [4]. 
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3.2.2 Debye Electrical Double Layer 
As a resultant of a cell’s polarization an electric double layer of charges are 
formed at the cell interface also referred to as the Debye or electric double layer 
(EDL). The EDL contains two layer of charges with potential difference, phase 1 
(conductive medium) has a net negative charge and phase 2 (cell) has a net positive 
charge or vice versa (equivalent to parallel plate capacitance). There are several 
models established to describe the charge layering phenomena: Hemholtz, Guoy-
Chapma, and Guoy-Chapman-Stern model.   
This information is important because during DEP experiments the 
movement of ions is the key factor to the polarization and the behavior of the ions in 
the EDL is an indicator of cellular dielectric properties.  The dielectric relaxation 
time is cell-specific and dictates how long it will take for a cell to adequately feel the 
applied electric field, also critical in cell separations. Also, to state more clearly, the 
key parameters associated with dielectrophoresis are permittivity and conductivity. 
These two properties are inversely related and the permittivity can be thought of as a 
resistance to the surface ion polarization induced by the applied AC electric field. 
The higher a cell’s permittivity the less resistant it is to the AC electric field and the 
polarization will occur quicker when compared to cells of similar size with smaller 
permittivity’s. Cell size is critical to interfacial polarization, the larger the cell the 
longer it will take for ions to move around, align, and induce movement, this is 
evident in Equation 1 for the DEP force. The Clausius-Mossotti factor is the 
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indicator in the DEP force equation that is directly correlated to a cell’s polarizability 
because it’s dependent on the cell’s permittivity and conductivity values.  
3.3 Dielectrophoretic Particle Polarization Models 
3.3.1 Geometry Overview 
Now, that the different particle polarizations have been discussed let’s look at 
the key equations developed to model the polarization response of cells. A particle’s 
polarization can be modeled using a series of equations dependent on a cells shape, 
complex permittivity, permittivity, and conductivity. A variety cell shapes can be 
modeled using the DEP polarization model equations, and cell complexity can be 
added to these models by adding layers that account for a cells internal structure 
(membrane, cytoplasm, nucleus, etc.). The most common cell shapes modeled in this 
manner are spherical, core-shell sphere, ellipsoid, and core-shell ellipsoid. The 
hMSCs are our focus, and their main shape is spherical like or star-shaped, which 
can be modified to spherical via ELP-PEI treatment.  Thus, this section will focus on 
the spherical and core-shell spherical DEP polarization model.  
3.3.2 Homogeneous Sphere DEP Polarization Model 
The homogenous sphere, used for polystyrene beads in Chapter 5, simplifies 
the cell structure to not contain any internal organelles. For a homogeneous spherical 
particle, the fCM is given by [1, 4],  
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In Equations 4 – 6  is the permittivity of the surrounding medium (unitless), 
Re[fCM] is the real part of the Clausius-Mossotti factor (unitless), cell?~  is the complex 
permittivity of the cell (unitless), med?~  is the complex permittivity of the medium 
(unitless), is the permittivity of the cell (unitless), is the conductivity of the 
cell (S/m), and is the conductivity of the medium (S/m). If a particle 
experiences pDEP, then fCM is positive which indicates that the DEP force displaces 
the particle in the electric field gradient towards areas of high electric field density. 
Vice versa is true for a particle experiencing nDEP, fCM is negative and the particle is 
displaced in the electric field gradient towards areas of low electric field density. 
When fCM equals zero, cross-over frequency (fxo), the particle experiences no DEP 
force ( ). The fxo is the point at which a cell (or particle) transitions from 
experiencing pDEP to nDEP or nDEP to pDEP. The fxo is important because at this 
transition point the dielectric properties of cells (or particles) can be determined, 
along with other data points from the DEP spectra [9]. fCM is dependent on the 
complex permittivity of the cell and the medium (Equation 5-6). If > , then
fCM will be negative and if the   > , then fCM will be positive. The real part of 
med?
cell? cell?
med?
med? cell?
cell? med?
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the fCM is further dependent on the permittivity and conductivity of the medium and 
cell, with four cases summarized in Table 3.1. From Equation 1, the cell size plays a 
role in the DEP force experienced by the cells. As cell size changes the cell DEP 
force changes.  
Table 3.1. High and low frequency examination of the Clausius-Mossotti factor, fCM. 
Case 1 Case 2 Case 3 Case 4 
High 
Frequency 
If > , 
then fCM is 
dependent on 
permittivity  
If < , 
then fCM is 
dependent on 
permittivity 
If  > 
 then 
fCM is 
positive 
If   < 
then 
fCM is  
negative 
Low 
Frequency 
If > , 
then fCM is 
positive 
If < , 
then fCM is 
negative 
If  > 
 then 
fCM is 
positive 
If < 
then 
fCM is 
negative 
The permittivity of a cell is a resistance to the electric field, and cells with 
higher permittivities have less resistance to the electric field and are easier to 
polarize. This can be thought of time take for ions in a suspending solution take to 
rearrange around the cells once the AC electric field is applied. The homogeneous 
sphere does not represent the complexity of a cell, so it’s not frequently used to 
model cell’s DEP response. However, the homogeneous sphere of polystyrene beads 
is useful in evaluating new microdevice designs, and experimental techniques, 
because PS bead structure is homogeneous. 
cell? med? cell? med? cell?
med?
cell?
med?
cell? med? cell? med? cell?
med?
cell?
med?
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The homogeneous spherical DEP polarization model has been used to 
examine how the fCM changes as a function of frequency at varying medium 
conductivities. The results of this model are in Figure 3.3, which illustrates that an 
increase in solution conductivity shift fCM, model doesn’t account for cell internal 
organelles. 
Figure 3.3 Homogeneous sphere DEP polarization models for the fCM of hMSCs in 
varying conductive mediums. Plot generated in MATLAB using Equations 4-6 [1], 
where ?cell = 1????o???med ??????o???o = 8.85*10-12???????cell = 10-6 S/m. This model 
does not account for hMSCs internal structure. 
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3.3.3 Core-Shell Spherical DEP Polarization Model 
Because the spherical DEP polarization model does not account for cells 
structural organelles such as the membrane and cytoplasm, and therefore, it is not an 
accurate representation of cell’s DEP response spectra. A more appropriate model is 
the core-shell spherical DEP polarization model, which treats cells as a layered 
particle and accounts for the conductivity and permittivity of both the cell membrane 
and cytoplasm. Consider a layered spherical cell suspended in a conductive medium 
in a nonuniform AC electric field, the DEP force acting on the cell will be the same 
as in Equation 1. The difference in this case appears in how the fCM is defined 
because a third region describing the electrostatic potential on the layered cell is 
added creating an additional boundary condition. Now the complex permittivity of 
the cell has to account for the complex permittivity of the cell membrane and 
cytoplasm. This is accomplished by replacing the cell by an equivalent homogeneous 
sphere defined with the same radius. By solving the new layered spherical 
electrostatic potential problem the Clausius-Mossotti Factor is now given as [1, 4], 
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In Equation 7  is the effective complex permittivity of the cell, which 
takes into account the complex permittivity of the cytoplasm ( cyto?~  ) and cell 
membrane ( mem?~ ), permittivity of the cytoplasm ( cyto?  ) and cell membrane ( mem? ), 
as well as the conductivity of the cytoplasm ( cyto? ) and cell membrane ( mem? ). Here 
the size of the cell plays a very important role and the size is accounted for in the 
radii. Here is where knowing hMSCs morphology, cell size, and protein expression 
becomes important, because larger cells will have a different DEP response than 
smaller cells. The overall goal of this research is to characterize the dielectric 
behavior of hMSCs and its differentiated progeny.   
Figure 3.4 illustrates that for a core-shell sphere a conductivity increase shifts 
(increases) the fCM, similar trend to the homogeneous sphere case. As the cell size 
changes the cell DEP force changes. The core-shell spherical DEP polarization 
model was also plotted to show size effects on fCM in a medium with 0.01 S/m 
conductivity, Figure 3.5. In Figure 3.5 as the size of the cell increases fCM increases. 
'
cell?
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Figure 3.4 Schematic of core-shell spherical cell and equivalent spherical with the 
core-shell spherical DEP polarization model for hMSCs fCM in varied conductive 
mediums. Plot generated in MATLAB using Equations 7-10 [1, 4] where ?cyto = 
????o???mem = 0.50??o???med ??????o???o = 8.85*10-12???????cyto = 0.63 ??????mem = 10-6
S/m.   
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Figure 3.5 Effect of membrane size difference on hMSCs fCM directly correlates to 
DEP response spectra [5]. Generated using Equations 7-10 ?????????????????cyto
??????o???mem = 0.50??o???med ??????o???o = 8.85*10-12???????cyto = 0.63 ??????mem = 
10-6 S/m, and R = 10, 20, 40, 60μm.  
This modeling is key in the exploration of cells (or particles) because it 
predicts cellular behavior at specific frequencies. These DEP models can be 
compared to the experimentally determined DEP response spectra and optimized to 
determine the dielectric properties membrane/cytoplasm permittivity, conductivity, 
and membrane capacitance. Once the fxo is determined based on the experimental 
DEP spectra fxo can be correlated to the membrane capacitance, and then correlated to 
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the membrane permittivity. Membrane capacitance, Cmem, is a function of fxo and 
given by [10, 11] 
, (11) 
where r is the cell radius (?m).  Further, the membrane permittivity is proportional to 
Cmem,
, (12) 
where d is the membrane thickness and ?0 is the vacuum permittivity.  Therefore, the 
fxo and Cmem can be used as indicators of treatment-induced hMSC changes and can 
be lumped into ?mem, a key dielectric property. To obtain the dielectric properties, the 
membrane and cytoplasm conductivity and permttivity values are adjusted until good 
aggreement is made between experimental data and theory predictions. The 
experimentally determined fxo is used to estimate the experimental membrane 
capacitance.
Modeling hMSCs as core-shell spherical particles is a more accurate 
representation of their complexity but is not 100% accurate. There are morphological 
variations within an hMSC population ( as mentioned in Chapter 2), and in order to 
have reproducible DEP responses as well as detect biosurface protein markers these 
variations need to be removed from the DEP measurement. To achieve this, elastin-
like polypeptide (ELP) polyethyleneimine (PEI) was employed as a standardization 
technique and Chapter 4 reports results.  
0
24 ??? r
dCmem
mem ?
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This research uses a quadraple microelectrode design in order to achieve DEP 
motion within experiments. There are many other microelectrodes possible, and they 
will be briefly discussed in the next section. 
3.4 Types of Dielectrophoresis Electrode Designs 
Different types of DEP are characterized by the electrode design, and specific 
design utilization are dependent on the application necessary. Traditional DEP is 
classified by common electrode designs implemented into experimental studies, 
which are interdigitated, castellated, curved and quadrapole; insulator/contactless 
DEP is alternative method to traditional DEP and it prevents cells from coming in 
contact with operational electrodes, and lastly traveling wave DEP is used from 
cell/fluid pumping. This section will overview these designs in more details and 
show their current use in research.  
3.4.1 Traditional DEP 
Traditional DEP uses a couple of different electrode configurations. For each 
design type the electrodes are patterned along the bottom of a microchannel or 
microchamber [12]. These designs include: interdigitated, castellated, curved, and 
quadrapole (design used in this research); this list in not all inclusive. Figure 3.6 (a-
d) illustrates these different electrode designs. The electrode design selection is made 
based on specific functions needed. Traditional DEP electrode designs are typically 
used for cell separations or enrichment. Each design shapes the electric field gradient 
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differently, and the position where the gradient is highest is marked with a red circle 
in Figure 3.6 (a-d). The advantages to using these designs are that they are fabricated 
easily, and require low electric fields to induce cell movement, which is critical to 
maintain cell viability. The disadvantage to these designs are that they expose cells 
to AC electric fields which means the electrode material used has to be 
biocompatible [12]. Typical electrode materials used are gold and titanium [8].   
Figure 3.6 Common traditional DEP electrode designs (a) interdigitated, (b) 
castellated, (c) curved, (d) quadrapole. Each device design is used for cell trapping 
based on cell dielectric properties. Adapted from [12]. 
Interdigitated, castellated, curved, and quadrapole electrodes are all used for 
cell trapping either in the high electric field gradient area, pDEP, or in the low field 
electric field gradient area, nDEP. Table 3.2 summarizes the applications these 
electrode designs have been used in. 
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Table 3.2 Summary of electrode configuration applications. 
Configuration Particle Application Ref. 
Interdigitated Prostate circulating 
tumor cells 
DEP immunocapture 
system 
[13] 
Human neonatal dermal 
fibroblast and mouse 
embryonic stem cells 
Estimation of 
dielectric properties 
based on % trapping 
[14] 
Viral nano-lysate HIV virus detection [15] 
3T3 and embryonic stem 
cells 
DEP-based cell 
pairing 
[16] 
Castellated Latex nanoparticles DEP image 
processing and 
dielectric property 
measurement 
[17] 
Murine embryonic stem 
cells 
Embryoid formation 
for stem cell 
differentiation 
[18] 
Mycobacterium 
smegmatis bacterial cells 
Alive dead cell 
isolation 
[19] 
Porcine oocytes Healthy oocyte 
selection for in vitro 
fertilization 
[20] 
Curved Tungsten trioxide and 
polystyrene nanoparticles 
Particle concentration 
mapping  
[21] 
Yeast cells Live and dead cell 
sorter 
[22] 
Latex microbeads microdevice utility 
for continuous cell 
sorting 
[23] 
Quadrapole Polystyrene beads and 
red blood cells 
Frequency sweep rate 
data collection utility 
[8] 
Red blood cells Blood typing [24] 
Colloidal crystals Colloidal assembly 
manipulations 
[25] 
HeLa cells AC electrothermal 
flow trapping 
[26] 
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3.4.2 Insulator/contactless DEP (iDEP or cDEP) 
Another type of DEP separation is insulator DEP also known as contactless 
DEP (cDEP), this method uses insulating postings within the microfluidic channel to 
assist separations and the electrodes are located along the edges of the microdevice, 
Figure 3.7.  Specifically, the electrodes are isolated from the main microfluidic 
channel by a thin membrane [27], and polyermic posts are placed in the channel to 
distort the field creating a gradient [28]. The posts can have varied geometries such 
as diamonds, circles, and triangles. DEP force equation and Clausius-Mossotti factor 
remain the same with these setups.  
Some applications for iDEP/cDEP are ABO-Rh blood typing [29], separation 
of yeast cell and polystyrene bead mixture [30], P. aeruginosa and S. mitis bacteria 
strain level discrimination [31], particle focusing [32], and high performance particle 
trapping on a silicon substrate [33].  
The advantages to this method are simple fabrication, DEP force is 
distributed over large area (increases throughput), low AC fields used for 
separations, and single cell analysis. A disadvantages is the possibility of joule 
heating [12], applied AC field releases heat increasing system temperature [34]. 
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Figure 3.7 Varied insulating posts design inside iDEP microdevices. (a) rounded 
triangluar [27], (b) circular [33], (c) elongated [32], and (d) triangular [30]. 
Reproduced with permission from [27, 30, 32, 33]. 
3.4.3 Traveling Wave DEP (twDEP) 
Pumping is another operation strategies that can be implemented using DEP 
with a slightly different electrode setup consisting of rectangular parallel electrode 
array pattern, Figure 3.8. This electrode design facilitates horizontal particle 
movement in a nonuniform electric field, and the electric field gradient maxima 
occurs at the center of the electrodes therefore cells travels in wave down the center 
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of the electrodes.  This electrode design functions by turning on two electrodes at a 
specific frequency, and then turning one electrode off and stepping to the next 
electrode (turning on the next electrode). This causes the electric field gradient to 
move or travel down the electrodes, hence the name traveling wave DEP (twDEP). 
The time-average DEP force equation is now dependent on the real and imaginary 
part of the Clausius-Mossotti factor  [35], 
? ? ? ?? ???? ??? 223 ImRe2 EfEfRF CMCMmedDEP (11) 
The velocity of the cells in the electric field is critical and specific to cell being 
examined, different dielectric properties affects cell movement or mobility. Velocity 
is dependent on fCM and is given by [35], 
? ?
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twDEP has been used as an alternative to FACS and MACs cell sorting 
method by van den Driesche et al., in their work they separated jurkat cells from with 
S. cervisiae (yeast) and Lactobacillus casei (bacteria found in the mouth and 
intestine). The separation was achieved by first determining a separation frequency 
fxo for jurkat cells using a quadrapole electrode design and choosing a device 
operation frequency such that target cells experienced a small nDEP force away from 
the electrodes. The twDEP was applied perpendicular to the flow, so that the 
untargeted bacteria were adhered to the electrodes. Hydrodynamic flow allowed the 
targeted jurkat cells to be collected [36]. Figure 3.8 illustrates the device setup and 
real images of cell separation. 
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Figure 3.8 twDEP separation of jurkat cells from S. cervisiae and Lactobacillus 
casei bacteria. Jurkat cells were separated by flowing along the twDEP field gradient 
with nDEP force and the bacteria cells were adhered to the electrodes with pDEP 
force. Reprint produced with permission from [36]. 
The main applications of twDEP is to pump cells for sorting and other cell 
systems be explored using this technique are red blood cells [37],  yeast, and 
microparticles [38]. Each method discussed above traditional DEP, iDEP/cDEP, and 
twDEP are useful in particle manipulation and determining the dielectric properties 
of biological cells. In this dissertation the quadrapole electrode design is used due to 
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is simple fabrication process. The quadrapole electrode DEP microdevice used in 
this work is easily networked with syringe pumps, a function generator, and 
microscope to complete experimental tests.   
3.5 Microdevice Dielectrophoretic Applications 
3.5.1 General Applications and Stem Cell Studies 
Dielectrophoretic technology has been around for awhile with the earliest 
work occurring in 1974 completed by Chen and Pohl. In this work single yeast cells 
were exploited in nonuniform electric fields created with platinum wires. Individual 
cell characteristics, permittivity and age, were tabulated using voltage release 
response.  The effective polarizability varied from cell to cell, but variations were 
reproducible. The voltage response spectrum was able to detect variability within the 
yeast cell population indicative of subpopulations (similar to hMSCs). This dielectric 
response varied with cell age condition, dead cell excess permittivity decreased, 
parameters may be useful in cell studies [5]. This study is at the core of all other 
DEP studies to follow over the next 40 years.  
Studies have now transformed to look at many animal and human cell 
lineages. In a study completed by Muratore et al., myoblast C2C12 cells were 
examined because of their similarities to stem cells (i.e. they differentiate). This 
work detected different membrane capacitance signatures for fibroblasts, 
differentiated C2C12, and undifferentiated C2C12 cells using a symmetrical 
electrode design that funneled cells during sorting to the outlet, Figure 3.9a. The 
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cells were tested in 0.12S/m conductive medium, and the membrane capacitance 
difference between the undifferentiated C2C12 and fibroblast cells were attributed to 
surface microvilli, with SEM images adding supporting evidence, Figure 3.9b [39].  
Figure 3.9 Shows the cell sorting microdevice and corresponding SEM images of 
sorted fibroblasts and undifferentiated C2C12 cells. Reproduced with permission 
from editor  [39]. 
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Another DEP study by Duncan et al., explored the Cl-, K+, and Ca+2 ionic 
contributions to the cytoplasm conductivity of drug resistant and nondrug resistant 
leukemic cells (K562 and K562AR, respectively). K562 and K562AR were treated 
with verapamil (calcium channel blocker), quinine (potassium channel blocker), and 
NPPB (chloride channel blocker) and the cells spatial variation were tabulated in the 
presence of AC electric fields at 0.0025S/m.  The channel blocker treatments altered 
K562 and K562AR DEP response indicating reductions in their cytoplasm 
conductivity. As a result Cl-, K+, and Ca+2 ionic contributions to K562’s and 
K562AR’s cytoplasmic conductivity were found to be K562: 0.13S/m K+, 0.08S/m 
Ca+2, and 0.09S/m Cl-; K562AR: 0.16S/m K+, 0.08S/m Ca+2, and 0.25S/m Cl-. Based 
on the ionic contributions it can be inferred that the physiological difference between 
K562 and K562AR is associated with the presence of extra chlorides (increased 
chloride channel activity). This work demonstrates that DEP is a good analysis tool 
to detect ion channel activity within cells [40]. 
DEP is also a good research tool for stem cells studies. In some of the first 
stem cell DEP research it was demonstrated that hematopoietic stem cells could be 
concentrated from a mixed cell population without requiring cell manipulation [41, 
42]. Adipose-derived putative stem cells were also concentrated by coupling DEP 
and field-flow fractionation (FFF) [41, 43]. Flanagan et al., examined the dielectric 
properties of mouse neural stem/precursor cells (NSPCs) using parallel electrodes 
(50μm in width with 100μm gaps) with an AC electric field. Figure 3.10 below 
shows an image of the real microfluidic device used. In this study the NSPCs were 
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suspended in a sucrose buffer solution with a conductivity of 150 μS/cm and 
injected in a microchannel. An electric potential of 8V was applied and the 
frequency was varied from 25kHz to 25MHz using a function generator. The DEP 
response of the cells was recorded in 10 to 15 second videos and analyzed. The 
results of this study show that NSPCs, neurons, and astrocytes have unique dielectric 
properties that were detected in the system in Figure 3.10. These unique dielectric 
properties were detected by looking at the percent of cells trapped at specific 
frequency, trapped cell are those attracted to the electrodes or positive DEP [44]. 
These results are given in Figure 3.11. The work completed by Flanagan et al., did 
not calculate the dielectric properties of NSPCs, and there was no connection made 
with the to the biochemistry aspect of the stem cells. 
Figure 3.10 Real image of the parallel electrode microfluidic device used to examine 
the dielectric behavior of NSPCs. Reproduced with permission from editor [44]. 
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Figure 3.11 Percent trappings results for NSPCs, neurons, and astrocytes. Each cell 
type has distinct percentage of cells trapped at particular frequencies, which is an 
indication of unique dielectric properties among each cell type. Reproduced with
permission from editor [44]. 
DEP is a versatile technology and has been implemented in other studies 
looking at the effects of DEP treated hydrogen peroxide on enamel teeth whitening 
[45], pesticide detection [46], water quality testing [47, 48], and DNA electrical 
property determination [49].    
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3.5.2 DEP Studies to Determine Cell Membrane Capacitance 
A cell’s DEP spectra can be correlated to its membrane capacitance, which is 
an indicator of biosurface proteins. This is of particular interests in hMSCs DEP 
separations because the biosurface proteins are attributed to hMSCs subpopulations. 
hMSCs membrane capacitance up to this point has not been explored (we 
accomplish this in chapter 4), so the membrane capacitance of other cell systems will 
be discussed in this section.  
Table 3.3 summarizes the cell membrane capacitance of neural 
precursor/stem progenitor cells (NSPCs) with neurogenic progenitor (NP) and 
astrogenic progenitors (AP); embryonic (E12.5 or E16.5) mouse NSPCs; multiple 
lineages of oral squamous carcinoma cells (CaLH3, H357, OSCC1, and DOK); 
adipose-derived stem cells (ADSCs); adipogenic progenitors; osteogenic progenitors; 
and ADSCs differentiated to osteoblasts. These cell systems were tested in varied 
conductivity solutions ranging from 0.01S/m to greater than 1S/m (cell culture 
media). The oral squamous carcinoma cells were characterized based on 
subpopulations identified by their adhesiveness: rapid adherent cells (RAC), middle 
adherent cells (MAC), and late adherent cells (LAC). Each of these adhesive 
subpopulations were correlated to tumorigenic capability with RAC > MAC > LAC 
[50], which indicates that DEP can be used to detect the tumor cells from healthy 
cells, useful for cancer therapeutics. Lastly, the measured membrane capacitance for 
each cell system is consistent with theory, higher capacitance values are 
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experimentally determined in higher conductivity mediums due to their proportional 
relationship (Equation 11).  
Table 3.3 Summary of cell membrane capacitance studies using DEP. 
Cell Type Conductivity 
(S/m) 
Cmem 
(pF) 
Ref 
 NSPCs-NP biased 0.01 3.3 [51] 
 NSPCs-AP biased 0.01 4.3 [51] 
 E12.5 mNSPCs 0.01 1.6 [51] 
 E16.5 mNSPCs 0.01 2.8 [51] 
SW Treated-E16.5 
mNSPCs 
0.01 4 [51] 
CaLH3 RAC 0.10 4.1 [50] 
MAC 3.4 
LAC 2.9 
H357 RAC 0.10 3.3 [50] 
MAC 2.9 
LAC 2.3 
OSCC1 RAC 0.10 1.6 [50] 
MAC 1.3 
LAC 1.1 
DOK RAC 0.10 5.1 [50] 
MAC 5.1 
LAC 5.8 
ADSC >1.0 6.6 [52] 
Adipogenic-
progenitor 
>1.0 9.0 [52] 
Osteogenic-
progenitor 
>1.0 6.9 [52] 
Differentiated 
osteoblasts 
>1.0 5.7 [52] 
To review, the advantages to using density centrifugation paired with FACS 
and MACS for hMSC separation are high selectively, automated, commercial 
availability, and continuous processes [53]. The disadvantages of these processes are 
that long process times, high cost, large electronic systems, and the antigen labeling 
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necessary to achieve target cell isolation [54]. A cell separation system that can 
improve upon these disadvantages will provide an alternative method for hMSC 
separation, which may be more suitable for hMSC clinical therapeutics. 
With that being said the advantages of using DEP microdevices over FACS 
and MACs systems are the potential for low cost (microdevices can be mass 
produced), electric fields are nonharmful to biological cells [55], quick separation 
times (less than 5mins) [8], decreased resources necessary to achieve separations (μl 
sample volumes) [7], and the versatility within microdevices [56]. In a FACS or 
MACS system the only procedure that can be accomplished is cell separation based 
on biosurface markers (ideal). DEP microdevices gives cell separations added 
versatility such as further bioprocessing like cell culturing [57], lysis [58], 
microreactor chambers for differentiation [59], and viability screening [60]. These 
steps can all be concurrently combined on a single microfluidic platform.    
3.6 Conclusions 
DEP is a versatile analytical technique that has been employed to study 
biological cell systems. At the foundation of DEP technology is electronic 
polarization that occurs due to ion movement around a cell, Maxwell-Wagner 
interfacial polarization dominant at radio frequencies. Cells response to the ion 
movement is not instantaneous and dielectric relaxation time is required for the cell 
to respond to ion movement. This time is cell specific and was utilized in the design 
of a new DEP data collection technique in chapter 5.  
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Additionally, the core-shell spherical DEP polarization model provides 
adequate predictions of hMSCs DEP response (Chapter 4). The DEP spectra for cells 
is dependent on cell size, dielectric properties, and medium conductivity. Cells 
suspended in a higher medium conductivity will experience a shift in the DEP 
spectra due to the increased number of ions present in the suspending solution. The 
dielectric properties can be extracted from the DEP response spectra because the 
membrane is directly related to fxo and the entire DEP spectra. A variety of electrode 
designs are available for DEP experiments but the design type used is dependent on 
the function required by the microdevice. Our work uses the quadrapole electrode 
design because its easy to fabricate. Many particle/cell systems have been studied 
with DEP technology jurkat cells, leukemic cells, and mouse neural precursor/stem 
progenitor cells, just to name a few. However, hMSCs have not been studied with 
DEP, therefore this dissertation work extends DEP technology to this novel cell 
system for separations that can be utilized for type 1 diabetes therapeutics.  
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Chapter 4 Characterizing the Dielectric Properties of 
Human Mesenchymal Stem Cells and the Effects of Charged 
Elastin-like Polypeptide Copolymer Treatment [1] 
1 T.N.G. Adams, P.A. Turner, A.V. Janorkar, F. Zhao, and A.R. Minerick
4.1 Abstract 
Human mesenchymal stem cells (hMSCs) have three key properties that make 
them desirable for stem cell therapeutics: differentiation capacity, trophic activity, and 
ability to self-renew.  However, current separation techniques are inefficient, time 
consuming, expensive and in some cases alter hMSCs cellular function and viability. 
Dielectrophoresis (DEP) is a technique that uses alternating current (AC) electric 
fields to spatially separate biological cells based on the dielectric properties of their 
membrane and cytoplasm.  This work implements the first steps toward the 
development of a continuous cell sorting microfluidic device by characterizing native 
hMSCs dielectric signatures and comparing them to hMSCs morphologically 
standardized with a polymer.  A quadrapole Ti-Au electrode microdevice was used to 
quantify the dielectric properties based on the DEP frequency spectra and cross-over 
frequency of hMSCs from 0.010-35MHz in dextrose buffer solutions (0.030S/m and 
1 The material contained in this chapter was previously published in 
Biomicrofluidics, 2014. 8: p. 054109. 
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0.10S/m).  The membrane capacitance and permittivity were found to be 2.2pF and 
2.0 in 0.030S/m and 4.5pF and 4.1 in 0.10S/m, respectively.  Elastin-like polypeptide 
(ELP-) polyethyleneimine (PEI) copolymer was used to control hMSCs morphology 
to spheroidal cells and aggregates.  Results demonstrated that ELP-PEI treatment 
controlled hMSCs morphology, increased experiment reproducibility, and 
concurrently increased hMSCs membrane permittivity to shift the cross-over 
frequency above 35MHz.  Therefore, ELP-PEI treatment may serve as a tool for the 
eventual determination of biosurface marker-dependent DEP signatures and hMSCs 
purification. 
Key Words: Dielectrophoresis, human mesenchymal stem cells, elastin-like 
polypeptide polyethyleneimine, cross-over frequency, membrane capacitance, 
membrane permittivity 
Common abbreviations: Human Mesenchymal Stem Cells (hMSCs), 
Dielectrophoresis (DEP), Alternating Current (AC), Elastin-like polypeptide (ELP), 
Polyethyleneimine (PEI), positive dielectrophoresis (pDEP), negative 
dielectrophoresis (pDEP) 
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4.2 Introduction 
Human mesenchymal stem cells (hMSCs) are an interesting cell source to 
researchers because of their regenerative [1, 2] and immunological properties [3, 4].  
hMSCs are isolated from the bone marrow and other locations in the body [5] due to 
their beneficial properties.  They have a high differentiation capacity (adipocytes, 
chondrocytes, osteoblasts, etc.) [6-10], self-renew [11, 12], and secrete bioactive 
molecules (trophic activity) [2, 3, 13, 14].  hMSCs trophic activity is substantial to 
their function because signals are sent to surrounding cells triggering tissue repair [13] 
causing apoptosis inhibition, proliferation, and matrix production [13, 14].  hMSCs 
are being pursued as a therapeutic option for many chronic diseases such as lupus [15], 
diabetes mellitus [16], cardiomyopathy [17], liver cirrhosis [18], and Crohn’s disease 
[19].   
For therapeutic treatments, obtaining hMSCs is a multistep process.  hMSCs 
are a heterogeneous population [20, 21] therefore following bone marrow isolation 
they are centrifuged via density gradient solution (step 1), adhered to plastic cell 
culture dish (step 2), and separated using trypsinization (step 3) [17].  This method is 
inefficient and time consuming [22], so other techniques are employed, fluorescent- 
and magnetic-activated cell sorting (FACS and MACS), which implement unique cell-
surface antigens or other recognition elements to tag target cells.  This ‘labeling’ of 
cells alters cellular function, which is not desirable [22-24].  FACS and MACS require 
expensive raw materials and are labor intensive.  There is not a unique biosurface 
marker that distinguishes hMSCs from other cell populations [21, 25], the minimum 
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requirements established by the International Society for Cellular Therapy are: (1) 
plastic adherence (generic cellular property [6]); (2) positive expression of CD105, 
CD73, and CD90; (3) negative expression for CD34, CD45, CD11a, CD19, CD14, 
and HLA-DR; and (4) adipogenic, osteogenic, and chondrogenic differentiation 
potential [8, 16].  hMSCs have differing biosurface marker expressions on their 
membrane [26] making it difficult to establish a unique biosurface marker for 
characterization.  
Additionally, hMSCs morphology has variations, which can create 
subpopulations [27].  Therefore a label-free, one-step cell purification technique that 
rapidly purifies hMSCs by accounting for their morphology without altering cellular 
function is needed. 
Dielectrophoresis (DEP) is a separation technique that has potential to 
overcome the shortcomings of density gradient centrifugation, FACS, and MACS and 
could provide an electrical biomarker for hMSCs.  DEP technologies enable a variety 
of particle polarizations with nonuniform AC electric fields on microchips [28, 29] to 
achieve particle manipulation.  DEP has been used to study other cell systems such as 
red blood cells [30, 31], cancer cells [32, 33], white blood cells [34], and yeasts cells 
[35, 36].  The red blood cell DEP studies are important because different ABO-Rh 
surface antigens were distinguishable from the DEP spectra.  The long-term goals of 
characterizing  hMSCs dielectric properties are to discern unique biosurface markers 
specific to hMSC subcultures.  
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Advances have been made in the study of stem cells using dielectrophoresis. 
Flanagan et al. [37], looked at the affects AC electric field expsosure times have on 
cell viabilty.  They found that for human and mouse neural stem/progenitor cells short 
exposure times (30s-1min) between 0.010-10MHz did not affect cell viability and 
metabolic activity.  However, longer exposure times, 5–30mins, at the same 
frequencies induced 20 to 40% decrease in cell viability and metabolic activity.  These 
results establish experimental parameters, and aligns with cell viability results found 
in this work after 90s AC field exposure hMSC cell viability remained intact.  Wu and 
Morrow [38] conducted a one patient clinical study on stromal vascular fraction (SVF) 
cells separated via DEP.  The SVF cells were obtained, separated at 15Vpp, 0.10-
1.0MHz and autologously transplanted to a patients hand to treat muscle atrophy. 
Positive results were achieved indicating that DEP treated cells were not harmful and 
they accelerated the healing process over 3 months (as compared to control).  The 
advantages to coupling DEP with microfluidics are microliter sample size, quick 
analysis  (~minutes to achieve results),  little sample preparation, and minimal waste 
production.  Disadvantages are that extended electric field exposure times (>5mins) 
negatively affect cells properties and  viability [37].  
4.3 Background 
DEP utilizes nonuniform electric fields for cell movement based on the 
polarizability and dielectric properties (permittivity and conductivity) of their 
membrane, cytoplasm, and other structurally dominant organelles [39].  Cells have 
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distinct dielectric dispersions that can be used as an identification tool for cell 
purification.  A cell’s complex permittivity is frequency dependent and characterized 
???????????????????????????????????????????????????? ?? ? ?? ?) [40].  At radio frequencies 
(?-region), 0.010–10MHz, the dielectric dispersion of cells are affected by their 
membrane; high frequencies penetrate a cells surface and interogates the internal 
structure.  Therefore, a plethora of information can be obtained about a cell population 
in the  ?-region; many researchers complete their experiments within this frequency 
range.   
In the ?-region, Maxwell-Wagner interfacial polarizations dominate the DEP 
response phenomena.  Based on permittivity and conductivity, polarized cells will 
exhibit either positive DEP (pDEP), cells move to areas of high electric field gradient, 
or negative DEP (nDEP) force; cells move to areas of low electric field gradient [41, 
42].  The DEP force is given by,  and this cell motion 
in the electric field is defined by the Clausius-Mossotti factor, fCM, for core-shell 
spherical particles [39, 41] 
,  (1) 
, (2) 
? ? 23 Re2 EfRF CMmemmedDEP ? ??
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, (3) 
where R is the radius of the cell cytoplasm and membrane (Rcyto and Rmem), is the 
complex permittivity, ?i is the permittivity, and ?i is the conductivity where i = cell, 
cytoplasm, membrane, or medium.  The complex permittivity , is also dependent on 
the angular frequency ( ) [41].  fCM is dependent on the complex permittivity of the 
cell and the medium, equation 2.  If a cell experiences pDEP then fCM (equation 1) is 
positive indicating the cell is more polarizable than the suspending medium,  >
, and the cell moves toward areas of high electric field density [41].  For nDEP, 
the fCM is negative and the cell is less polarizable than the suspending medium,  >
, and the cell moves towards areas of low electric field density [41].  When fCM is 
zero, known as the cross-over frequency fxo [39], cells experience no DEP force (FDEP
= 0) as they transition from nDEP to pDEP or pDEP to nDEP.  This fxo is an important 
component of a cell’s DEP spectra because the dielectric properties of cells can be 
estimated along with other data points from the DEP spectra.  
The DEP behavior of cells is quantified experimentally by measuring the pDEP 
and nDEP at specific frequencies within a given buffer solution.  The fxo can be 
extrapolated between the two nearest pDEP and nDEP frequencies.  Cells typically 
display two fxo’s, which are dominated by its membrane structure.  The low fxo is 
determined by the cell’s size, shape, and membrane with typical values between 0.010-
0.10MHz (?-region), but reported as high as ~4MHz [43].  The high fxo is dominated 
med?~
med?~
118 
by the cell’s cytoplasm and is typically above 10MHz in low conductivity media [44].  
For the experiments described in this work, the high fxo value falls outside of the range 
of our function generator (?-region).  Membrane capacitance, Cmem, is a function of fxo
and given by [44, 45] 
,         (4) 
where r is hMSCs radius (?m).  Further, the membrane permittivity is proportional to 
Cmem,   
 ,        (5) 
where d is the membrane thickness and ?0 is the vacuum permittivity.  Therefore, the 
fxo and Cmem can be used as indicators of treatment-induced hMSC changes and can be 
lumped into ?mem, a key dielectric property. 
To eliminate variation in cell morphology and increase DEP response 
reproduciblity within our hMSC sample population, elastin-like polypeptide (ELP) 
polyethyleneimine (PEI) was employed.  ELP-PEI is a postively charged copolymer 
that directs cells morphology to a spheroidal shape with a propensity to form 
aggregates.  Similar to mammalian elastin, ELP is synthesized from amino acids 
including valine, proline, and glycine and has been utilized to induce spheroid 
formation and differentiation of H35 rat hepatocytes.  ELP-PEI has also elucitated 
affects of free fatty acids and cytokines  in 2D and 3D rat hepatoma cell cultures [46, 
47].  
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In this paper, the first steps toward the development of a continuous cell sorting 
microdevice were completed by characterizing the dielectric signature of hMSCs and 
standardizing their morphology with ELP-PEI treatments.  We demonstrate that DEP 
can quantify hMSCs ?mem, ?mem, and Cmem based on measured DEP spectra.  We also 
characterize the DEP behavior of ELP-PEI treated hMSCs for comparison to the native 
hMSCs.  Determing hMSCs dieletric properties and removing morphology variations 
is essential to increase reproducibility and magnify different membrane biosurface 
markers.  
4.4 Materials and Methods 
Microdevice Fabrication: The microdevice in Figure 4.1b was fabricated 
using prior published techniques [30] with 100?m wide and 200?m spaced electrodes. 
A 2000?m deep by 3000?m wide microwell made with PDMS was sealed on top of 
the quadrapole array.  Figure 4.1b shows the quadrapole Ti-Au electrode microdevice 
setup.  
hMSC Cell Culture: Nitrogen stored bone marrow derived hMSCs were 
recovered by thawing cells in 37°C water bath.  500mL alpha minimum essential 
medium (?MEM) with L-glutamine, without ribonucleosides or deoxyribonucleosides 
(Catalog # M20350, Atlanta Biologicals, Atlanta, GA) was completed with 50mL fetal 
bovine serum (FBS, Catalog # S11550, Atlanta Biologicals), 3mL L-glutamine 
(200mM in 0.85% NaCl, Catalog # 25030081, Life Technologies, Carlsbad, CA), and 
3mL penicillin/streptomycin (Catalog # 15140122, Life Technologies).  Thawed 
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hMSCs were placed in 15mL complete ?MEM in sterile cell culture flask and 
incubated overnight at 37°C, 5%CO2.  After 24hrs, phosphate buffer solution (PBS, 
Catalog # 6508-OP, EMD Millipore, Chicago, IL), 0.25% trypsin/1mM EDTA 
(Catalog # 25200072, Life Technologies) and complete ?MEM were warmed to 37°C.  
Old complete ?MEM was removed from the flask and attached hMSCs were washed 
with 10ml PBS.  4mL trypsin was added to the flask and hMSCs were incubated at 
37°C, 5%CO2 for 3-4mins for full cell detachment (monitored with microscope).  After 
detachment 5mL of complete ?MEM was added to flask to inactivate trypsin, and the 
hMSC suspension was placed in sterile centrifuge tubes.  hMSCs were centrifuged for 
10 minutes at 494 relative centrifugal force (RCF).  The supernatant was removed and 
hMSCs were resuspended in 5mL of fresh completed ?MEM.  1mL of hMSC 
suspension was placed in new cell culture flask with 15mL complete ?MEM for the 
next passage.  hMSCs were incubated until 90% confluent (~5 days) and passaged 
following the same trypsin detachment procedure.  Multiple flasks of hMSCs were 
cultured for DEP tests, with an extra hMSC flask continually passaged every 4-5days 
for subsequent DEP testing.  DEP tests were completed when cells reached 106 cell/mL 
concentration (~5-7 days).  
DEP Solution Preparation: 1M NaOH (Catalog #S318-500, Fisher Scientific, 
Waltham, MA) solution, 3M salt stock solution, 4% bovine serum albumin (BSA, 
Catalog # A7906-100G, Sigma Aldrich, St. Louis, MO)-Epure H2O pH 10 solution, 
0.030S/m and 0.10S/m dextrose solutions were prepared to complete hMSCs DEP 
testing.  The 3M salt stock was comprised of 1M KH2PO4 (Catalog # 7100, 
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Mallinckrodt Chemicals, St. Louis, MO), 1M NaCl (Catalog # 7581, Macron 
Chemicals,  Swedesboro, NJ), and 1M K2HPO4 (Catalog # BDH0266-500G, VWR, 
West Chester, PA) in 20mL Epure H2O.  A 4% BSA pH 10 solution was utilized to 
pretreat the microdevice surface.  The 0.030S/m dextrose solution was prepared to 
0.30M with 0.30M dextrose (Catalog # D9434-500G, Sigma Aldrich) and 9.1x10-4M 
salt stock, then balanced to pH 7 with 1M NaOH (as necessary).  4% BSA was added 
and thoroughly vortexed.  The 0.10S/m dextrose solution was prepared to 0.28M with 
0.27M dextrose and 7.5x10-3M salt stock, then balanced to pH 7 with 1M NaOH (as 
necessary).  4% BSA was added and thoroughly vortexed.  Final dextrose solution 
conductivities were verified using a conductivity meter (AB30, Fisher Scientific).  
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Figure 4.1 (a) hMSCs cartooned to emphasize the differing cell membrane biosurface 
markers and thus properties.  After ELP-PEI treatment, cartooned spheroidal 
morphology.  (b) Quadrapole microdevice with 200?m spaced Ti-Au electrodes used 
for DEP experiments.  (c) hMSCs in device with field off, and the DEP response 
observed with field on.  At a single frequency, both nDEP and pDEP were observed 
due to differing membrane biosurface markers within an hMSCs population.  
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DEP Experimental Procedure: For DEP tests, centrifuged untreated hMSCs 
were resuspended to a concentration of 1.3x106cells/mL in either 0.030S/m or 0.10S/m 
dextrose solution.  The microdevice was presoaked in 4% BSA-Epure H2O adjusted 
to pH 10 to prevent cell adhesion.  The hMSC dextrose suspension was loaded into 
the quadrapole chamber using a micropipette.  A function generator (Agilent 33250A, 
Agilent, Santa Clara, CA) was connected to the microdevice via copper leads (Figure 
4.1b).  Static frequency measurements were completed using 10Vpp AC sine wave, 
0.010MHz to 35MHz for 90s.  More than 300 untreated hMSCs (n > 300) were tested 
at each static frequency.  Untreated hMSCs static DEP responses were compared to 
static measurements of ELP-PEI treated hMSCs.  To achieve ELP-PEI hMSC 
treatment, ELP-PEI was synthesized as described in [46, 47] and dissolved in Epure 
H2O (5mg/mL) in a sterile centrifuge tube.  5mL ELP-PEI Epure H2O solution was 
added to a vented cell culture flask and dried for 48hrs at 37°C.  After 48hrs, excess 
water was removed and the coated flask was decontaminated under UV light for 
5mins.  90% confluent hMSCs were trypsinized and placed in ELP-PEI coated flask 
for 24hrs.  hMSC images were taken before and after ELP-PEI treatment.  After 24 
hours, ELP-PEI treated hMSCs were tested within the DEP microdevice using AC 
fields and static frequencies. 
Data Acquisition: 30 fps video recordings using LabSmith SVM Synchronized 
Video Microscope 10x objective (LabSmith, Livermore, CA, USA) were collected.  
DEP behaviors of the untreated hMSCs and ELP-PEI treated hMSCs were quantified 
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with ImageJ (NIH, Bethesda, MD) by recording cell position and number after 90s in 
the AC electric field.  Percent cell responses (Rc) were calculated by tabulating the 
number of cells, ni, exhibiting nDEP and pDEP behaviors (where i = nDEP, pDEP, 
pDEP-nDEP) divided by the total number of cells, nT, tested. 
, (6) 
Rc was plotted as a stacked column chart to show hMSC nDEP, pDEP, and 
pDEP-nDEP behavior at individual static frequencies, Figure 4.3a and 4.3b.  Next, Rc 
was translated to a traditional DEP spectra plot (inspired by [48]) by scaling the nDEP 
responses by fCM,min and pDEP responses by fCM,max calculated via Equations 1-3 for 
each conductivity.  The scaled equations were, 
, (7) 
 . (8) 
At 0.030S/m, fCM,min = -0.45 and fCM,max = 0.72 and for 0.10S/m, fCM,min = -0.49 and 
fCM,max = 0.36.  If the magnitude of the scaled Rc,nDEP was larger than the scaled Rc,pDEP 
then Rc,nDEP was selected if not then Rc,pDEP was selected.  The DEP spectra transitions 
from nDEP to pDEP when Rc,nDEP Rc,pDEP = 0.50 (at the fxo) as illustrated in Figure 
4.3c. 
Comparison to Model: The resulting DEP spectra for untreated and ELP-PEI 
treated hMSCs were separately fit to the core-shell spherical DEP polarization model. 
The starting literature values were ?mem = 6.5 [49-51, 14, 52], ?mem = 10-6 [49-51, 14], 
min., CM
T
nDEP
nDEPc fn
nR ??
max., CM
T
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?
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?cyto = 60 [49, 50, 14, 52], ?cyto = 0.63S/m [49-51, 14, 52].  These dielectric parameters 
(?mem, ?mem, ?cyto, and ?cyto) were iteratively adjusted in Equations 1-3 starting from the 
literature values, then varied to obtain the best curve fit to experimental data.  R = 
20?m was used for each optimization.  Cmem was calculated from fxo to obtain 
parameters for ?mem via equations 4 and 5. 
4.5 Results and Discussion 
Static frequency measurements were completed from 0.010MHz to 35MHz to 
establish hMSCs DEP response spectra to then calculate untreated and ELP-PEI 
treated hMSCs dielectric properties.  Static measurements were completed at 10Vpp 
for 90s at each individual frequency and Figure 4.2 illustrates the hMSC spatial cell 
counts and subsequent Rc at 0.010, 1.0, and 10MHz for untreated hMSCs.  The 
notation nDEP-pDEP indicates cells that initially exhibit pDEP and then transition to 
nDEP, a behavior that is pronounced near fxo (see Figure 4.3).  
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Figure 4.2 (a) Microscope images of untreated hMSCs DEP response with the field 
off and at 0.010, 1.0, and 10MHz after 90s in 0.10S/m dextrose solution.  At 
0.010MHz, hMSCs only display nDEP and display both nDEP and pDEP at 10MHz. 
(b) Table of total cells for each image.  (c) DEP responses tabulated as % cell response 
(Rc) into a stacked column chart.  nDEP dominates at 0.010MHz and at 10MHz pDEP 
is 79% dominant. 
To examine the medium conductivity dependence, hMSCs were tested in 
0.030S/m and 0.10S/m at fixed 10Vpp for 90s at each individual frequency.  
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Experiments were rerun until n > 300 cells and were tabulated at each frequency.  
Figure 4.3a and 4.3b show the stacked column representation of hMSCs DEP response 
in 0.030S/m and 0.10S/m, respectively.  In 0.030S/m media, nDEP (gray) is the 
dominant behavior up to ~0.65MHz, at which point the DEP behavior transitions to 
pDEP (green) dominance.  Individual cells experiencing both pDEP and nDEP (red) 
within one experimental run are seen between 0.10–2MHz.  In 0.10S/m media, nDEP 
is dominant until ~1MHz and then transitions to pDEP behavior following a similar 
trend as the lower conductivity but with the frequency response shifted higher.  Figure 
4.3c illustrates the translation of the Rc responses to hMSCs DEP spectra at 0.030S/m 
and 0.10S/m, respectively.  The DEP spectra curve shift is more apparent with this 
plot format.  Thus, hMSCs display different fxo’s dependent on the conductivity of the 
suspending solution, 0.030S/m fxo = 0.62MHz and 0.10S/m fxo = 1.3MHz.  The 
frequency shift of 0.68MHz is consistent with other medium conductivity experiments 
in the literature [39].  It was also observed that the DEP force weakened (slower hMSC 
movement) as the fxo was approached. 
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Figure 4.3 (a) Percent cell response Rc for untreated hMSCs in 0.030S/m dextrose 
solution.  (b) Rc for untreated hMSCs in 0.10S/m dextrose solution.  For both 
conductivities, nDEP dominates lower frequencies while pDEP dominates higher 
frequencies.  (c) Data from a and b translated into DEP response spectra for untreated 
hMSCs at 0.030S/m and 0.10S/m.  This format best illustrates 0.030S/m fxo estimated 
as 0.62MHz and 0.10S/m fxo estimated as 1.3MHz.   
The experimental data in Figure 4.3 was compared to the core-shell spherical 
DEP polarization model (equations 1 - 3) as illustrated in Figure 4.4.  The experimental 
fxo’s were used in equations 4 and 5 to calculate Cmem and ?mem of 2.2pF and 2.0, 4.5pF 
and 4.1 for 0.030S/m and 0.10S/m, respectively.  The ?mem’s were utilized along with 
starting model parameters specified in materials and methods and optimized ????mem = 
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0.79, ?mem = 10-6, ?cyto = 60, and ?cyto = 0.50S/m for 0.030S/m (Figure 4.4a solid curve 
and Table 4.1).  0.030S/m experimental data (open green diamonds) has good 
agreement with the core-shell spherical polarization model, with an overall 23% error.  
For 0.10S/m, model parameters were separately optimized ????mem = 1.1, ?mem = 10-6,
?cyto = 60, ?cyto = 0.50S/m (Figure 4.4a dashed curve and Table 4.1) and agreed well 
with the experimental data (open blue triangles), with an overall 17% error.  
Figure 4.4  (a) Untreated hMSC DEP responses at 0.030 and 0.10S/m compared to 
the core-shell spherical model.  (b) hMSC membrane capacitance and (c) membrane 
permittivity based on experimentally determined cross-over frequency. 
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In order to elucidate the morphology contribution to the DEP response spectra, 
ELP-PEI treated hMSCs were examined following the same experimental procedures 
in 0.10S/m.  Figure 4.5 compares ELP-PEI treated to untreated hMSCs experimental 
images to DEP response spectra.  Figures 4.5a and 4.5b illustrate the morphological 
changes between untreated hMSCs attached to the bottom of the cell culture flask and 
ELP-PEI treated hMSCs spheroidal cells and cell aggregates, which do not adhere to 
the flask bottom.  These images indicate that treated hMSCs formed spheroidal 
aggregates consistent with liver cells, H35 rat hepatoma cells, and 3T3 mouse cells 
described in previous literature [46, 47]; therefore the ELP-PEI treatment on the 
hMSCs was successful in producing spheroidal morphology.  Figures 4.5c and 4.5d 
compare untreated and ELP-PEI treated hMSCs within the DEP microdevice with the 
electric field off.  With the field off, hMSC suspensions were randomly distributed 
within the microwell, although cell aggregates were apparent with the treated hMSCs. 
Figures 4.5e and 4.5f compare untreated and ELP-PEI treated hMSCs at 0.010MHz 
after 90s in the AC field.  Both the untreated and treated hMSCs display nDEP 
behavior, but the treated hMSCs were more aggregated.  At increased frequencies 
1.0MHz (Figure 4.5g and 4.5h) and 10MHz (Figure 4.5i and 4.5j), untreated hMSCs 
exhibit both nDEP and pDEP behavior while ELP-PEI treated hMSCs only exhibit 
nDEP.  
Figure 4.5k the corresponding DEP spectra for untreated hMSCs (open red 
triangles) and treated hMSCs (open red triangles).  At high frequencies (>10MHz), 
ELP-PEI treated hMSCs exhibit primarily nDEP with minor pDEP behaviors. 
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However, untreated hMSCs reveal nDEP behavior at lower frequencies, and pDEP at 
higher frequencies with the fxo ~1.3MHz.  There was not a fxo value within the tested 
frequency range for treated hMSCs, so Cmem and ?mem were estimated to be >0.13pF 
and >0.12 with fxo>35MHz.  For untreated hMSCs, cell counts were at least 300 for 
each static frequency tested.  Treated hMSCs were aggregated spheroids, therefore the 
cell counts are denoted n’.  Lower n’ numbers were tolerated at lower frequencies 
where nDEP clearly dominated the responses. 
Figure 4.5 Untreated hMSCs (first row) compared to ELP-PEI treated hMSC 
spheroidal morphology (second row), both in 0.10S/m dextrose solution.  (a) untreated 
hMSCs in cell culture flask, (b) treated hMSCs after 24hrs in cell culture flask, (c) 
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untreated and (d) treated hMSCs in microdevice with field off where black regions are 
the quadrapole electrodes.  Untreated and treated hMSCs at 10 Vpp and 0.010MHz (e 
and f), 1.0MHz (g and h), and 10MHz (i and j). (k) DEP response spectra of untreated 
and ELP-PEI treated hMSCs in 0.10 S/m.  Untreated cells transition from nDEP to 
pDEP at ~1.3MHz, while treated cells predominantly exhibit nDEP behaviors and 
formed spheroidal aggregates. 
The ELP-PEI treated hMSCs DEP experimental data at 0.10S/m was also fit 
to the core-shell spherical DEP polarization model as shown in Figure 4.6.  Because 
fxo could not be directly measured, model parameters ?mem, ?mem???cyto???????cyto were 
systematically adjusted from theoretical values to arrive at best fit parameters in 
Figures 4.6a through 4.6d, respectively.  For each individual parameter optimization, 
the other three literature values were held constant as illustrated in Table 4.1.  
Membrane permittivity adjustments in Figure 6a revealed that decreasing ?mem from 5 
[49-51, 14, 52] to 0.050 better matched the experimental data.  Membrane conductivity 
adjustments in Figure 4.6b from ?mem 10-5 down to 10-7 [49-51, 14] had very little 
impact on achieving model/data agreement.  Cytoplasm permittivity adjustments in 
Figure 4.6c from ?mem 6 up to 100 [49, 50, 14, 52] also had very little impact on 
achieving model/data agreement.  Cytoplasm conductivity adjustments in Figure 4.6d 
from ?cyto 0.63S/m [49-51, 14, 52] down to 6.3 x 10-3 S/m, achieved good agreement 
with experimental data and may account for the nDEP behavior displayed by the ELP-
PEI treated hMSCs.  Figure 4.6e compares the optimized model parameters for 
untreated and treated hMSC.  These values are simultaneously summarized in Table 
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4.1.  All final model parameters lie within the range of previously reported literature 
values, except the membrane permittivity and cytoplasm conductivity, which were 
slightly lower than the lowest reported value of 6.5 [49-51, 14, 52] and 0.63 S/m [49-
51, 14, 52], respectively.  
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Figure 4.6 Key parameter optimizations for the core-shell spherical DEP polarization 
model for ELP-PEI treated hMSCs at 0.10S/m.  (a) Decreases from literature values 
in membrane permittivity better capture ELP-PEI treated hMSCs nDEP behaviors.  (b) 
Increases or decreases in membrane conductivity do not contribute to the 
experimentally observed nDEP.  (c) Decreases in cytoplasm permittivity also do not 
contribute.  (d) Decreases in cytoplasm conductivity may contribute to the nDEP 
behavior with ?cyto= 6.3 x 10-3 S/m fitting well.  (e) Model prediction for both untreated 
and treated hMSCs at 0.10 S/m using all optimal parameters for each.  Agreement 
between the model and the data is quite good with an overall 2.5% error. 
Table 4.1 Summary of literature and optimized parameters for core-shell spherical 
DEP polarization model for untreated and treated hMSCs in 0.030S/m and 0.10S/m. 
?mem ?mem 
(S/m) 
?cyto ?cyto (S/m) 
Literature Range 
(starting model 
values) 
[references] 
6.5-11 
(0.50) 
[49-51, 
14, 52] 
10-3-10-8 
(10-6) 
[49-51, 
14] 
50-100 
(60) 
[49, 50, 
14, 52] 
0.30-0.88 
(0.63) 
[49-51, 
14, 52] 
Untreated 
0.030S/m 
0.79 10-6 60 0.50 
Untreated 
 0.10S/m 
1.1 10-6 60 0.50 
ELP-PEI Treated 
0.10S/m 
0.050 10-6 60 6.3x10-3 
In review, there was an observable conductivity dependence on the DEP 
behavior of untreated hMSCs in 0.030S/m and 0.10S/m.  This dependency was most 
discernable near the hMSCs frequency transition region from nDEP to pDEP and the 
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fxo value, both were encompassed in the range of 0.61 and 1.4 MHz.  Maxwell-Wagner 
interfacial polarization mechanisms dominate in the frequency range from 0.010MHz 
to 10MHz in the ?-dispersion region [40] such that an observed fxo is influenced by the 
ionic interactions of the hMSCs membrane with  the surrounding medium.  As the 
frequency increases in the MHz range, this interfacial polarization transitions to being 
dominated by the membrane permittivity, which was more consistent with the 
optimized model parameters in Table 4.1.  Thus at 0.10S/m, the hMSCs membrane 
was electrically more permissive to the ions driven by the AC field evidenced by the 
shift in the DEP spectra to higher frequencies.  These experimental findings were 
consistent with the core-shell DEP polarization model optimization whereby the 
cytoplasm properities did not vary, but the membrane parameters did (Table 4.1 
summary).  These experimental observations were corroborated with increases in the 
calculated membrane capacitance, 2.2 pF and 4.5 pF at 0.030S/m and 0.10S/m, 
respectively.  Small deviations between the experimental data and the core-shell 
spherical DEP polarization model likely occurred because the model does not account 
for all of the hMSCs morphological and biosurface marker complexities. 
 To reduce the hMSCs morphological complexity, the cells were treated with 
ELP-PEI to yield a uniform spheroidal cell shape.  The ELP-PEI treatment 
concurrently caused some hMSCs to form spheroidal aggregates consistent with 
previous work [46, 47].  For low frequencies, 0.010–0.10MHz, untreated and ELP-
PEI treated hMSCs similarly exhibited nDEP, suggesting comparable membrane 
resistance at those frequencies.  Above 0.10MHz, ELP-PEI treated hMSCs only 
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exhibited nDEP behavior, which deviated from untreated hMSCs that transitioned to 
pDEP behavior.  There are a few possible scenarios to explain this behavior: (1) the 
ELP-PEI may be incorporating itself into the hMSCs membrane, (2) small 
concentrations of ELP-PEI could be present in the dextrose solution surrounding the 
cells, and/or (3) cells aggregating into spheroids could shield membrane polarization 
effects.  
Within hypothesis (1) context, that ELP-PEI may have intercolated into the 
hMSCs membrane, the core-shell spherical DEP polarization model key parameters in 
Figure 4.6 and Table 4.1 illustrate that decreases in hMSCs membrane permittivity 
were necessary to match experimental data (?mem is 0.050).  A decrease in cytoplasm 
conductivity from 0.63 S/m to 6.3 x10-3 S/m also supports this claim (Figure 4.7d), but 
since the DEP tests were completed in the ?-dispersion region, its unlikely that the 
DEP responses recorded were representative of the cytoplasm structure inside of 
hMSCs.   
Because the ELP-PEI treatment caused hMSCs to form spheroidal aggregates, 
size effects were examined.  Using the treated hMSCs starting model parameters 
(Table 4.1) in the core-shell spherical DEP polarization model, the size would have to 
reduce to 0.75?m to exhibit nDEP behavior similar to the observed experimental data. 
This was not feasible for the treated cells and their aggregates, which had average sizes 
of 17 ± 4?m and 43 ± 16?m, respectively.  The increased size of the treated hMSC 
aggregates would increase the exerted DEP force.  However, there was no evidence 
that this size increase would prevent interrogation of biosurface markers present on 
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hMSCs membranes.  Data did show strong media/membrane polarization behaviors, 
which are prerequisites for surface biosurface marker-induced stem cell separations in 
nonlinear AC electric fields.  We conclude that the ELP-PEI treatment did achieve 
standardization of the hMSCs morphology and simultaneously altered DEP behavior. 
4.6 Conclusions 
hMSCs are an important cell system due to their differentiation capacity, 
trophic activity, and their ability to self-renew.  Their therapeutic potential is currently 
being explored through clinical trials to treat lupus, Crohn’s disease, and diabetes 
mellitus.  For successful and effective stem cell therapies, hMSCs purification after 
bone marrow isolation could be considerably improved to increase selective recovery 
of the most highly viable cells.  Separation techniques like FACS and MACS are 
expensive and alter cellular function and viability due to antigen tagging.  User-
friendly DEP microdevices have previously demonstrated rapid cell separation and no 
loss in cell viability with low voltage AC electric fields [37].  hMSCs populations are 
heterogeneous with varied morphology, so the development of a continuous cell 
sorting microdevice needs to concurrently control for and accurately measure (1) 
hMSCs dielectric signatures and (2) cell morphology variations.  The later was 
accomplished in this work by morphologically standardizing the cell population with 
ELP-PEI.  Additionally, hMSC population heterogeneity correlates with biosurface 
marker expression predisposing cells for adipocytes, chondrocytes, and osteoblasts.  
Thus, after morphological standardization, precise measurements of DEP dielectric 
signatures may facilitate biosurface marker-dependent cell separations.  
138 
hMSCs have a distinct dielectric dispersion defined by internal structures, cell 
membrane and cytoplasm.  hMSCs membrane mostly affects the DEP response at 
radio frequencies in the ?-dispersion region; the radio frequencies polarize the hMSCs 
surface, facilitating a DEP force along the field gradient, and thus allowing 
interogation of the cell membrane dielectric properties.  The DEP results in this work 
reveal that the conductivity of hMSCs suspending solution is critical to the membrane 
polarization.  Higher conductivity solutions increase the membrane  permittivity 
shifting the DEP spectra to higher frequencies for 0.10S/m than 0.030S/m.  This 
translates to a membrane capacitance increase from 2.2 pF for 0.030S/m to 4.5pF for 
0.10S/m.  Similarly, the membrane permittivity increases from 2.0 for 0.030S/m to 4.1 
for 0.10S/m.  The solution conductivity dependence was also apparent at the fxo for 
hMSCs; 0.030S/m yields a lower fxo at 0.62MHz and 0.10 S/m yields a lower fxo at 
1.3MHz.  Frequency ranges tested did not enable measurement of the higher fxo.  This 
dielectric signature is unique for hMSCs because typical low fxo’s for other cell 
systems fall in the range of 0.010-0.10MHz [44].  These differing DEP spectra could 
be harnessed for hMSC cell separations from these other cell systems.  Complicating 
any separation endeavor is that the untreated hMSC DEP responses at static 
frequencies varied within a single culture, thus reproducible separations need to 
consider and control for biosurface marker expression. 
The ELP-PEI treatment successfully standardized hMSCs population 
morphology, although spheroidal cell aggregates were concurrently observed.  The 
ELP-PEI treatment concurrently increased the DEP response reproducibility.  This 
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standardization occurred because the polymer interacted with the cell membrane and 
shifted hMSCs polarization behaviors.  Only nDEP responses were observed from 
0.010–10MHz, which was substantially different from untreated hMSCs.  The 
spheroidal cell aggregates present after ELP-PEI treatment should increase the DEP 
force, which is proportional to cell radius cubed.  However, the strong 
media/membrane polarization behaviors observed suggest that this hMSC cell system 
is a good candidate for future surface biosurface marker-induced stem cell separations. 
With optimization of the ELP-PEI treatment, detection of molecular level differences 
in hMSCs may be realizable to aid understanding of biological functions and cell 
population purification for stem cell therapies.  
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Chapter 5 Frequency Sweep Rate Dependence on the 
Dielectrophoretic Response of Polystyrene Beads and Red 
Blood Cells [1] 
1T. N. G. Adams, K. M. Leonard, and A. R. Minerick 
5.1 Abstract 
Alternating current (AC) dielectrophoresis (DEP) experiments for biological 
particles in microdevices are typically done at a fixed frequency. Reconstructing the 
DEP response curve from static frequency experiments is laborious, but essential to 
ascertain differences in dielectric properties of biological particles. Our lab explored 
the concept of sweeping the frequency as a function of time to rapidly determine the 
DEP response curve from fewer experiments. For the purpose of determining an ideal 
sweep rate, homogeneous 6.08?? polystyrene (PS) beads were used as a model 
system.  Translatability of the sweep rate approach to ~7?? red blood cells (RBC) was 
then verified. An Au/Ti quadrapole electrode microfluidic device was used to 
separately subject particles and cells to 10Vpp AC electric fields at frequencies 
ranging from 0.010–2.0 MHz over sweep rates from 0.00080 to 0.17 MHz/s. PS beads 
exhibited negative DEP assembly over the frequencies explored due to Maxwell-
Wagner interfacial polarizations. Results demonstrate that frequency sweep rates must 
1 The material contained in this chapter was previously published in 
Biomicrofluidics, 2013. 7: p. 064114. 
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be slower than particle polarization timescales; sweep rates near 0.00080 MHz/s 
yielded DEP behaviors very consistent with static frequency DEP responses for both 
PS beads and RBCs. 
Key Words: Dielectrophoresis, frequency sweep, polystyrene beads, red blood cells, 
interfacial polarization, microfluidic devices 
5.2 Introduction 
Microfluidic and dielectrophoretic (DEP) technologies enable a wide variety 
of particle polarizations with nonuniform electric fields on microchips [2, 3] to achieve 
particle manipulation, concentration, separations, and property-based identification. 
Particles [4-6] include bioparticles (DNA [7], virus [8], protein [9]) as well as cells 
(blood cell types [10, 11], cancer [12-14], stem cells [15], and yeast [16]).  The 
advantages to coupling DEP with microfluidics are small sample size (on the order of 
microliters), rapid analysis (approximately minutes to achieve results), minimal 
sample preparation, and minimal waste production [17, 18].  Traditionally, DEP 
experiments are completed at static, fixed frequencies such that maximum particle 
polarization can be achieved and measured.  Multiple experiments are conducted, each 
at discrete frequencies over the range of interest to stitch together DEP response 
spectra; this is a labor-intensive approach.  Further disadvantages are that extended 
field exposure times at fixed frequencies can change particle properties [15] or cell 
viability [19].  Prior research has used rapid frequency sweeping to increase cell 
separation efficiency [20-24], but to the best of our knowledge, frequency sweeping 
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has not been explored to generate continuous DEP spectra.  Therefore, a detailed study 
examining the effects of frequency sweeping on particle polarization is pertinent and 
timely.  In this paper, we demonstrate that frequency can be swept with time in the ?-
dispersion region thus enabling interrogation of cells at multiple frequencies within a 
short time period.  The benefits of using a frequency sweep technique are that nearly 
continuous DEP response curves, when coupled with automated response analysis, can 
be compiled in near real time and the number of experiments needed to obtain particle 
DEP spectra are greatly reduced.  
DEP enables phenotypically similar biological cells to be discriminated based 
on dielectric properties including the conductivity and permittivity of the membrane, 
cytoplasm, and other structurally relevant organelles.  Cell components and structure 
contribute to a cell’s signature dielectric dispersion [3, 16].  A particle’s complex 
permittivity is frequency dependent and characterized by dielectric dispersion regions 
?????????????? ??????? ???? ????) specific to an applied frequency.  This work explores 
0.010 to 2.0 M???????????-dispersion region [25] because the Clausius-Mossotti factor, 
which governs sign and polarization strength, for polystyrene beads is nearly constant 
over this range.  Maxwell-Wagner theory describes the polarization mechanism of 
??????????????????-dispersion region as interfacial polarization where moving charges 
build around the interface of a charged or charge-neutral particle and exchange ions 
with the suspending medium (ref. [26], pp.33-38).  Interfacial particle polarization 
creates an induced dipole moment such that the particle experiences disproportionate 
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forces in each half cycle of the alternating current (AC) field resulting in net particle 
movement (ref. [26], pp. 8-11).  
Polarized particles can exhibit either positive dielectrophoresis (pDEP) or 
negative dielectrophoresis (nDEP) as a consequence of the frequency-dependent 
polarizability of the particle in the surrounding medium (ref.[26], p.10) [27].  Particles 
that exhibit pDEP move to high electric field regions and particles that exhibit nDEP 
move to low electric field regions [3, 16].  This motion up and down electric field 
gradients is described by the Clausius-Mossotti factor for spherical particles [16] 
, (1) 
, (2) 
where is the complex permittivity of the particle (i=p) and of the medium (i=m),
which are both functions of conductivity ?????permittivity ???????? angular frequency
????) [26]. 
Polarization is not an instantaneous event [28]; charge transport into the 
interface takes a few microseconds in response to the electric field. Maxwell-Wagner 
dielectric relaxation is a physical phenomena related to the transport delay of cation 
and anion alignment in and around the interface of the dielectric particle [29].  At 
lower frequencies (<~10 MHz), particle polarization is driven by this conductive 
polarization.  At higher AC frequencies, charges do not have enough time to move into 
and around the interface double layer, so particles experience polarization lag time as 
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a result of the rapidly modulating field and do not reach maximum polarization.  
Maxwell-Wagner dielectric relaxation is char???????????????????????????????MW, which
is unique to each particle or cell due to the time constant’s dependence on the cell 
dielectric properties.  The time required for a particle to reach maximum polarization 
given by (ref. [26] ,p. 27) [25, 30] 
. (3) 
Typical relaxation times for particle polarization vary from pico to microseconds (ref. 
[26],p. 37) [25, 30], and the calculated ?MW for polystyrene (PS) beads in our Epure 
H2O medium at 2.5x10-4 S/m is 3.5 μs.  Thus, a single AC cycle is on the order of 0.01
to 2 μs; the time delay in ion transport within a static frequency field of 0.010 to 2.0 
MHz is such that 2 to 350 AC cycles must be completed before the particle experiences 
full polarization.   
The Maxwell-Wagner dielectric timescales for charge transport into and 
around the interface becomes important when the frequency is swept, i.e. changes as 
a function of time.  Figure 5.1a crudely cartoons the Maxwell-Wagner particle 
polarization at the interface under static frequency as well as slow and fast frequency 
sweep rates.  At a static frequency in the ?-dispersion region, the particle experiences 
a constant frequency field such that the relaxation time is not a factor and the particle 
fully polarizes.  A particle in a field with a slowly changing frequency sweep has 
relaxation time, ??FS, that is less than ?MW and thus the particle interface fully polarizes. 
In contrast, a particle in a fast frequency sweep has a relaxation time, ??FS, that is larger 
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than ?MW and the particle interface does not have time to fully polarize in the field.  PS 
beads are lossy dielectric particles treated as homogeneous spheres and are thus an 
idealized particle to examine new techniques, devices or approaches to 
dielectrophoretic characterizations.  Our system is easily able to discern pDEP and 
nDEP transitional behavior and adaptable to our new frequency sweep technique.  The 
homogeneous spherical DEP polarization model for PS beads ???????????????????????-
5 S/m) suspended in Epure H2O displays only nDEP behavior over 0.010 to 2.0 MHz.  
In this study, dielectrophoretic responses of PS beads (model system) were 
quantified at both static frequencies and frequency sweeps at rates ranging from 
0.00080 to 0.17 MHz/s ??????????-dispersion frequency range of 0.010-2.0 MHz in 
Epure H2O medium at 2.5x10-4 S/m.  At these experimental conditons AC 
electroosmosis, normally at 100-500kHz, and electrothermal flow, normally occurs in 
high conducitivity media 1 S/m or greater, was not a factor [31].  PS bead motion in 
the electric field was imaged with video microscopy and analyzed using three 
techniques: intensity profiles, transient response, and particle velocities.  Image 
intensity analysis has been used by other researchers to quantify the pDEP and nDEP 
behavior of particles representing particle concentration [32], voltage trapping [33], 
cell counting [34], and noncontinuous DEP spectra [35, 36].  Our intensity analysis 
method is used to develop a continuous DEP response spectra and data shows that 
frequency sweep rates impact particle polarization due to dielectric relaxation 
limitations.  This frequency sweep technique was further extended to negatively 
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charged biconcave red blood cells (RBCs), which are an important cellular system for 
medical disease diagnostics [37-39].  
Figure 5.1 (a) Dielectric relaxation mechanism for PS beads showing cases when i) 
particle polarization occurs at a static frequency, ii) ?MW is shorter than the slow 
frequency sweep rate (??FS) allowing the bead interface time to polarize in response to 
the nonuniform AC field, and iii) ?MW is longer than the ??FS for fast frequency sweep 
rates and the bead interface does not have time to fully polarize. (b) Schematic of the 
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quadrapole electrodes micro patterned onto a glass slide, and (c) microdevice with 
PDMS fluidic layer bonded above the quadrapole electrodes silver epoxies to copper 
leads. 
5.3 Materials and Methods 
The microdevice shown in Figure 5.1c was fabricated according to previously 
published microfabrication techniques [7], with the 1???? wide electrodes spaced 
????? apart aligned at 90o along the bottom ??? ?? ??? ??? ????? ??? ????? ????????
microfluidic chamber as shown in Figure 5.1b.  Polystyrene beads (Cat No. PP-60-10, 
Spherotech, Lake Forest, IL, USA), 6.08 ?? in diameter were centrifuged at 1300 min-
1 for 5 mins to separate the beads from the liquid. The PS beads were resuspended in 
Epure H2O ???? ???????????-4S/m) at a 1:10 (bead to water) volumetric dilution ratio 
and vortexed.  Microdevice was pre-rinsed with Epure H2O and Alconox precision 
cleaner (Cat No. 1104, Alconox Inc, White Plains, NY, USA) to prevent bead 
adhesion.  PS bead-Epure H2O suspension was pumped to the microchamber using a 
syringe.  Time was allowed for inlet and outlet pressures to equalize and flow to stop. 
The function generator (Agilent 33250A, Agilent, Santa Clara, CA, USA) was 
connected via copper leads to produce a 10Vpp AC sine wave with frequencies 
ranging from 0.010-2.0 MHz at specific frequency sweep rates 0.00080, 0.0011, 
0.0030, 0.0063, 0.013, 0.021, 0.028, 0.042, 0.056, 0.083, and 0.17 MHz/s.  Frequency 
sweeps linearly increased the applied frequency as a function of time.  Greater than 
five (n>5) static frequency experiments were completed at each frequency 0.010, 
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0.020, 0.030, 0.040, 0.050, 0.20, 0.40, 0.60, 0.80, 1.0, 1.2, 1.4, 1.6, 1.8, and 2.0 MHz 
by applying 10Vpp for 90s.  These DEP static frequency responses were compared to 
each frequency sweep rate DEP responses. For the static and frequency sweep 
experiments, the PS bead concentration was between 238-263 beads in the t=0 field of 
view.  Video recordings of experiments were taken at 30 fps at 640x480 pixels/image 
using LabSmith SVM Synchronized Video Microscope with a 10x objective 
(LabSmith, Livermore, CA, USA). 
Video recordings of PS beads DEP behaviors were analyzed with ImageJ 
(NIH, Bethesda, MD) using intensity, transient slope, and velocity measurements. 
Since PS beads only exhibit nDEP over the frequency range of interest, intensity data 
acquisition from images was completed by drawing a rectangular box at the device 
center, ICTR, and background, IBK measured in a location with no PS beads present (See 
Figure 5.2a).  ImageJ Z Project function was used to average the pixel intensities in 
the specified boxed region.  The initial background, IBK(t=0) and center intensity,
ICTR(t=0) were subtracted from the center and background intensity at each time, 
ICTR(t) and IBK(t), and then a normalized intensity was calculated by dividing by the 
maximum intensity experienced by the PS beads, 
(4) 
This normalized intensity tracked the real-time magnitude of the PS bead DEP 
response, which had two distinct regions: transient where beads moved with nDEP 
toward the center, and steady-state (SS) where beads achieved tight packing at the 
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device center.  These two responses were analyzed separately via transient slope and 
particle velocity.   
The transient response of the PS beads was extracted from the steady-state 
response via signal processing in which the delay and rise time were quantified.  The 
PS bead delay time, td, was characterized as the time required for the intensity response 
to reach 50% of the final intensity response for the first time.  The rise time, tr, was 
determined as the time needed for the intensity response to reach 100% of the final 
intensity response for the first time (ref. [40], pp. 517-518).  This allowed the transient 
response to be segmented and a linear trend line was fit between td and tr where td< tr. 
A comparison of the transient slope for frequency sweep rates and static frequency 
measurements is given in Figure 5.3c.  PS bead velocities were determined from the 
original video by tracking the x-, y-pixel position of individual PS beads from 0-50s. 
???????? ??????????????????????? ?????????? ?????????? ????????? ??? ???????? ???? ????????
electric field gradients.  This procedure was repeated for at least 10 beads in each 
specific frequency sweep rate and static experimental video.  
For the experiments involving human RBCs, blood type O+ was obtained from 
a single donor and centrifuged at 1400 rpm for 5 mins to separate the packed RBCs 
from the plasma and leukocytes.  The packed RBCs were removed, then resuspended 
at 1:75 v:v in 0.10 S/m isotonic dextrose buffer doped with 0.75% BSA (Cat No. 
A7906, Sigma Aldrich, St. Louis, MO, USA) to prevent cell/device adhesion.  This 
RBC suspension was syringe-pumped to the microchamber, time allowed for flow to 
stop and the 10Vpp signal applied over 0.010-0.50 MHz (range reduced to avoid pDEP 
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behavior) at frequency sweep rates of 0.00080, 0.0063 and 0.056 MHz/s (n=7).  RBC 
static frequency experiments were completed at 0.010, 0.10, 0.25 and 0.50 MHz at 
10Vpp for 90s (n=7).  Video microscopy at 25x and 1 fps was obtained with a Zeiss 
Axiovert Inverted Light Microscope (Zeiss, Germany).  The video images were 
analyzed as described above for the PS beads. 
5.4 Results & Discussion 
Frequency sweep rates ranging from 0.00080 to 0.17 MHz/s were explored to 
see if the nDEP response of PS beads would vary and/or correspond to static frequency 
measurements.  The frequency range was chosen for the relatively consistent Clausius-
Mossotti factor, Re(fCM) for a homogeneous lossy polystyrene sphere of 0.26 to 0.48 
(see Figure 5.2c) over the frequency range of 0.010 to 2.0 MHz.  Static frequency 
experiments were completed at fixed values in this same frequency range.  Figure 5.2a 
shows still images from both static frequency experiments and the frequency sweeps 
at 0.20, 0.60, and 1.0 MHz.  For static frequencies, the response 45 seconds after field 
application is shown while for frequency sweeps of 0.0063, 0.056, and 0.17 MHz/s, 
the image is shown at the time stamp when the specified frequency is reached.  The 
electrodes are visible as black shadows in the images and the PS beads assemble due 
to nDEP forces at the central electric field gradient minima.  Data was examined to 
determine the sweep rate that most closely approximated the static frequency response. 
Frequency sweeps 0.00080 and 0.0063 MHz/s (shown) tracked static frequency, or 
true, DEP responses while the slightly faster sweep of 0.056 MHz/s begins to lag the 
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true DEP responses and at 0.17 MHz/s and faster, particles were unable to achieve 
sufficient polarization to respond sufficiently in the electric field.  
nDEP responses were quantified via intensity analysis as described in materials 
and methods for all sweeps and all static frequency experiments.  Figure 5.2b 
illustrates the frequency (and time) dependent intensity for the 0.0063 MHz/s sweep 
rate images shown in Figure 5.2a.  This quantification of the PS bead nDEP response 
was correlated to total bead packing via the calibration shown in the inset.  The 188-
bead count at the center deviates slightly from the initial, field off, bead count of 245 
because PS beads also move down the electric field gradient to regions outside of the 
image field of view.  
Figure 5.2 (a) nDEP behavior of 6μm PS beads suspended in E-pure H2O 2.5x10-4
S/m and 250Vpp/cm 0.0063, 0.056 and 0.17 MHz/s sweep rates from 0.010 MHz to 
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1.0 MHz. (b) Raw intensity profile of PS beads in the center nDEP region (boxes 
shown at 0.20 MHz) at 0.0063 MHz/s sweep rate. Inset is a calibration of intensity per 
bead. (c) Clausius-Mossotti factor for the PS beads from 0.010 MHz to 2.0 MHz at 
three conductivities of 2.5x10-4, 1.0x10-3, and 1.0 S/m. PS bead assembly at slower 
frequency sweep rates track static frequency responses while 0.056 MHz/s illustrates 
transitional behavior and frequency sweeps above 0.17 MHz/s substantially lag the 
true static frequency DEP responses. 
Normalized intensities, Eq. (4), were compiled in Figure 5.3a for SS (i.e. 45 
seconds) static frequency nDEP responses and 0.00080, 0.0063, 0.056 MHz/s 
frequency sweep rate nDEP responses.  The time for sweep responses to achieve the 
true nDEP static response decreases as the sweep rate decreases.  Frequency sweep 
rates 0.00080 and 0.0063 MHz/s are within the 95% confidence intervals (n=7) of the 
static steady-state responses.  Figure 5.3a inset shows that the slowest 0.00080 MHz/s 
sweep rate more quickly aligns closely with the static frequency responses.  Figure 3b 
compares average 0.0063 MHz/s (n=8) to 0.17 MHz/s (n=7) with the dashed lines 
signifying the upper and lower limits of the 95% confidence intervals for IDEP.  The 
confidence intervals around the transient 0.0063 MHz/s sweeps are smaller than for 
0.17 MHz/s over much of the frequency range indicating greater reproducibility at 
slower sweep rates.  Faster sweep rates either do not reach SS or have a lag before 
reaching SS (compare to Figure 5.2a) suggesting the bead interface does not fully 
polarized and thus displays attenuated nDEP motion. 
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The transient behavior was quantified for all static frequencies and frequency 
sweeps via a transient slope analysis as compiled in Figure 5.3c.  Four static frequency 
measurements 0.010, 0.60, 1.0 and 2.0 MHz are shown compared to 0.00080, 0.0063, 
0.028, 0.056, and 0.17 MHz/s frequency sweep rates.  Static frequency transient slopes 
range between 0.023-0.095 and are within the 95% (p<0.05) confidence intervals of 
0.00080, 0.0063, and 0.028 MHz/s frequency sweep transient slopes.  These slower 
sweep rates and 0.056 MHz/s differ at p<0.001 from the fastest sweep rate of 0.17 
MHz/s, which is also significantly different at p<0.001 from the static measurements 
(except for 1.0x104 Hz with p<0.01).   
Individual bead velocities were compiled for static as well as frequency sweeps 
in Figure 5.3d.  PS bead velocity corroborates the intensity profile and the slope 
analysis that 0.00080 MHz/s frequency sweep rate closely tracks the bead velocity at 
static frequencies.  0.056 MHz/s gives good estimations of static frequency bead 
velocity at times greater than 20s.  Based on intensity, transient slope, and velocity 
analysis, the slow frequency sweep rate of 0.00080 MHz/s is most consistent with 
static frequency DEP responses.  
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Figure 5.3 (a) ?????PS beads nDEP intensity profiles for 0.00080, 0.0063, and 0.056 
MHz/s and static steady state (SS) measurements (black diamonds).  Intensity analysis 
captures bead assembly to the quadrapole center with transient and SS regions. The 
slowest frequency sweep rate of 0.00080 MHz/s best predicts the static DEP responses. 
(b) Bead assembly profiles for 0.0063 (n=8) and 0.17 MHz/s (n=7) with 95% 
confidence upper and lower limits shown as dashed lines.  (c) Transient slope 
comparison for static frequencies (0MHz/s) as well as frequency sweeps. (d) 
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Comparison of static frequency and frequency sweep PS bead velocities from 0 to 50s. 
0.00080 MHz/s results are consistently similar to the static frequency results. 
There is an observable inverse relationship between the frequency sweep rate 
and particle polarization, slower sweep rates result in comparable particle polarization 
characteristics to static frequency responses.  Dielectric relaxation is the driving force 
of this relationship; the calculated dielectric relaxation time Eq. (3) for PS beads in E-
pure H2O at 2.5x10-4 S/m is 3.5 μs, which corresponds to ~0.28 MHz.  There are two 
timescales that influence this behavior: the frequency itself and the change in 
frequency per time.  The Maxwell-Wagner, conductivity-driven interfacial 
polarization mechanism occurs below ~0.28 MHz; above this frequency threshold the 
interfacial polarization of the PS beads gradually decreases and the particle 
permittivity increasingly influences the DEP force.  The experimental frequencies 
tested were within the range dominated by Maxwell-Wagner polarization such that 
maximum particle interfacial polarization was possible.  
The second timescale of interest is the frequency change per time or frequency 
sweep rate, which determines how many consecutive cycles a particle experiences a 
specific frequency.  At slower sweep rates, the PS beads experience a specific 
frequency for a large number of cycles and thus the beads have time to polarize 
because the timescale of the frequency change is slower than the dielectric relaxation 
time.  A particle must experience a single frequency during the sweep for a minimum 
of 3.5 μs for maximum interfacial polarization to be achieved.  Upon polarization, the 
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particle, which its current DEP force has to overcome inertia and Stokes drag to 
achieve observable particle motion down the electric field gradient. At static 
frequencies, it takes roughly 5 s for maximum velocity to be attained (see Figure 5.3d, 
AC field applied at t = 5s) and as much as 45s for final SS at the field gradient minima 
to be reached.  As the sweep rate increases, the dielectric relaxation time and the rate 
of change of the frequency approach the same order of magnitude.  Results suggest 
that 0.056 MHz/s is a transitional sweep rate because the DEP behavior roughly 
corresponds to the static behavior of the PS beads.  With further increases in frequency 
sweep rates, the timescale for frequency change surpasses the dielectric relaxation 
timescale such that particles are unable to fully polarize resulting in an attenuated DEP 
response as shown with data in Figures 5.2, 5.3a, and 5.3b.  Figure 5.3b also 
demonstrates that the transient behavior of the PS beads is more reproducible at slower 
frequency sweep rates, which can be attributed to the interfacial polarization timescale 
of the beads.  Implications of the intensity, slope, and velocity analysis compared with 
static frequencies are that slow frequency sweep rates accurately predict the DEP 
response of PS beads because the changes in frequency are slower than the 
characteristic Maxwell-Wagner dielectric relaxation. 
Thus, a frequency sweep approach can be utilized to attain accurate DEP 
behavior of PS beads, provided the sweep rate is slower than conductivity mediated 
interfacial polarization timescale.  This result is reliable over frequency ranges where 
particle polarization is dominated by the conduction of free charges from the media. 
The charges are moving around the PS beads through the particle-liquid interface 
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inducing a dipole, which causes PS bead movement down the electric field gradient to 
the electrode center.  At different sweep rates the rate of movement of the charges 
varies which varies the rate of the dipole being induced, observed as dielectric 
relaxation.  Each sweep rate has a unique dielectric relaxation time and our results are 
consistent with Maxwell-Wagner interfacial polarization theory. 0.00080 MHz/s is the 
optimal sweep rate necessary to predict the true DEP behavior of PS beads because it 
allows for full or partial (when the frequency is above 0.28 MHz) polarization. 
Given that the sweep methodology yielded accurate DEP responses for the 
ideal system of PS beads, the same methodology and frequency sweep rates were 
explored with human RBCs.  The three most successful PS bead frequency sweep rates 
were reproduced with human red blood cells: 0.00080 MHz/s, 0.0063 MHz/s and 
0.056 MHz/s.  Static frequency experiments were also performed at 0.010 MHz, 0.10 
MHz, 0.25 MHz and 0.50 MHz.  Seen in Figure 5.4a are 25x microscope images taken 
of the t=45s final static frequency frames aligned above the sweep time points that 
correspond to those four static frequencies.  Qualitatively, the only sweep rate that 
accurately matches the static frequency behavior of the human RBCs is 0.00080 
MHz/s.  This behavior was further verified by the same intensity analysis as for PS 
beads.  In Figure 5.4b, the scaled intensity is plotted for 0.00080, 0.0063 and 0.056 
MHz/s experiments (n=8) as compared to the static frequency intensities.  After the 
initial 10s transition for the red blood cells to polarize and overcome drag, the slowest 
frequency sweep of 0.00080 MHz/s accurately predicts the static frequency behavior 
and is highly reproducible, with a very narrow 95% confidence interval range (Figure 
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5.4c).  The fastest sweep rate of 0.056 MHz/s does not predict the static behavior of 
the human RBCs and is much less reproducible, as evidenced by the large 95% 
confidence interval in Figure 5.4c.  From these experiments, we conclude that the 
optimal frequency sweep for determining the accurate DEP behavior of RBCs is 
0.00080 MHz/s.  Due to the complex dielectric properties of cells, it is necessary to
carefully compare frequency sweep rates with static frequency behaviors to ascertain 
optimal frequency sweep rates that accurately interrogate the cell of interest. 
Figure 5.4 (a) nDEP behavior of RBCs suspended in 0.1S/m dextrose buffer and 
250V/cm at 0.00080 MHz/s, 0.0063 MHz/s and 0.056 MHz/s sweep rates from 0.010 
MHz to 0.50 MHz. (b) RBCs nDEP intensity profiles for 0.00080, 0.0063, and 0.056 
MHz/s and static measurements. (c) 0.00080 and 0.056 MHz/s RBC assembly profiles 
n=8, with 95% confidence interval upper and lower limits shown as dashed lines. 
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The inverse relationship between the frequency sweep rate and particle 
polarization exists for RBCs.  RBC dielectric relaxation is the driving force and the 
calculated dielectric relaxation time is 4.6 μs corresponding to ~0.21 MHz.  By 
choosing to sweep at a rate slower than this relaxation time the researchers are insured 
that the response during the sweep is the same as that at a static frequency.  Further 
work is being done to explore the DEP response of RBCs when subjected to a wider 
range of sweep conditions.  
5.5 Conclusions 
Traditional DEP measurements are completed at single static frequencies in 
order to compile frequency by frequency, the DEP spectrum for a particle or cell 
system.  This method is laborious, and as illustrated in this work, requires time for 
particles to fully polarize for accurate observed DEP responses.  This work 
investigated the use of frequency sweeps as a means to more efficiently interrogate 
multiple frequencies in a single experimental run and systematically compared the 
responses to the nDEP response at fixed frequencies between 0.010 and 2.0 MHz.  It 
was observed that frequency sweep rates influence the DEP response of PS beads and 
RBCs and further, the permissible frequency sweep rate is particle or cell dependent.  
The underlying mechanism appears to be the same.  At slower sweep rates, 
particles have more time to polarize in the electric field and therefore a more accurate 
and reproducible DEP spectrum can be obtained.  At faster frequency sweep rates, the 
particles are unable to achieve maximum interfacial polarization because of the 
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dielectric relaxation time scale so the observed DEP response does not match the true 
DEP behavior of the particle.  
For polystyrene beads at frequency sweep rates below 0.0063 MHz/s, 
responses correlate closely with dielectric responses of particles subjected to a static 
frequency potential.  In the PS bead system, 0.056 MHz/s is the transitional sweep rate 
where the particle dielectric relaxation is approximately the same order of magnitude 
as the shifts in frequency within the sweep.  Dielectric responses continue to track the 
static frequency responses, although reproducibility is diminished.  However as this 
sweep rate is increased further, conductivity dominated interfacial polarizations 
cannot be established and the PS bead frequency sweep data does not coincide with 
static frequency measurements.  
For full utility in DEP experiments, this frequency sweep rate methodology 
must be translatable to cell systems.  Results illustrated that only 0.00080 MHz/s 
accurately predicted the static frequency DEP responses of human RBCs.  Red blood 
cells are substantially more morphologically and dielectrically complex than 
polystyrene beads.  Calculation of the dielectric relaxation time, taking into account 
only the membrane permittivity and conductivity of 4.4 and 10-7 S/m, respectively [41] 
yields ?????????????????????????????????????????????????????????????????????????????
relaxation time is larger than the PS bead relaxation time of 3.5 μs, so the optimal 
frequency sweep rate for red blood cells would be slower than that for PS beads.  This 
result suggests that for each new cell system of interest it is imperative to determine 
the optimal frequency sweep rate to accurately and reproducibly interrogating the 
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behavior of that cell.  This work outlines a systematic technique to make comparisons 
between frequency sweep rate and static frequency shown.  For all cell systems, sweep 
rates that are too fast will not allow the cell adequate time to polarize and will result 
in inaccurate and less reproducible DEP responses.  An optimal frequency sweep rate 
can be estimated by calculating the Maxwell-Wagner dielectric relaxation time for the 
particle/cell of interest, provided the cell’s permittivity and conductivity is known. 
The frequency sweep rate chosen for the DEP study should then remain at frequencies 
below the inverse dielectric relaxation ????? ???? ?MW) for 5-45s (longer times spent 
below the threshold give better DEP predictions).  This is necessary because frequency 
sweep rates allow for particles/cells to be polarized incrementally with faster sweep 
rates, larger frequency step size, not allowing sufficient polarization time.  Slower 
sweep rates, small frequency step size, allow particles to remain at lower frequencies 
for longer yielding full particle polarization consistent with static polarization 
measurements. 
Since the cell’s permittivity and conductivity are determined from the 
frequency dependent DEP spectrum, this presents a cyclical situation.  However, this 
work has demonstrated that frequency sweep rates slower than 0.00080 MHz/s can 
yield accurate DEP response of PS beads as well as RBCs.  This sweep rate may 
therefore be translatable to other cell systems.  In addition, at higher frequencies where 
the polarization mechanism is more heavily influenced by charge permittivity effects 
through the membrane and cell cytosol, it is possible that slow frequency sweep rates 
can still accurately capture DEP response spectra.  Lastly, this frequency sweep rate 
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technique will enable researchers to obtain accurate and continuous DEP response 
spectra in shorter experiment times. 
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Chapter 6 Conclusions: Knowledge Gained from the 
Dielectrophoretic Study of hMSCs for Type 1 Diabetes 
6.1 Summary of Human Mesenchymal Stem Cells, Type 1 Diabetes, and 
Dielectrophoretic Background Knowledge 
More than 108,000 children have type 1 diabetes with 16,000 new cases 
diagnosed each year in the U.S. [1]. There is growing evidence that links gene 
mutations, viral infections, and bacteria to the autoimmune disruption that causes type 
1 diabetes [2-25].  Because the immune system destroys the insulin producing beta 
cells [26], insulin injections are used as a management tool [27, 28]. No cure exists 
and the various complications necessitate the need for a curative therapeutic option, 
which would negate the need for insulin management strategies and reduce the risk of 
complications from the disease. An effective cure will preserve surviving beta cells, 
produce new beta cells, and protect all from autoimmune destruction in the pancreas 
[29, 30]. hMSCs have been explored as a minimally invasive therapeutic option for 
beta cell replacement therapy, and there are chemical modifications [31-34], genetic 
modification [35, 36], and nonstimulus methods [37, 38] available to differentiate 
hMSCs toward insulin producing cells.  
hMSCs have been explored because they hold high promise as a therapeutic 
treatment option for type 1 diabetes due to their differentiation ability [39], 
replenishing capacity [40], and trophic activity [41]. hMSCs are easily obtained from 
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bone marrow as a heterogeneous population [42] and require separation and 
purification before utilization in therapeutics. Within a single hMSC population, there 
are a variety of progenitor cells (adipogenic-progenitor, osteogenic-progenitor, 
chondrogenic-progenitor, etc.) and these cells have a proclivity to differentiate toward 
a specific cell type.  Since proclivity is not a 100% response, purification for individual 
therapeutic options is important.  
Thus far, hMSCs have not been well characterized and there is not a unique 
catalog of biosurface markers available that distinguishes hMSCs or separate 
progenitor cells from other cell populations. To compensate, current methodologies 
utilize density centrifugation paired with either fluorescent-activated cell sorting 
(FACS) or magnetic-activated cell sorting (MACS) to achieve hMSC subpopulation 
separations [43]. The main disadvantages for FACS and MACS methods are 
processing complexity and time, high cost, throughput, and cell antigen labeling; these 
tedious multistep separation processes are not ideal for clinical scale-up [44]. 
Therefore, this research explored dielectrophoretic (DEP) microdevices as an 
alternative. DEP first served as an hMSCs characterization technique and was used to 
complete the first steps necessary for the design of a microdevice to achieve hMSCs 
separations for type 1 diabetes therapeutic advancements.  
DEP was used in this research because a) surmounting evidence shows that AC 
electric fields are not harmful to biological cells [45], and b) separations/dielectric 
signature quantification have been achieved with neural precursor/stem progenitor 
cells [46], oral squamous cell carcinomas [47], adipose-derived stem cells [48], and 
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ovarian cancer cells [49]. Prior research has shown that DEP is a quick, low cost, 
noninvasive separation method, with non-damaging AC electric fields [50]. With a 
custom DEP quadrapole electrode microfluidic device, hMSCs dielectric properties 
were discerned with membrane capacitance and permittivity measurements. Further, 
ELP-PEI standardization of hMSC morphology was achieved and dielectric properties 
were measured within the same DEP device. The specific objectives accomplished in 
this dissertation research are summarized below.  
6.1.1 hMSC Dielectrophoretic Characterization – Objective 1 
A strong case has been made to use DEP as a characterization tool to determine 
the dielectric signature for hMSC separation. User-friendly DEP microdevices with 
low voltage AC electric fields have been demonstrated to rapidly separate cells with 
no loss in cell viability and virility. The hMSC populations tested in this work were 
heterogeneous with varied morphology; therefore the development of a continuous 
cell sorting microdevice should concurrently control and accurately measure hMSCs 
dielectric signatures independent of cell morphology variations. hMSCs morphology 
standardization was successfully achieved with ELP-PEI to regulate morphology 
variations. Additionally, hMSC population heterogeneity correlates to biosurface 
marker expression predisposing cells for adipocytes, chondrocytes, and osteoblasts. 
Thus, after morphological standardization, precise measurements of DEP dielectric 
signatures of individual progenitor cell subpopulations may next facilitate biosurface 
marker-dependent cell separations.  
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hMSCs dielectric dispersion is defined by their internal structure, cell 
membrane and cytoplasm [50].  Our work has found that hMSCs membrane is 
??????????????????????????????????????????-dispersion region.  The radio frequencies 
polarize a cell’s surface, facilitating a DEP force, and allowing interogation of the cell 
membrane dielectric properties [51]. hMSC suspending solution conductivity was 
found to be critical to cell membrane polarization; higher conductivities increase 
membrane permittivity shifting the DEP spectra inflection points to higher 
frequencies. The solution conductivity dependence was apparent at the cross-over 
frequency, fxo; 0.030S/m yields a lower fxo at 0.62MHz and 0.10 S/m yields a lower fxo 
at 1.3MHz. This dielectric signature is unique for hMSCs because typical low fxo’s for 
other cell systems fall in the range of 0.010-0.10MHz.  Based on these results, these 
differing DEP spectra could be readily harnessed for hMSC cell separations from other 
cell systems. It should be noted that untreated hMSC DEP responses at static 
frequencies varied within a single culture, thus reproducible separations targetting 
hMSC subpopulations need to consider and control for biosurface marker expression. 
This work also explored ELP-PEI treatment, which successfully standardized 
hMSCs population morphology to spheroids with some cell aggregates observed. This 
treatment concurrently increased DEP response reproducibility of the ELP-PEI treated 
hMSCs over the untreated hMSCs. This standardization was facilitated by polymer 
interaction with the hMSCs cell membrane, which altered membrane dielectric 
properties and shifted the entire cell’s polarization behaviors within the nonuniform 
AC fields.  For ELP-PEI treated cells, only nDEP responses were observed from 
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0.010–10MHz, which was substantially different from native hMSCs. Solution 
media/membrane polarization behaviors implicate hMSCs are good candidates for 
future biosurface marker-induced stem cell separations. With optimization of the ELP-
PEI treatment, detection of molecular level differences in hMSCs may be realizable to 
aid understanding of biological functions and cell population purification for stem cell 
therapies.  
Therefore, objective 1, as follows, for this disseratioin was successfully 
accomplished. 
Objective 1: Characterize the dielectrophoretic response of hMSCs to determine the 
DEP spectra including the cross-over frequency.  
Objective 1a:  Standardize hMSCs morphology with ELP-PEI to 
reduce size-dependent DEP variations. Characterize the DEP spectra of 
ELP-PEI treated hMSCs, then compare to native hMSCs in order to 
identify conditions for cell separations.  Subpopulation variations are 
expected to be based on molecular level expression. 
6.1.2 hMSC Dielectric Properties Modeled – Objective 2 
hMSCs distinct DEP spectra in the ?-dispersion region were correlated to their 
dielectric properties membrane permittivity and capacity in Chapter 4. Data indicated 
that higher conductivity solutions increase the membrane permittivity shifting the DEP 
spectra to higher frequencies.  The experimentally determined DEP spectra for hMSCs 
at 0.030S/m and 0.10S/m were modeled and optimized with the core-shell spherical 
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DEP polarization model. The measured conductivity dependence was translated to a 
membrane capacitance increase from 2.2 pF for 0.030S/m to 4.5pF for 0.10S/m. 
Similarly, the membrane permittivity increases from 2.0 for 0.030S/m to 4.1 for 
0.10S/m.  Each optimization was a good fit to experimental data. These differing 
membrane capacitance values are indicative of hMSCs unique dielectric signature; 
these values are a consistent order of magnitude as values reported within the 
literature.  Thus, these unique dielectric signatures may be harnessed for hMSC cell 
separations from other cell populations.  It should be noted, however, that additional 
research, discussed in the Future Work section 6.2, should delve into utilizing DEP to 
discern individual hMSC biosurface markers in order to discern hMSC progenitor cell 
subpopulations.   
Therefore objective 2 for this dissertation research was successfully 
accomplished. 
Objective 2: From the experimentally derived DEP spectra obtained in Objective 1, 
model the dielectric properties of human mesenchymal stem cells using MATLAB and 
the Core-Shell Spherical DEP Polarization models.  Use these models to calculate the 
dielectric properties of hMSCs.  
Objective 2a: Correlate these properties with known phenotypical 
molecular expressions of hMSCs. 
Objective 2b: Compare dielectric properties with other cell systems, 
Table 6.1. 
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Table 6.1 Cell membrane capacitance comparison between hMSCs and other cell 
systems. Neural stem/progenitor cells (NSPCs) membrane capacitance was 
characterized based on its progenitor cells neurogenic progenitor (NP) and astrogenic 
progenitor (AP) [52]. Human mesenchymal stem cells (hMSCs) membrane 
capacitance was characterized by work completed in this dissertation [53]. CaLH3, 
H357, OSCC1, DOK are oral squamous cell carcinomas characterized into three 
subpopulations based on cell adhesion: rapid adherent cells (RAC), middle adherent 
cells (MAC), and late adherent cells (LAC), which correlates to the cells tumorigenic 
capabilities [47]. Adipose-derived stem cells membrane capacitance was characterized 
based on subpopulations determined by differentiation (osteoblasts), and progenitor 
cells (adipogenic and osteogenic) [48]. 
Cell Type Conductivity 
(S/m) 
Cmem 
(pF) 
Ref 
 NSPCs-NP biased 0.01 3.3 [52] 
 NSPCs-AP biased 0.01 4.3 [52] 
 E12.5 mNSPCs 0.01 1.6 [52] 
 E16.5 mNSPCs 0.01 2.8 [52] 
SW Treated-E16.5 
mNSPCs 
0.01 4 [52] 
hMSCs 0.03 2.2 [53] 
hMSCs 0.10 4.5 [53] 
treated hMSCs 0.10 <4.5 [53] 
CaLH3 RAC 0.10 4.1 [47] 
MAC 3.4 
LAC 2.9 
H357 RAC 0.10 3.3 [47] 
MAC 2.9 
LAC 2.3 
OSCC1 RAC 0.10 1.6 [47] 
MAC 1.3 
LAC 1.1 
DOK RAC 0.10 5.1 [47] 
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MAC 5.1 
LAC 5.8 
ADSC >1.0 6.6 [48] 
Adipogenic-
progenitor 
>1.0 9.0 [48] 
Osteogenic-
progenitor 
>1.0 6.9 [48] 
Differentiated 
osteoblasts 
>1.0 5.7 [48] 
6.1.3 Frequency Sweep Rate Dielectrophoretic Experimental Method 
hMSCs dielectric signature quantification in Chapter 4 was achieved using 
traditional DEP data collection and analysis techniques, which translates to long 
experimental days and laborious data analysis (months to collect and fully analyze 
data). A rapid data collection procedure with automated data analysis is beneficial as 
an alternative technique to quicken the process for DEP characterizations and 
separations. 
Traditional DEP measurements are completed at individual frequencies in 
order to compile frequency by frequency, the DEP spectrum for a particle or cell 
system [54].  This method requires time for individual particles to fully polarize and 
for the dielectrophoretic test region to reach steady state.  This can take upwards of 
45s and is necessary in order to observe accurate DEP responses. An alternative 
technique is to sweep the frequency or increase frequency via a linear ramp or with 
small steps over time within a single experiment. This approach allows individual 
particles to incrementally polarize as the frequency is incrementally increased, thus 
greatly reducing response time. It was found that frequency sweep rates influence the 
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DEP response of polystyrene (PS) beads and red blood cells (RBCs) and further, the 
permissible frequency sweep rate is particle or cell dependent. At slower sweep rates, 
particles have more time to polarize in the electric field yielding an accurate and 
reproducible DEP response and thus quantified spectrum.  At faster frequency sweep 
rates, particles are unable to achieve maximum polarization due to dielectric relaxation 
of the charges around the particle surface, so the observed DEP response does not 
match the particle’s true DEP behavior.  
For PS beads at frequency sweep rates below 0.0063 MHz/s, responses 
correlate closely with dielectric responses of particles subjected to a static frequency.  
However, at 0.056 MHz/s, responses began to deviate from static responses, so this 
was the transitional sweep rate where PS bead dielectric relaxation was approximately 
the same order of magnitude as the frequency shifts within the sweep. As the sweep 
rate further increased, conductivity dominated polarizations were not established and 
the PS bead frequency sweep data did not coincide with static frequency 
measurements. Similar experiments were completed with red blood cells and results 
illustrated that 0.00080 MHz/s accurately predicted the static frequency DEP 
responses of human RBCs.  
Dielectric relaxation is cell specific, so our work demonstrated that for each 
new cell system it is imperative to determine the optimal frequency sweep rate to 
accurately and reproducibly interrogate a cell’s DEP response. An optimal frequency 
sweep rate can be estimated by calculating the Maxwell-Wagner dielectric relaxation 
time for the particle/cell of interest. The applied frequency sweep rate should remain 
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at frequencies below the inverse dielectric relaxation ??????????MW) for ~5s to achieve 
slow incremental polarization.  This ultimately yields full particle polarization 
consistent with static frequency polarization measurements. This new frequency 
sweep rate DEP method will enable researchers to obtain accurate and continuous DEP 
response spectra in much shorter experiment times and requiring fewer cells. 
Therefore, objective 3 of this dissertation work was successfully accomplished. 
Objective 3: A new DEP data collection technique, frequency sweep rate, was 
established for rapid compilation cell’s DEP spectrum. An optimization procedure was 
identified for the operational frequency sweep rate for effective characterization of 
specific cells DEP spectrum. The method was successfully verified with polystyrene 
beads and red blood cells. Additional semi-automated data analysis was tested on 
polystyrene beads and red blood cells; a patent disclosure has been filed on this work, 
with the full patent application to be submitted in September 2014.  
In summary, dielectrophoretic microdevice versatility has been demonstrated 
within this dissertation research through hMSC quantification, hMSC treatment, and 
the development of a new DEP data collection and quantification technique. New 
knowledge has been contributed to the field including hMSCs DEP spectra, membrane 
capacitance, permittivity, interactions with ELP-PEI, and the development of the new 
frequency sweep rate DEP data collection/analysis technique. 
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6.2 Future Work 
The first steps toward the development of a continuous cell sorting DEP 
microdevice was completed in this dissertation through the quantification of a 
heterogeneous hMSCs population’s dielectric signature and the implementation of an 
ELP-PEI morphological standardization technique. The next generation hMSC 
microdevice should include an optimized DEP sorting chamber, which bifurcates into 
additional microchannels and outlet collection ports.  Such a design could be 
optimized to allow continuous flow for hMSCs separation, thus moving the current 
system from a batch to a continuous process. This work is achievable by the utilization 
of the microfabrication facility in the M&M building on campus, and would allow a 
tailor made device to be developed for hMSCs. 
Further investigations should be completed, with the new continuous cell 
sorting DEP microdevice, to achieve hMSCs separations based their progenitor cell 
phenotype. This is crucial in designing a device specifically for clinical therapeutics, 
and allows cell fate prediction. 
Another parameter that should be further explored is the ELP-PEI treatment. It 
should be noted that only one concentration of ELP-PEI was tested.  The concentration 
was based upon the optimal concentration required for hepatocyte cells [55]. 
However, the hMSC cells displayed not only spheroidal shape, but also a tendency to 
form into spheroid aggregates of multiple cells.  To avoid these cell-cell interactions, 
concentration optimization studies should be completed such that the minimal 
concentration of ELP-PEI is present in the system to adjust individual cell 
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morphologies. Additionally, further studies should be completed to assess the impact 
the ELP-PEI treatment has on hMSCs differentiation capacity and trophic activity. 
Although, further studies with hMSCs and ELP-PEI should be completed to 
fully understand molecular level interactions together, it is important to mention that 
utilizing this treatment will have a positive impact on hMSCs separation because of 
the substantial shift in cross over frequency and DEP spectra. As a result of the 
treatment, the nDEP behavior observed over a wide frequency range in the future will 
allow separation from other cell systems. Dissolution studies and time necessary for 
the ELP-PEI coating to be removed from hMSCs, should to be explored in order to 
design a washing step on the microfluidic device. This step will allow ELP-PEI to be 
removed before purified hMSCs are cultured and used in type 1 diabetes therapy. 
Also within this body of work, the DEP data collection and analysis technique 
was further improved using a frequency sweep rate method, which allows multiple 
frequencies, be examined within one experimental test. This method is currently semi-
automated using data analysis with ImageJ. For further improvement toward fully 
automated data collection, MATLAB code should be instituted to automatically 
analyze data collected with the microdevice. This rapid, fully automated system is 
advantageous for separations of both hMSC from other cell types and hMSC 
progenitor cell subpopulations. This is necessary to make this approach competitive 
with FACS and MACS. Further, dielectric signatures may vary slightly from donor to 
donor, so being able to rapidly quantify donor specific hMSC membrane capacitance 
and then in situ adapt operating conditions would provide the versatility to 
185 
concurrently separate hMSCs from other cells in heterogeneous populations.  Thus, 
dielectrophoretic separations have the potential to serve as a powerful separation tool 
that would enable large-scale, more cost-effective type 1 diabetes autologous therapy. 
6.3 References 
1. Federation, I.D. IDF diabetes atlas. 2013  [cited 2014 March 25]; 6:[Available
from: http://www.idf.org/diabetesatlas.
2. Bacchetta, R., et al., Defective regulatory and effector T cell functions in
patients with FOXP3 mutations. Journal of Clincal Investigation, 2006. 116(6):
p. 1713-1722.
3. Bell, G.I., S. Hortia, and J.H. Karam, A polymorphic locus near the human
insuline gene is associated with insulin-dependent diabetes-mellitus. Diabetes,
1984. 33(2): p. 176-183.
4. Bennett, S.T., et al., Susceptibility to human type-1 diabetes at IDDM2 is
determined by tandem repeat variation at the insulin gene minisatellite locus.
Nature Genetics, 1995. 9(3): p. 284-292.
5. Bottini, N., et al., A functional variant of lymphoid tyrosine phosphastase is
associated with type 1 diabetes. Nature Genetics, 2004. 36(4): p. 337-338.
6. Bussone, G. and L. Mouthon, Autoimmune manifestations in primary immune
deficiencies. Autoimmunity Reviews, 2009. 8(4): p. 332-336.
7. Clements, G.B., D.N. Galbraith, and K.W. Taylor, Coxsackie-B virus-infection
and onset of childhood diabetes. Lancet, 1995. 346(8969): p. 221-223.
186 
8. Craig, M., et al., Viruses and type 1 diabetes: a new look at an old story.
Pediatric Diabetes, 2013. 14(3): p. 149-158.
9. Dai, Y.D., et al., Slc11a1 enhances the autoimmune diabetogenic T-cell
response by altering processing and presentation of pancreatic islet antigens.
Diabetes, 2009. 58(1): p. 156-164.
10. Dippe, S.E., et al., Lack of causal association between coxsackie-B4 virus-
infection and diabetes. Lancet, 1975. 1(7920): p. 1314-1317.
11. Gamble, D.R., et al., Viral antibodies in diabetes mellitus. British Medical
Journal, 1969. 3(5671): p. 627-630.
12. Guberski, D.L., et al., Induction of type-1 diabetes by kilham's rat virus in
diabetes-resistant BB/WOR rats. Science, 1991. 254(5034): p. 1010-1013.
13. Lonnrot, M., et al., Enterovirus infection as a risk factor for beta-cell
autoimmunity in a prospectively observed birth cohort- the finnish diabetes
prediction and prevention study Diabetes, 2000. 49(8): p. 1314-1318.
14. Lonnrot, M., et al., Enterovirus RNA in serum is a risk factor for beta-cell
autoimmunity and clincal type 1 diabetes: a prospective study Journal of
Medical Virology, 2000. 61(2): p. 214-220.
15. Lowe, C.E., et al., Large-scale genetic fine mapping and genotype-phenotype
associations implicate polymorphism in the IL2RA region in type 1 diabetes.
Nature Genetics, 2007. 39(9): p. 1074-1082.
16. Pak, C.Y., et al., Association of cytomegalo-virus infection with autoimmune
type-1 diabetes. Lancet, 1988. 2(8601): p. 1-4.
187 
17. Ueda, H., et al., Associaton of the T-cell regulatory gene CTLA4 with
susceptibility to autoimmune disease Nature 2003. 423(6939): p. 506-511.
18. Undlien, D.E., et al., HLA-encoded genetic predisposition in IDDM - DR4
subtypes may be associated with different degrees of protection. Diabetes,
1997. 46(1): p. 143-149.
19. Vaarala, O., M.A. Atkinson, and J. Neu, The "perfect storm" for type 1 diabetes
- the complex interplay between intestinal microbiota, gut permeability, and
mucosal immunity. Diabetes, 2008. 57(10): p. 2555-2562.
20. Van Belle, T.L., K.T. Coppieters, and M.G. Von Herrath, Type 1 diabetes:
etiology, immunology, and therapeutic strategies. Physiological Reviews,
2011. 91(1): p. 79-118.
21. Villasenor, J., C. Benoist, and D. Mathis, AIRE and APECED: molecular
insights into an autoimmune disease Immunological Reviews, 2005. 204: p.
156-164.
22. Wildin, R.S., et al., X-linked neonatal diabetes mellitus, enteropathy, and
endocrinopathy syndrome is the human equivalent of mouse scurfy. Nature
Genetics, 2001. 27(1): p. 18-20.
23. Yoon, J.W., et al., Virus-induced diabetes-mellitus - isolation of a virus from
the pancreas of a child with diabetic ketoacidosis. New England Journal of
Medicine, 1979. 300(21): p. 1173-1179.
24. Yoon, J.W., T. Onodera, and A.L. Notkins, Virus-induced diabetes-mellitus.
XV. beta cell damage and insulin-dependent hyperglycemia in mice infected
188 
with coxsaxkie virus-B4. Journal of Experimental Medicine, 1978. 148(4): p. 
1068-1080. 
25. Zanone, M.M., et al., Association of cytomegalovirus infections with
recurrence of humoral and cellular autoimmunity to islet autoantigens and of
type 1 diabetes in a pancreas transplanted patient. Transplant International,
2010. 23(3): p. 333-337.
26. Galadari, S., et al., Role of ceramide in diabetes mellitus: evidence and
mechanisms. Lipids in Health and Disease, 2013. 12: p. 98.
27. Jang, Y.K., et al., Optimization of the therapeutic efficacy of human umbilical
cord blood-mesenchymal stromal cells in an NSG mouse xenograft model of
graft-versus-host disease. Cytotherapy, 2014. 16: p. 298-308.
28. Malik, F.S. and C.E. Taplin, Insulin therapy in children and adolescents with
type 1 diabetes. Pediatric Drugs, 2014. 16(2): p. 141-150.
29. Aguayo-Mazzucato, C. and S. Bonner-Weir, Stem cell therapy for type 1
diabetes mellitus. Nature Reviews Endocrinology, 2010. 6(3): p. 139-148.
30. Zheng, G.P., et al., Mesenchymal stem cells in the treatment of pediatric
diseases. World Journal Pediatrics, 2013. 9: p. 197-211.
31. Fiorina, P., J. Voltarelli, and N. Zavazava, Immunological applications of stem
cells in type 1 diabetes. Endocrine Reviews, 2011. 32(6): p. 725-754.
32. Sun, Y., et al., Differentiation of bone marrow-derived mesenchymal stem cells
from diabetic patients into insulin-producing cells in vitro. Chinese Medical
Journal, 2007. 120(9): p. 771-776.
189 
33. Volarevic, V., et al., Concise review: mesenchymal stem cell treatment of the
complications of diabetes mellitus. Stem Cells 2011. 29(1): p. 5-10.
34. Xie, Q.P., et al., Human bone marrow mesenchymal stem cells differentiate
into insulin-producing cells upon microenvironmental manipulation in vitro.
Differentiation, 2009. 77(5): p. 483-491.
35. Karnieli, O., et al., Generation of insulin-producing cells from human bone
marrow mesenchymal stem cells by genetic manipulation. Stem Cells, 2007.
25(1): p. 2837-2844.
36. Li, Y.H., et al., Generation of insulin-producing cells from PDX-1 gene
modified human mesenchymal stem cells Journal of Cellular Physiology, 2007.
211(1): p. 36-44.
37. Lee, R.H., et al., Multipotent stromal cells from human marrow home to and
promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid
mice. PNAS, 2006. 103(103): p. 17438-17443.
38. Leeb, C., et al., New perspectives in stem cell research: beyond embryonic stem
cells Cell Proliferation, 2011. 44: p. 9-14.
39. Salem, H.K. and C. Thiemermann, Mesenchymal stromal cells: current
understanding and clinical status. Stem Cells, 2010. 28: p. 585-596.
40. He, S., D. Nakada, and S.J. Morrison, Mechanisms of stem cell self-renewal.
Annual Review of Cell and Development Biology, 2009. 25: p. 377-406.
41. Caplan, A. and J.E. Dennis, Mesenchymal stem cells as trophic mediators.
Journal of Cellular Biochemistry, 2006. 98: p. 1076-1084.
190 
42. Wu, H.W., C.C. Lin, and G.B. Lee, Stem cells in microfluidics.
Biomicrofluidics, 2011. 5: p. 013401.
43. Diogo, M.M., C. Lobato de Silva, and J.M.S. Cabral, Separation technologies
for stem cell bioprocessing. Biotechnology and Bioengineering, 2012. 109: p.
2699-2709.
44. Gonzalez-Gonzalez, M., et al., Current strategies and challenges for the
purification of stem cells. Journal of Chemical Technology and Biotechnology,
2012. 87: p. 2-10.
45. Lu, J., et al., Advancing practical usage of microtechnology: a study of the
functional consequences of dielectrophoresis on neural stem cells. Integrative
Biology, 2012. 4: p. 1223-1236.
46. Flanagan, L.A., et al., Unique dielectric properties distinguish stem cells and
their differentiated progeny. Stem Cells, 2008. 26: p. 656-665.
47. Liang, X., et al., Human oral cancer cells with increasing tumorigenic abilities
exhibit higher effective membrane capacitance. Integrative Biology, 2014. 6:
p. 545-554.
48. Bagnaninchi, P.O. and N. Drummond, Real-time label-free monitoring of
adipose-derived stem cell differentiation with electric cell-substrated
impedance sensing. PNAS, 2011. 108: p. 6462-6467.
49. Salmanzadeh, A., et al., Sphingolipid metabolites modulate dielectric
characteristics of cells in a mouse ovarian cancer progression model.
Integrative Biology, 2013. 5: p. 843-852.
191 
50. Pethig, R., Review Article-Dielectrophoresis: Status of the theory, technology,
and applications. Biomicrofluidics, 2010. 4(2): p. 35.
51. Adams, T.N.G., K.M. Leonard, and A.R. Minerick, Frequency sweep rate
dependence on the dielectrophoretic response of polysytrene beads and red
blood cells Biomicrofluidics, 2013. 7: p. 064114.
52. Nourse, J.L., et al., Membrane biophysics define neuron and astrocyte
progenitors in the neural lineage. Stem Cells, 2014. 32: p. 706-716.
53. Adams, T.N.G., et al., Characterizing the dielectric properties of human
mesenchymal stem cells and the effects of charged elastin-like polypeptide
copolymer treatment Biomicrofluidics, 2014. submitted.
54. Gagnon, Z.R., Cellular dielectrophoresis: Applications to the
characterization, manipulation, separation and patterning of cells.
Electrophoresis, 2011. 32(18): p. 2466-2487.
55. Janorkar, A.V., et al., Use of three-dimensional spheroids of hepatocyte-
derived reporter cells to study the effects of intracellular fat accumulation and
subsequent cytokine exposure. Biotechnology and Bioengineering, 2011. 108:
p. 1171-1180.
192 
Appendix A: A Tunable Microfluidic Device for Drug 
Delivery 
1Tayloria Adams, Chungja Yang, John Gress, Nick Wimmer, Adrienne R. Minerick 
Michigan Technological University 
USA 
A.1 Introduction 
The field of microfluidics, small-scale tests from nanoscale to microscale, has 
grown dramatically over the past two decades as evidenced by greater than 30,000 
papers published over the last 10 years on the topic [Web of Knowledge search using 
‘microfluidic’ terms October 2011]. Microfluidic platforms, also known as lab-on-a-
chip (LOC), include a set of miniaturized integrated unit operations that are touted to 
lead to fast, easy, precise control in biological and chemical systems. LOCs include 
the development of point-of-care (POC) medical diagnostic devices with the 
advantages of increased sensitivity, lower sample volumes, lower reagent volumes, 
low energy, low cost, low labor need, and less likelihood of human error (Xiao & 
Young, 2011). Due to these advantages, LOCs have substantial potential to be widely 
utilized in medicine for analytical and diagnostic assays, biosensors, and drug delivery. 
1 The material contained in this Appendix was previously published in Advances in 
Microfluidics, 2012. 
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Microfluidic technology has been used for a wide variety of applications such 
as forensics, cell phone facilitated micro-imaging, and analytical testing.  In 2006 
Bienvenue at al., compared the use of microfluidic technology with a commercial kit 
that utilized dithiothreitol to extract and purify DNA from sperm samples. The sample 
volume was less than 10 μL and the resulting electropherograms were very similar for 
both techniques (Bienvenue et al., 2006). DNA separation has also been studied by 
Aboud et al. Pentameric short tandem repeat (STR) markers were tested in a 
microfluidic device on single-stranded DNA. Coupling microfluidics with pentameric 
STRs improved allele resolution by 3.7 times (Aboud et al., 2010). In these cases, 
microfluidics can be used as a rapid screening tool for forensic DNA analysis to help 
resolve the backlog of DNA casework (Aboud et al., 2010; Bienvenue et al., 2006). 
Zhu et al., combined optofluidics with cell phone technology. A cell phone was 
converted to a microscope analysis tool by integrating optofluidic fluorescent 
cytometry with compact optical attachments. The cell phone optical attachment 
included a lens, plastic color filter, two light emitting diodes, and batteries, which 
altogether weighed less than 1 lb. To test the effectiveness of this new imaging system, 
the density of white blood cells were measured using the cell phone-based fluorescent 
image cytometry and compared with the white blood cell density found with a 
commercial hematology analyzer. The blood sample was injected into the microfluidic 
chamber using a syringe pump and the cell phone recorded the fluorescent emission. 
This study demonstrated that the densities found by both systems were a good match 
with less than 5% error and that cell phone optofluidic fluorescent imaging cytometry 
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was useful for rapid blood cell counts or screening of water quality (Zhu et al., 2011). 
Research into microfluidic devices tailored for the medical field is extensive. 
Weng et al., developed a suction type microfluidic device to detect the dengue virus. 
This three-layer device used pneumatics, mixing, and transport to detect the virus in 
30 minutes (Weng et al., 2011). Digital microfluidic devices transport biochemical 
materials in the form of miniature discrete droplets (Xiao & Young, 2011) and have 
been used for immunosensing, proteomics, DNA, and cell based assays (Vergauwe et 
al., 2011). Dielectrophoresis (DEP) has been incorporated into microfluidic devices 
for transport, separation, and blood typing (Minerick et al., 2008; Srivastava et al., 
2011; C. Wang et al., 2011). DEP phenomena is the movement of cells from an 
external applied electric field and has been used to continuously separate breast cancer 
cells from normal blood cells (Alazzam et al., 2011). The device developed by 
Alazzam et al. can potentially be used as an early detection method for cancer.     
Professor Robert Langer and other researchers at MIT investigated the idea of 
a “pharmacy on a chip”. They performed controlled release studies to determine if a 
microfluidic platform could act as a pulsatile release drug delivery system. Pulsatile 
release is a common controlled release method used to treat people with disorders that 
require drugs to be delivered at varying rates over time. A prototype microchip made 
from silicon was developed. The microchip had multiple reservoirs for drug storage 
and the reservoirs were covered with gold membranes. The reservoirs were filled with 
sodium fluorescein and calcium chloride using ink jet printing. To release the drugs 
an electric potential of approximately 1V was applied and the gold membranes were 
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dissolved in 10 to 20 seconds. The results from this study revealed that storage and 
on-demand delivery of drugs can be achieved from microfluidic LOC technology.  
One major advantage of using microfluidic platforms for drug delivery is that small 
microchips can be implanted inside the body to locally treat diseases (Santini et al., 
1999, 2000). Farokhzad et al. gave a possible application of microfluidic technology 
in the field of urology (Farokhzad et al., 2006). Other researchers have implemented 
the proof-of-concept that Langer demonstrated for ambulatory emergency care 
treatment. A plethora of drug delivery systems that can be embedded in the body have 
been researched for use in chronic and non-chronic diseases. When treating chronic 
and non-chronic diseases drugs are delivered over long periods of time. These systems 
are now modified to rapidly deliver drugs in emergency situations (Elman et al., 2009). 
Elman et al. developed a smart microchip implant to deliver a drug bolus when disease 
symptoms are detected. The device is composed of three layers: reservoir layer where 
drug solution is stored, membrane layer where reservoir is sealed and location of drug 
is released, and actuation layer where bubbles are formed to trigger the release of the 
stored drugs. The actuation layer triggers the operation of the device. Micro-resistors 
heat the drug to generate bubbles, pressure is produced, and the membranes burst 
????????????????????????????? rapidly from the device to its target area in 45 seconds. 
In this work vasopressin was used as the drug and it was found that 92.5% of the 
solution loaded into the device was released. Devices of this nature have the potential 
to accompany cardiac devices such as defibrillators and pacemakers (Elman et al., 
2009). Langer’s findings have even been extended to nanotechnology. Brammer et al., 
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has shown that silicon nanowires are a viable drug delivery system for antibiotics. It 
was shown that silicon nanowires sustained drug release levels for 42 days (Brammer 
et al., 2009).  
Despite this wide breadth of research success, commercial implementation of 
POC devices for diagnostics assays, biosensors, and drug delivery have been much 
slower than originally predicted. A feature article in Time magazine in 2001 
exemplified this dream touting safer and more effective drug delivery techniques 
(Bjerklie & Jaroff, 2001). However, only a few notable LOC platforms have come to 
market and are most advanced in the areas of bioassays (pregnancy/ovulation tests, 
etc.) and gene chips. Bioassay companies include eBioscience, and Chembio 
Diagnostic Systems, Inc. Notable gene profiling chips include those by Affymetrix, 
Fluidigm, Gyros, and Sage. Blood chemical analyzers are marketed by PiccoloXpress, 
while versatile analytical LOCs are marketed by Caliper and Dolomite Microfluidics.  
Commercialization is more advanced in the diagnostics arena than in the drug delivery 
area due to the complexity of sensing the concentration of the drug and controlling the 
release of new drug. However, as demonstrated by the growth in foundational 
research, popular news source stories, and commercialization of products, new 
innovations in this area are being sought. 
Cancer is a disease that touches everyone in the world; people are either 
directly affected by cancer or know someone suffering from the disease. Globally, 
cancer is responsible for 1/8th of all deaths, which is more than HIV/AIDS, malaria, 
and tuberculosis combined (American Cancer Society, 2011). It is estimated that 1.5 
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million new cases of cancer will be diagnosed in the U.S. in 2011. Cancer is growing 
at an increasingly high rate and it is expected that there will be 21.4 million new cases 
of cancer in 2030 and 13.2 million cancer deaths (American Cancer Society, 2011). 
Gastric cancer is malignant cell growth originating in the gastro-intestinal tissue lining 
and kills 650,000 people with 870,000 new cases diagnosed annually (Balcer-
Kubiczek & Garofalo, 2009).  It is the second most fatal disease in the world (Balcer-
Kubiczek & Garofalo, 2009; National Cancer Institute, 2010) and has a poor prognosis 
due in part to late stage development of any symptoms. People diagnosed with gastric 
cancer often do not experience symptoms until the disease is metastatic and spreading 
elsewhere in the body. This then dictates systemic chemotherapy treatment, which 
traditionally is conducted with regular injections or an embedded catheter. These 
methods add suffering and additional pain beyond the discomforts of chemotherapy. 
Further, these methods of drug delivery have large variations in patient exposure 
concentrations over the course of the treatment; survival rates for gastric cancer 
suggest this approach is not entirely effective.  Therefore, there is a great need for 
development of new technology to treat cancer patients.   The new technology should 
have two goals (1) effectively treat cancer patients to eradicate disease and (2) make 
cancer treatments as painless and noninvasive as possible. Here we wish to combine 
four unique technologies into a microfluidic device to provide novel nanoscale drug 
delivery for cancer patients via a wrist device resembling a watch. Figure A.1 shows 
the global view of our chemotherapy drug delivery system and Figure A.2 shows the 
how these four technologies fit together on the drug-delivery microfluidic device and 
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are then discussed separately in the following sections. 
Figure A.1 Global view of chemotherapy drug delivery system, (i) path of emulsified 
drug from the wrist microdevice through the human body and (ii) enlarged view wrist 
devices depicting the chemotherapy drug delivery system. The encapsulated 
chemotherapy drug droplets travel from the wrist device to the intestines contacting 
circulating tumor cells (CTCs) to treat the gastric cancer. 
In Figure A.2(i), the reservoirs for each drug are centralized into larger 
chambers above the layers shown in Figure A.2(iv). There is a primary and three 
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secondary reservoirs for oil (one for each drug), and the same for saline. The primary 
reservoir allows the flow rate of each drug to be independently controlled. This device 
uses microchannels and tunable electrodispersion to form in-line emulsions of the 
chemotherapy drug, which are then delivered to the patient using adjustable 
dielectrophoretic pumping and painless microneedles that penetrate the dermis of the 
skin. The focus of this new technology has been to specifically treat gastric cancer, but 
can be adapted to treat many other types of cancer and possibly other diseases. 
Figure A.2 Microfluidic drug delivery device for cancer treatment. (i) Overview of 
fluorouracil drug system including drug, oil and saline storage including (a) 
electrodispersion electrodes and (b) dielectrophoretic micropumping electrodes. 
Microchannel dimensions are 25 μm (width) x 25 μm (height). (ii) Termination of 
microchannels into the microneedle system. (iii) Top view of ECF droplet 
microdevice. And (iv) Side view of multilayered system for droplet dispersion and 
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flow to the microneedles. The abbreviations are S = saline, O = poppy seed oil, F = 
fluorouracil, E = epirubicin, and C = cisplatin.  
Chemotherapy is a common treatment option for gastric cancer. Several single 
chemotherapy drugs have been used to treat gastric cancer including 5-fluorouracil, 
mitomycin, doxorubicin, cisplatin, etoposide, docetexal, and methotrexate. Efficacy 
of these drugs are typically measured via clinical response rates, which is the 
percentage of patients that respond to cancer treatment such that cancer cells are no 
longer detected. The response rates to these drugs were poor ranging from 15-35% 
(Cleveland Clinic Foundation, 2010; Hershock, 2006; Levi et al., 1979). More 
effective treatments use a combination of two, three or more chemotherapy drugs. 
Combining two chemotherapy drugs has been examined by Levi et al. and response 
rates for drug cocktails increased to 40-50% (Levi et al., 1979). McDonald et al. 
combined three chemotherapy drugs fluorouracil, doxorubicin, and mitomycin and 
results showed a 55% response rate (Levi et al., 1979).  Rivera et al. studied docetexal, 
a newer chemotherapy drug, in combination with cisplatin and 5-fluorouracil (DCF). 
DCF was compared with docetexal/cisplatin (DC) and cisplatin/5-fluorouracil (CF), 
and the objective response rates for DCF were 37-43%, 26% for DC, and 25% for CF. 
Based on these results it can be concluded that a combination of three chemotherapy 
drugs are more effective than two chemotherapy drugs (Rivera et al., 2007). Other 
combination chemotherapy drugs have been studied, and their response rates were: 
epirubicin, cisplatin and, 5-fluorouracil (ECF) 71%; 5-fluorouracil, adriamycin, and 
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mitomycin 50% and 9%; 5-fluorouracil, leucovorin, and cisplatin 44%; 5-fluorouracil, 
adriamycin, mitomycin, and methotrexate 42%; cisplatin, epirubicin, leucovorin, and 
5-fluorouracil 43%  docetexal, cisplatin, and 5-fluorouracil 37-43% (Hershock, 2006; 
Power et al., 2010). Epirubicin, cisplatin, and 5-fluorouracil (ECF) had the highest 
response rate of 71%. In summary, response rate data suggests that combination 
chemotherapy drug treatment is the superior treatment option. Therefore, the 
microfluidic device described here will utilize the combination of ECF.  In the device 
depicted in Figures A.1 and A.2 each individual drug in the ECF drug system is stored 
in separate reservoirs so their dosage can be independently controlled via feedback 
electronics. There is also redundancy in the microchannels and microneedles for 
backup in case any of the channels become clogged over time. Within the 
microchannels each drug is sheathed in a biocompatible oil in order to protect the 
integrity and enhance drug efficacy over the dosage cycle.  
This chapter will further explore the integration of microchannels, 
electrodispersion, dielectrophoretic pumping, and microneedles in a dynamically 
controllable microfluidic platform to deliver ECF to gastric cancer patients. 
A.2 Technologies Utilized in the Drug Delivery Microfluidic Device 
A.2.1 Microchannels and Electrodispersion 
Emulsions are mixed dispersions of more than two immiscible fluids via 
encapsulation of one layer by the other layer.  These emulsion droplets are useful in 
areas such as foods, cosmetics, pharmaceutical drug delivery, and chemical synthesis. 
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Examples of foods include milk, yogurt, sauce, butter, etc. and cosmetics of lotion (oil-
in-water, O/W), cream (water-in-oil, W/O), hair, shaving, and bath products that are 
predominantly viscous liquids (Mezzenga, 2005; S.H. Kim et al., 2011). In chemical 
synthesis, droplets are being used as a new reaction platform due to their ability to 
function as a batch reactor such as antimicrobial agent and preservatives (Hamouda et 
al., 1999; Jensen & Lee, 2004; Mejia et al., 2009). The forms of emulsion droplets to 
contain various physical and chemical compositions are effective in delivering drugs 
and cosmetics in human body (Wibowo & Ng, 2001; Kiss et al., 2011).  
In this drug delivery microfluidic device, flow focusing (FF) hydrodynamics 
and electrodispersion technology are combined to dynamically generate oil-sheathed 
drug droplets on the order of 100 nm outer diameter dispersed in saline.  Poppy seed 
oil is used to decrease the toxicity of the chemotherapy drug (Pai et al., 2003) while 
maintaining its potency and efficacy once it reaches the target malignant cells, and 
saline is used to carry the droplets into the tissue during injection. Our drug delivery 
microdevice will combine both flow focusing and electrodispersion technologies in 
order to achieve narrower size distribution of particles by preventing droplet 
interactions and coalescence. Electric fields are added for chemotherapy drug droplet 
formation to decrease the size of droplets, improve robustness of continuity of the 
droplet thread formed, and increase velocity as droplets travel downstream in the 
microchannel. Thus, the main focus of our study is developing FF geometry with 
electrodispersion and adequate use of surfactants to generate submicron droplets (~100 
nm) with highly uniform sizes to promote a quick transport into cells.  
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Emulsion droplets of very narrow size distributions can be strategically 
generated by harnessing hydrodynamic behaviors within microfluidic systems (Anna 
et al., 2003; Martin-Banderas et al., 2005; W. Lee et al., 2009). FF geometries are used 
in mixing immiscible phases or encapsulating one phase within a second sheathing 
phase.  Typically, hydrophobic drops are dispersed in a hydrophilic fluid or vice versa. 
The drug delivery microdevice utilizes this technology in order to protect the inner 
fluid (drug) by an outer fluid (oil), which is then dispersed in a continuous saline 
stream. The inner phase is traditionally termed the dispersed phase while the outer 
phase is termed the continuous phase when they meet at an orifice.  Most microfluidic 
emulsions involve a single droplet dispersed in a continuous phase such as water-in-
oil (W/O) and oil-in-water (O/W) (Ha and Yang, 1999; Anna et al., 2003; W. Lee et 
al., 2009; Kiss et al., 2011). This concept can also be expanded to droplets that include 
more than one internal droplet such as double emulsions (W/O/W or O/W/O) (Utada 
et al., 2005; Seo et al; 2007; Liao and Su, 2010; S.H. Kim et al., 2011) and are the 
foundation for the drug delivery microdevice described in this chapter.  
During small droplet synthesis, mechanical shear stress was utilized in order 
to achieve small and highly stable emulsion droplets, but this approach yielded tens of 
nano- to hundreds of micro-scale droplets with large size distributions, which was 
problematic (Pacek et al., 1999; Abismaïl et al., 1999).  The key advantage of FF 
technique is precise control in producing droplets into the range of hundreds of 
nanometers (Anna et al., 2003; Thiele et al., 2010), but ambiguity remains regarding 
the lower limit of droplet sizes that can be achieved, the size distribution and continuity 
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of the droplet threads still remain unreported due in part to the difficulty of in-line 
droplet size analysis and the length of the droplet thread (Anna et al., 2003; W. Lee et 
al., 2009).  The goal in this drug delivery microdevice is to generate the smallest 
droplets possible because larger droplets are less stable and more likely to come in 
contact with each other, which leads to droplet deformation and coalescence. Other 
studies have determined that 50-150 nm droplets ensure an optimal intake in cells for 
drug delivery applications (Thiele et al., 2010). In addition, larger droplets are less 
stable and more likely to come in contact with each other which leads to droplet 
deformation and coalescence.  
Because the drug delivery microfluidic system dimensions are designed to fit 
within a wristwatch-like system on a human wrist, multilayered FF and 
electrodispersion is proposed for ECF chemotherapy drug emulsion and delivery, 
Figure A.2(ii-iv). The total dimensions of multilayered ECF drug system is small 
enough to be non-obtrusive, so that it can be worn for continuous drug delivery with 
minimal discomfort as shown in Figure A.1.  In the drug delivery microdevice, two 
FF orifice/junction geometries are utilized in series as shown in Figure A.3.  The two 
junctions whereby sheathing flows of poppy seed oil and saline are added to the main 
channel are 3mm long, 20 μm wide, and 20 μm deep in the microchannel, and the 
continuous and dispersed phases are injected through pressure regulated membrane 
deflection into the fluid reservoirs which operate as micropumps.  Such designs are 
also commercially available and meet the volume and portability limitations of the 
proposed wristwatch system, as well as the energy demand limitations (Lima et al., 
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2004). The flow rate inputs are 0.01 μl/min of drug, 0.1 μl/min for poppy seed oil, and 
1 μl/min for saline based on the reduction of the optimal flow conditions achieved by 
Zagnoni et al., 2009 & 2010 to meet our channel dimensions in which the ratio of the 
continuous and dispersed phase flow rate are held at 10 to achieve submicron droplets 
in the downstream microchannels. 
Achieving drug droplets with diameters at approximately 500 nm is feasible 
via the hydrodynamic flow focusing achieved with the 4 μm wide orifice and 
combined with the strategic use of surfactant chemistry (W. Lee et al., 2009).  Droplet 
size is determined initially by the orifice geometry; however, a surfactant mixed with 
either the continuous or dispersed phase balances interfacial tension and enables 
droplet sizes to be orders of magnitude smaller in comparison with those without a 
surfactant (W. Lee et al., 2009). That is, adding a proper surfactant can improve 
stability of the droplets and decrease the size of droplets because the surfactant 
molecules reduce the interfacial tension between different fluids in a droplet, thus 
avoiding the undesirable coalescence among droplets. For this chemotherapy drug 
delivery application, proper surfactant selection requires biocompatibility, which must 
be considered as well as long-term drug-surfactant interactions.  To avoid the later, 
surfactants will be dispersed in the oil phase and in the saline phase.   
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Figure A.3 Microchannel design for the chemotherapy drug emulsion formation with 
flow focusing and sheathing flow; appropriate scale not reflected. Dashed boxes (a) 
and (b) correspond to the placement of the electrodes for electrodispersion and 
dielectrophoretic micropumping, respectively. w2 is the orifice depth 4 μm, and w1 is 
the width of the junction 20 μm . The aqueous drug solution flows through the 
microchannel until it is dispersed into the continuous oil phase at junction 1. At the 
junction 1 orifice, drug-in-oil droplets are formed and flow until they are then 
dispersed into the saline phase at junction 2 to achieve an oil sheathing of the drug 
droplet in the continuous saline phase. Double emulsion chemotherapy droplet is 
produced via the second orifice. See Figure A.4 for the COMSOL simulation of this 
fluid flow. 
The droplet formation behavior is mainly determined by capillary number 
(Ca), which represents the balance between the viscous forces and interfacial tension 
at the surface of two fluids as defined ??????????????????????????????? is the viscosity 
of the co????????????????????????????????????????????????????????????????????????????????
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Capillary number is the most appropriate dimensionless number to describe droplet 
formation behavior because Reynolds number and Weber number are less significant 
in FF (W. Lee et al., 2009). In addition to Ca, the flow rate ratio (?), the viscosity ratio 
????? ???? ???? ?????????? ?????? (A) in Equations 2-4 (W. Lee et al., 2009) are also 
parameters to govern droplet formation because they balance viscous stresses and 
exerted shear stresses which result in droplet thread trajectory and velocity profile. In 
Equation 2, Qd and Qc are flow rate of dispersed phase and continuous phase, 
respectively. In Equation 3, μd and μc are viscosity of dispersed phase and continuous 
phase and w1 and w2 are depth of outside and inside orifice. 
(1) 
(2) 
(3) 
(4)
Accordingly, the size of droplets changes by capillary number due to viscous 
force and the interfacial tension. While flow rate ratio affects the droplet formation 
behavior significantly, the viscosity ratio has a relatively weak impact on the droplet 
diameter compared to capillary number (Ca) since the flow rate is associated with 
characteristic velocity of Ca. In addition, as the expansion ratio between the orifice 
and the junction depth decreases, a longer thread of smaller droplets is achieved, which 
is desired in the drug delivery microdevice.   Much remains to be learned in regards to 
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the underlying physics in the system as well as the stability of the droplet threads over 
long operation times.  Therefore, a few assumptions were made in the FF designs of 
the microdevice. These assumptions include the combination of the FF droplet 
formation with the electrodispersion design to decrease droplet size, increases velocity 
of droplets, as well as with regards to the continuous robustness of producing droplets 
over long operation times (days) of the device. 
Research has also been conducted in the related field of electrically 
manipulated emulsifications (H. Kim et al., 2007; Zagnoni et al., 2009; Zagnoni et al., 
2010).  Electric fields with a resonance frequency between 10Hz and 10MHz have 
been used as a separation method to remove water dispersed in oil for applications in 
the petroleum industry.  This data is applicable to droplets in the drug delivery 
microdevice since the frequency-modulated electric field utilized can be used as a 
deformation tool for emulsion droplets (Zagnoni et al., 2009; Zagnoni et al., 2010). 
Electric fields have also been used to focus and space nano and micro 
emulsions/particles in microchannels of 50 μm (width)* 50 μm (length)* 61 μm 
(height) orifice dimensions in DC fields (H. Kim et al., 2007).  H. Kim et al. studied 
electrospray emulsification and produced emulsion < 1 μm in diameter with ~2% of 
size distribution at a field of 1.4*102 - 5.5*103 V/m, and also Arya et al. successfully 
synthesized of hundreds of nm chitosan micro/Nano spheres for drug delivery 
application in 2.3*105- 4.7*105 V/m. Furthermore, Mejia et al. formed wax emulsions 
with high uniformity for water-proof painting, cosmetics, and adhesives that supports 
the idea of utilizing electric field (2.6-2.9 kV in 500 ml wax mixture) in the production 
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of fine emulsions. Compared to these literature values of the applied electric fields, 
the device operating condition of 5*106-107 V/m is several orders are higher. The 
electric energy acting on the particles cause the water-oil interface to charge such that 
it behaves as a capacitor, which leads to a tip of Taylor cone which enables tiny 
droplets and narrow size distribution ~2% (H. Kim et al., 2007). 
Castellation configuration electrodes (Zagnoni et al., 2009; Zagnoni et al., 
2010) were designed for electrodispersion because this design resulted in the highest 
localized electric field in the z-dimension, which has the potential to most efficiently 
manipulate the droplets and minimize deformation in the x- and y- directions. These 
are placed 200 μm downstream from both junction 1 and junction 2 as shown in Figure 
A.3(a).   This electric field energy does two things: a) it breaks apart the droplets from 
hundreds of nanometers in diameter into the more effectively adsorbed size of < 100 
nm and b) it spatially disperses the droplets in the continuous phase in order to 
minimize coalescence as droplets travel forward in microchannel.  
In order to simulate behaviors in the drug delivery microdevice, COMSOL 4.2 
was used to simulate the 3D electric field gradient of the electrodispersion design in 
Figure A.4, which is castellated gold electrodes of gap width 1 μm (x-direction), width 
2 μm (y-direction), and thickness 20 nm (z-direction). The electrostatics module with 
the electrostatic potential (Equation 5), a relationship between electric displacement 
and the electric field (Equation 6), and Gauss’s law (Equation 7) were used to simulate 
the electric field gradient in a fluid medium of saline.   
VE ??? ??    (5) 
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PED
??? ?? 0? (6) 
0?
?VE ??? ?? (7) 
In Equations 5-7, E
?
is the electric field, V is the electric potential, D
?
is the electric 
???????????????0 is the permittivity of a vacuum, P
?
is the electric polarization and was
???????????????????????????????? ????????????V is the space charge density.  Combining 
Equations 5-7 with zero electric polarization gives 
? ? VrE ??? ??? ?? 0 (8) 
Equation 8 is the governing equation used in to simulate the electric field gradient of 
the electrodispersion electrode design (Figure A.3). Equation 8 is modified slightly 
and employed in COMSOL as 
2
2
2
2
2
2
z
E
y
E
x
EE ?
???
???
??? (9) 
In COMSOL, the physical properties for water were altered slightly to simulate the 
saline such as 8.9 x 10-4 ????? ???????? ?????????? ???? ??? ????????? ?????????????? ????
physical properties used for poppy seed oil were dynamic viscosity 5.58 x 10-2 ?????
and relative permittivity of 4. Poppy seed oil is used to decrease the immediate toxicity 
of the chemotherapy drug (Pai et al., 2003) as it enters the tissue, and saline is used to 
carry the sheathed droplets and match tissue isotonicity during injection. Gold was the 
material used for the electrodes, and PDMS was the material used to form the orifices 
at the microchannel junctions (see Figure A.2 for orifice design) as reported in the 
literature (W. Lee et al., 2009). The initial flow rates in the microchannels were chosen 
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to be 0.01 μL/min for the drug, 0.1 μL/min for the poppy seed oil, and 1 μL/min for 
the saline. These initial flow rate values were chosen based on Zagnoni et al. 2009 and 
2010. 
The fluid flow velocity in the FF microchannel was modeled with the laminar 
flow module employing the Navier Stokes equation and the continuity equation, which 
were simplified by assuming a steady-state system and an incompressible fluid as 
follows: 
? ? ? ?? ? ST Fvvpvv ?????????? ??  (10)
0??? v    (11) 
In ??????????????????????????????????????????????????????????????????????????????????????????
pressure, μ is the viscosity, and FS is the volumetric force on the fluid resulting from 
surface tension.  
Two types of fluidic conditions of water (to represent drug and saline) and oil 
were employed, and the velocity of the formed emulsion droplets were calculated from 
the summation of pressure driven flow velocity and electro-osmotic velocity. The 
electro-osmotic flow velocity was calculated from Smoluchowski slip velocity 
equation via a wall boundary condition on the microchannel and added to simulate the 
velocity of the chemotherapy droplets in the field created by the electrodispersion, 
Figure A.3.  The zeta potential for PDMS was assumed at -0.1V (Kirby and 
Hasselbrink Jr., 2004). The boundary condition for electrical potential was an applied 
DC field of 10V and ground across each pair of electrodes. The velocities without 
electrodes were calculated from pressure driven flow in the x-, y-, and z-direction and 
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expressed with ui. The governing equations for electro-osmotic flow used for this 
simulation are Equation 12-16 below, 
?
???? 0rE ? (12) 
iEiEOF Ev
??? ?,   where  i = x,y,z (13) 
In Equations 12 and 13, μE ???????????????????????????r is the relative permittivity of the 
??????? ?0 ??? ???? ????????????? ??? ?? ???????? ?? ??? ???? ????? ??????????? ?? ??? ???? ????????
viscosity, vEOF,i is the velocity due to electro-osmotic flow (EOF), and E
?
 is the electric
field. The normal EOF velocity and the total velocity of the droplets are given as 
vnorm ? vEOF ,x2 ? vEOF ,y2 ? vEOF ,z2 (14) 
2
,
2
,
2
, totalztotalytotalxtotal vvvv ??? (15) 
The EOF velocity is related to the total velocity by, 
2
,, iEOFitotali vuv ??   where  i = x,y,z (16) 
The total velocity is displayed in the simulation scale bar next to each COMSOL 
diagram in Figures A.4 and A.5. 
Figure A.4 shows the electric field gradient with and without the droplets. The 
maximum electric field gradient without droplets is 1.1 x 107 V/m and the maximum 
electric field gradient with droplets is 2.3 x 107 V/m. This difference is because when 
the droplets pass in between the two electrodes, the droplets have an induced field, 
which influences the applied field gradient by reducing the gap over which the 
potential acts. The electric field is tuned to the resonant frequency of the droplets in 
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order to break apart the ~500 nm droplets into < 100 nm droplets as well as distribute 
the droplets spatially within the continuous fluid phase.  
Figure A.4 COMSOL simulations of the electric field gradient as well as the velocity 
profiles (without and with the E field active) at the midpoint (x, y plane at z = 10 μm 
height) of the microchannel.  (i) Channel level view of electrodes with cartooned drug 
droplets, (ii) electric field magnitude, (iii) fluid velocity above the inactivated 
electrodispersion electrodes at junction 1 (roughly 0.056 mm/s), and (iv) fluid velocity 
once the electric field is activated (roughly 73.0 mm/s).  The maximum observed 
electric field strength during fluid flow is 2.3 x 107 V/m.  
The drug delivery microdevice is designed so that it can be easily fabricated 
with standard UV-photolithographic methods in a Class 100 or greater cleanroom. The 
FF geometry integrated within the microchannel design is fabricated in poly 
(dimethylsiloxane) (PDMS) using standard printed masks, UV soft photolithography 
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techniques, and multilayer alignment of the channels from one layer to the next. The 
electrodes can be fabricated on a silicon or glass support via photoresist masking 
followed by deposition of a 10 nm titanium layer then a 10 nm gold layer by electron-
beam evaporation.  
Each layer of the molded channels can be sealed via oxygen plasma bonding 
procedures. PDMS is hydrophobic so that oil wets the walls, but surface treatment 
defines the required hydrophobic and hydrophilic patterns depending on fluid phases 
used. The dispersed drug phases will be hydrophilic (viscosity, μc= 6 mPa?s) and a 
biocompatible surfactant will be mixed with either the continuous phase at a 
concentration approximately 2.5 times greater than the critical micelle concentration 
(CMC) which is a moderate surfactant concentration and is favorable to test a wide 
flow rate range (W. Lee et al., 2009). The presence of the surfactant does not 
substantially change the viscosity as evidenced by W. Lee et al.  
A positive displacement chamber pump connected across a membrane to a 
pressurized canister will be used to drive the fluids from each inlet into the FF 
microchannels. Separate micropumps will connect to each solution reservoir such that 
flow in each channel can be separately controlled to achieve a feedback controlled 
fluidic system that can be worn on a wrist (Lima et al., 2004). Pressure drops for flows 
between 0.01 and 1 μL/min are not expected to cause deformation of microchannels 
due to either high-pressure injection or the PDMS elasticity used in our drug 
microdevice (Soller et al., 2011). If necessary, Thermoset Polyester (TPE) would be 
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the best alternative material of PDMS due to its high rigidity and suitability with 
droplet microfluidics (Soller et al., 2011). 
In order for a stable, efficient, and continuous small dosage of drug delivery, 
optimized selection of a surfactant, microfabrication condition, and pumping system 
are discussed. The unique combination of FF and electrodispersion to generate drug 
droplets protected by a sheathing layer of biocompatible poppy seed oil is described.  
Further, the electric field and fluid flow conditions were simulated and results used to 
optimize the design. The droplets exiting the flow focusing and electrodispersion 
region must then be accelerated in the drug delivery microdevice channel in order to 
generate a high enough pressure difference for the fluid to exit the microneedles into 
the dermis of the skin to achieve drug delivery. 
A.2.2 Dielectrophoretic Pumping 
Traveling wave DEP (twDEP) is incorporated into the drug delivery 
microdevice in order to accelerate the chemotherapy droplets as they travel to an array 
of microneedles for painless injection into the body. DEP is an efficient nondestructive 
way to manipulate bioparticles (Cheng et al., 2011), and twDEP is being investigated 
as a possible drug delivery technique (Bunthawin et al., 2010). The electrode 
configuration consists of an array of parallel rectangular electrodes configured in an 
intercalated pattern as shown in Figure A.1(ib). The intercalated configuration of the 
electrodes facilitates horizontal movement of particles when a non-uniform AC field 
is applied that is offset by 90° with each successive electrode. This causes the field 
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maxima to travel in waves down the array of electrodes thus driving the particle 
forward.  Typically the spacing between the electrodes is fixed to the width of one 
single electrode with the optimal width of an electrode being close to the diameter of 
the target particle. The spacing between the electrodes is usually 10 μm to 50 μm and 
remains constant (Lin & Yeow, 2007). 
Parallel electrodes are used for collecting, transporting, and/or separating 
particles. For the drug delivery microdevice, we will be using the parallel electrodes 
for transporting the oil-sheathed chemotherapy droplets. To help facilitate 
transportation the frequency and conductivity of medium is chosen specifically to 
induce the largest positive DEP force on the dielectric particles. Positive DEP is the 
movement of particles up the electric field gradient. When the AC field is applied to 
the electrodes a dipole moment is induced in the particles and the time-average DEP 
force, <FDEP>, is given as (Pethig, 2010) 
? ? ? ?? ???? ??? 223 ImRe2 EfEfRF cmcmmDEP (17) 
In Equation 17 ?m is the absolute permittivity of the medium, R is the radius of the 
particle, fcm is the Clausius-Mossotti factor, E is the amplitude of the electric field, and 
? is the phase. The Clausius-Mossotti factor is related to the polarizability of the 
particle and? ??2E , is the summation of the magnitude and phase of each field
component. The Clausis-Mossotti factor, fcm, for a spherical, homogeneous particle is 
given as (Pethig, 2010) 
mp
mp
cmf ??
??
2?
?? (18) 
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In Equation 18 ?p is the complex permittivity of the particle and ?m is the complex 
permittivity of the medium defined as (Pethig, 2010) 
?
???
j
p
pp ?? (19) 
?
???
j
m
mm ?? (20) 
In Equation 19 and 20 ?p is the absolute permittivity of the particle, ?p is the 
conductivity of the particle, ?m is the conductivity of the medium, ? is the angular 
frequency and j is the imaginary number. It is important to note that the DEP force for 
twDEP is dependent on both the real and imaginary part of the Clausius-Mossotti 
factor which causes particles to experience both an in-phase force (real part) and the 
out of phase force (imaginary part). Classical DEP force is only dependent on the real 
portion of the Clausius-Mossotti factor, ? ? 23 Re2 EfRF cmmDEP ? ?? .
Further, the assumption that the oil-sheathed droplets of aqueous drug can be 
represented as a first approximation homogeneous particle is acceptable because the 
conductivity of the oil layer is substantially different ???1 nS/m) from the supporting 
saline medium that the Clausius-Mossotti factor is nearly 0.50 – 3.36*10-8i and varies 
very little (4.8x10-8%) over the anticipated frequency range of interest from 1 Hz to 
10 MHz (Durr et al., 2003; Felten et al., 2008). Since twDEP is being used to transport 
chemotherapy droplets, it’s important to have an expression that relates the particle 
electrophoretic mobility with twDEP force. The DEP force can also be written 
utilizing the zeta potential ?p (Kang & Li, 2009), 
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REF rpDEP ???6?
?
(21) 
The DEP force written in this form allows it to be related to the electrophoretic 
mobility of the particle given as (Kang & Li, 2009) 
?
???? prE 0? (22) 
? ? EfRv cmrDEP ?? ?
??
3
Re0
2
(23) 
In equations 21-23?p is the zeta potential, ?r is the relative permittivity of the medium, 
R is the radius of the particle, E is the magnitude of the electric potential, ?0 is the 
permittivity of free space, Re[fcm] is the real-part of the Clausis-Mossotti factor, and ? 
is the dynamic viscosity of the medium. 
Parallel electrodes were added to the end of the microchannels, Figure A.2(ib), 
to increase the velocity of the chemotherapy droplets to ensure the droplets reach the 
microneedles at the end of the device with sufficient velocity to penetrate the dermis. 
The desired velocity at the microneedle tips was 10 μm/s based on modeling of 
transdermal delivery (Lv et al., 2006).  COMSOL was used to simulate the electric 
field gradient via the conservation of electrical potential between the insulating 
channel walls and the velocity of the droplets via the Navier-Stokes (Equation 12) and 
conservation relationships (Equation 13). Equations 5-9 developed in section 2.1 were 
used to obtain the electric field gradient with and without droplets in the channel as 
shown in Figure A.5. Droplets were defined as separate spherical  
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Figure A.5 COMSOL simulation of traveling wave dielectrophoretic pumping 
electrodes before and during fluid flow in the microchannel. The combined total length 
of the electrodes including gaps is 22 μm (i) channel level view of electrodes, (ii) 
normalized electric field strength from twDEP electrodes, (iii) velocity distribution in 
the channel view. In (i) when the twDEP electrodes are energized at an instantaneous 
half cycle with max potential of 10Vpp to ground at subsequent electrodes. The 
maximum observed electric field strength before fluid flow is 7.2 x 106 V/m, and the
maximum electric field strength during fluid flow is 1.1 x 107 V/m. The droplet fluid 
velocity was 70 mm/s in this DEP pumping region at z = 10 μm.  
fluids with the laminar flow module in COMSOL. The material selected in COMSOL 
for the particles was oil as previously described in section 2.1 and modified water to 
represent saline.  It can be seen in Figure A.5 that the electric field gradient decreases 
by 65% when the droplets are present because of the change in the electric charge of 
the dielectric oil layer.  Further, the droplets align along the centerline of the electrode 
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configuration because the DEP force is directed toward the symmetric centerline. This 
phenomenon is observed because electric field interact with droplets and induce force 
due to the dielectric property difference between immiscible phases (water and oil) 
since free charges can accumulate on the interface between inner and outer fluid.  The 
droplet equilibrium height is 10 microns above the bottom of the channel.  DEP forces 
are predicted to be on the order of 152 pN for the 10 Vpp field over the 22 μm 
electrodes. 
The electrophoretic mobility was used to simulate the velocity of the 
chemotherapy droplets in the field created by the dielectrophoretic pumping 
electrodes. In this drug delivery microdevice system, the droplet is a chemotherapy 
drug coated with poppy seed oil in a continuous phase of saline. In order to look at 
electric field effect, electrophoretic mobility was an added term.  
In Figure A.5, the fluid velocities increased by over 5000 times from 
0.021mm/s to 109 mm/s by implementing dielectrophoretic pumping at 10 Vpp via 
the electrode designs in the COMSOL simulation. Comparing without and with 
dielectrophoretic pumping (Figure A.4(iv) and Figure A.5(iii), respectively), the 
velocities with electrodispersion and DEP pumping electrodes remarkably changed as 
demonstrated in Figure A.6. These increases in velocity are necessary to move the 
drug droplets forward to the microneedles for injection. 
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Figure A.6 The top of each simulation shows x-y plane, top view, and bottom of each 
simulations shows z-x plane to display overall velocity profile. COMSOL simulation 
of fluid velocity without (i) and with (ii) dielectrophoretic pumping electrodes. 
Interdigitated dielectrophoretic pumping electrodes were added to the end of the 
microchannel to increase the velocity of the chemotherapy drug droplets to ensure 
sufficient velocity for microneedle injection. (i) The maximum fluid velocity inside 
the microchannel without electrodes was 0.025 mm/s reached at junction 2, (ii) the 
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maximum fluid velocity with electrodes was 109 mm/s also at junction 2. The 
magnified sections for (i) and (ii) show that the fluid velocity substantially increases 
from 0.0056 mm/s to 35 mm/s at the end of the microchannel once the pumping 
electrodes are added.   
A.2.3 Microneedles 
The skin is a common area for drug delivery, and offers advantages over other 
non-invasive drug delivery techniques. Drug delivery through the skin avoids drug 
metabolism by enzymatic reactions and the gastro-intestinal system, has the potential 
for continuous drug delivery (Migalska et al., 2011), and facilitates reaching 
circulating tumor cells (CTCs) that metastacized from their origin. Hypodermic 
needles are commonly used as the dominant method for transdermal drug delivery for 
gastric cancer treatment. Needles are painful, inconvenient and require professional 
administration for each dose (P.M. Wang et al., 2006). Another problem is that drugs 
are delivered all at once which causes an immediate spike in drug concentration 
profiles, which then rapidly diminishes. This can cause physiological instabilities, 
other dosage-related side-effects and can potentially fail to completely eradicate the 
tumor and/or CTCs (Zahn et al., 2004). To overcome these drawbacks, this work 
proposes a novel drug delivery microdevice amenable to feedback control; the device 
integrates microchannel hydrodynamic flow focusing, electrodispersion to decrease 
drug droplet size, dielectrophoretic pumping, and microneedles together in one 
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microdevice to deliver chemotherapy drugs in the form of droplets to a gastric cancer 
patient.  
The skin has four layers: (1) the stratum corneum, principal barrier composed 
of corneocytes, (2) epidermis, (3) dermis, and (4) subcutaneous tissue (Escobar-
Chavez et al., 2011). The four layers of the skin are barriers to transdermal drug 
delivery and microneedles are used as physical enhancers for transdermal drug 
delivery. They are designed to increase the permeability of the skin up to four orders 
of magnitude, so that drug passage through the stratum corneum and outer most layer 
of the epidermis becomes simple (Escobar-Chavez et al., 2011; K. Lee et al., 2011). 
Microneedles allow for drugs to be delivered across the skin in four ways: (1) “poke-
with-patch”, this method uses a solid microneedle array to penetrate the skin creating 
micropores, the microneedle array is removed and drugs are delivered through the 
micropores via a transdermal patch, gel or solution; (2) “coat-and-poke”, this method 
coats an array of microneedles with a drug and inserts the coated microneedles into 
the skin; and (3) “poke-and-release” embeds the drug molecules into the structure of 
polymer, biodegradable microneedles and inserts them into the skin; and (4) “poke-
and-flow”, uses hollow microneedles to insert liquid drugs into the skin (Migalska et 
al., 2011).  There are advantages and disadvantages to each approach and these vary 
with the application. Micropores created by microneedle penetration last for more than 
a day when left covered and they last for less than 2 hours when left uncovered. 
Microneedles that dissolve under the skin are perceived as the safest with the least 
chance of prolonged irritation (K. Lee et al., 2011). Methods 1, 2, and 3 are best suited 
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for applications where a one-time dose or daily dose of drug is desired.  However, for 
the chemotherapy drug delivery microdevice, method 4 is optimal.  The microneedles 
would remain inserted in the skin and held in place via a wristband as shown in Figure 
A.1.  
Microneedles can be inserted into the skin easier than hypodermic needles 
because stress on the skin is inversely proportional to the area of the top (Zahn et al., 
2004). Microneedles require sharpness to overcome stress forces on the skin surface 
as well as strength against fracturing, bending, and buckling, sufficient flow rate, and 
biocompatibility of the needle material (Nguyen & Wereley, 2006). The insertion 
force can be lowered by utilizing kinetic energy such as vibration which can reduce 
the force by as much as 30% (Nguyen & Wereley, 2006), and provides an increase in 
infusion flow rate (P.M. Wang et al., 2006). Retracting the microneedles after insertion 
by approximately 100-300 ?m also achieves a much greater flow rate (P.M. Wang et 
al., 2006).  
Microneedles have been shown to increase the transdermal delivery of many 
molecules including aminovulinic acid, anthrax, bovine serum albumin, 
desmospressin, erythropoirtin, meso-tera(N-methyl-4-pyridyl)porphine tetra tosylate, 
ovalbumin, plasmid DNA, low molecular weight tracers to proteins, and nanoparticles. 
Insulin is the most widely studied drug with microneedles and enhanced skin 
permeability has been reported in vivo and in vitro (Donnelly et al., 2011; Escobar-
Chavez et al., 2011). Recently researchers have looked into using microneedles 
fabricated from maltose to deliver methotrexate to rats via iontophoresis to treat 
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cancer. The result of this study was a synergistic 25-fold increase of drug delivery 
(Escobar-Chavez et al., 2011).    
Microneedles are a painless drug delivery method and create larger transport 
pathways for larger molecules; our device extends this to nanometer droplets. The 
painless characteristics of microneedles allow them to overcome the limitation of 
hypodermic needles. Advantages of microneedle technology are that the transport 
mechanisms are not dependent on the diffusion into the tissue, placement in the 
epidermis allows for drugs to reach target areas more readily, while only penetrating 
the stratum corneum without piercing nerve endings thus reducing pain, infection, or 
other injury.  The microneedles are nontoxic, minimally invasive, can be mass-
produced for a range of materials such as silicon dioxide and polymers, are easily 
disposable/interchangeable, and can be made from biodegradable materials. Some 
disadvantages to using microneedles are local inflammation and skin irritation. 
Another disadvantage is that the microneedles may break and be left under the skin; 
to avoid this, the diameter of the microneedle should be smaller than the diameter of a 
??????? 50 μm (Escobar-Chavez et al., 2011). In comparison hypodermic needles are 
inconvenient, not easily self-administered, and have poor targeted delivery because 
they have to be manually injected (P.M. Wang et al., 2006). 
Our microdevice uses an array of microneedles, Figure A.7, to deliver drug-in-
oil microdroplets, applying the “poke-and-flow” method. Figure A.7(i) shows the 
design of a single microneedle wherein the diameter of hole in the microneedles is 
approximately 40 μm which is sufficiently large to allow delivery of the oil sheathed 
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drug droplets without disruptive shearing effects while simultaneously being large 
enough to avoid breakage in the skin. Figure A.7(ii) is color coded to show the array 
of microneedles for each of the chemotherapy drugs with blue representing epirubicin, 
red representing cisplatin, and green representing fluorouracil. Each microneedle is 
connected to its own flow-focusing channel as shown in Figure A.2.  Figure A.7(iii) 
shows a photograph of an array of microneedles (Baek et al., 2011) fabricated from 
polylactic acid. The fluid emulsion velocities are approximately 35 mm/s as they leave 
the DEP pumping electrode region. Once the emulsions enter their final descent, to the 
microneedles the midchannel linear velocity decreases to approximately 30 to 40 mm/s 
as the channel expands followed by velocity increases within the microneedle tip, as 
constrained by the continuity equation.  
Several methods are used to fabricate hollow microneedles and most are made 
from silicon or silicon-based materials. This drug delivery microdevice requires a 
relatively straight channel with minimal bends so that the microdroplets are not 
sheared and are delivered to the dermis intact. The pyramid-shaped microneedles were 
chosen because fabrication is simple and thus it has the best shape to achieve tip 
sharpness and strength (Moon & Lee, 2003). The pyramid microneedles can be 
fabricated by an inclined LIGA process combining lithography, electroplating, and 
molding techniques. This process utilizes X-ray’s directed towards a protective 
electroplated gold mask over a poly(methyl methacrylate) (PMMA) substrate on a 
silicon wafer (Moon & Lee, 2003).  
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As discussed in this section, optimal material, design, and operating conditions 
were gleaned from the literature.  This information was combined to simulate electric 
field and hydrodynamic flow behaviors in each section of the microdevice.  The design 
was iteratively optimized based on these simulation results and then integrated 
together into the drug delivery microdevice. 
Figure A.7 Microneedle design to deliver chemotherapy emulsion to cancer patient, 
(i) pyramid-shaped hollow microneedle for delivery of 3 chemotherapy droplets 
(epirubicin, cisplatin, and fluorouracil) and the COMSOL simulation of the fluid 
velocity in the microneedle, (ii) microneedle array, and (iii) real image of a 
microneedle array. The initial velocities of the fluids in the microchannel were 4.2*10-
4 m/s drug, 4.2*10-3 m/s poppy seed oil, and 4.2*10-2 m/s saline, and the exiting 
velocities from the microneedles is approximately 40mm/s. In (iii) microneedles are 
made out of poly-lactic acid (Baek et al., 2011).  
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A.3 Integration of Technology into Fully Conceived Device 
This microfluidic drug delivery device will operate in sequence as described 
in sections 2.1 through 2.3. First, three different chemotherapy drugs, Epirubicin, 
Cisplatin, and Fluorouracil, will be separately dispersed into oil and then subsequently 
into saline by proven flow-focusing microchannel technology. Current state of the art 
results in this field suggest droplets formed will be approximately 500 nm in diameter. 
This design utilizes two stages of interdigitated electrodes on the bottom surface of the 
microchannel leaving the flow focusing junction in order to electrodisperse the 
droplets into <100nm droplets and to evenly disperse them spatially as they flow 
downstream to reduce coalescence.  The oil-sheathed drug droplets are then pumped 
down the microchannel using traveling wave DEP technologies before flowing into an 
array of microneedles inserted into the dermis layer of the skin.  This entire system is 
packaged inside of a small unit that can be worn on the wrist.  The reservoirs for each 
drug, poppy seed oil, saline, and pressurized air to pump from the reservoirs can be 
individually replaced based on usage.  Further, integrated electronic feedback control 
and monitoring (not described here) can be utilized to monitor chemotherapy drug 
delivery into the dermis and subsequently the blood stream of a cancer patient. The 
main components of this microfluidic device were optimized from literature data and 
COMSOL simulations.  
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A.4 Conclusions and Perspectives for Future Integrated Microdevice 
Technologies 
There is a great need for new technologies to effectively treat all forms of 
metastasized cancer. Gastric cancer provides a poignant example because patient 
symptoms typically do not arise until the cancer has progressed to stage IV.  Any new 
technologies developed should increase the comfort level of patients as well as 
concurrently improve treatment efficacy or even eradicate the disease. The goal of this 
work was to develop a novel drug delivery system to effectively treat gastric cancer 
patients with minimal pain or lifestyle interruptions while undergoing treatment. 
In addition, this work links together technologies that have been progressing 
in isolation from each other.  For example, electrodispersion integrated with flow 
focusing and surfactant stabilization is a novel technique with the potential to produce 
droplets less than 100 nm in diameter.  Smaller droplets are desired in diverse 
applications such as nanoparticle synthesis or pharmaceutical packaging.   One key 
advantage of this combined technique is that it can be integrated into lab-on-a-chip 
devices provided the capillary number and volumetric flow rate ratio are optimized 
and the surfactant required for optimizing interfacial tension increases the long-term 
stability of droplets. 
Traveling wave DEP is an advantageous technique for transport of droplets in 
microchannels, which has minimal power requirements and thus is ideal for portable 
microdevices operating on batteries. Incorporating traveling wave DEP electrodes into 
the drug delivery microdevice described increased the velocity of the droplets for 
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optimal microneedle injection rates.  Further, this technique has proven to be 
minimally disruptive to a particle, which is a key advantage with this adaption of the 
technology in the drug delivery microdevice. 
Microneedles have been explored in many forms as physical enhancers for 
drug delivery.  Within the drug delivery microdevice, the microneedle array was 
adopted to reduce pain and facilitate continuous delivery of the Epirubicin, Cisplatin, 
and Fluorouracil chemotherapy drug cocktail into the dermis.  Based on evidence from 
previous studies, the pain level can be greatly reduced and the chemotherapy droplets 
reach their target areas in a more efficient manner thus reducing side effects.  
For future work this drug delivery microdevice wrist system could be improved 
by incorporating a biosensor, in-line feedback control, and wireless reporting to 
measure the concentration and metabolites of the chemotherapy droplets in the blood 
stream, dynamically adjust dosage, and keep the primary care physician informed of 
progress. This will allow for real-time drug and treatment monitoring. The advantages 
of adding in this technology would be decreases in patient drug side effects, uniform 
maintenance of the critical drug concentration delivered to the gastric tumor and 
CTCs, increased treatment effectiveness, and increased patient comfort.  
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